Clustering O O
of O O
missense O O
mutations O O
in O O
the O O
ataxia B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O O
in O O
a O O
sporadic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
T I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cell I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
leukaemia I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
risk O O
of O O
cancer B B_DISEASE
, O O
especially O O
lymphoid B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neoplasias I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
is O O
substantially O O
elevated O O
in O O
A B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
T I I_DISEASE/I_MEASURE
patients O O
and O O
has O O
long O O
been O O
associated O O
with O O
chromosomal O O
instability O O
. O O

In O O
marked O O
contrast O O
to O O
the O O
ATM O O
mutation O O
pattern O O
in O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
most O O
frequent O O
nucleotide O O
changes O O
in O O
this O O
leukaemia B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O O
missense O O
mutations O O
. O O

These O O
clustered O O
in O O
the O O
region O O
corresponding O O
to O O
the O O
kinase O O
domain O O
, O O
which O O
is O O
highly O O
conserved O O
in O O
ATM O O
- O O
related O O
proteins O O
in O O
mouse O O
, O O
yeast O O
and O O
Drosophila O O
. O O

The O O
resulting O O
amino O O
- O O
acid O O
substitutions O O
are O O
predicted O O
to O O
interfere O O
with O O
ATP O O
binding O O
or O O
substrate O O
recognition O O
. O O

Two O O
of O O
seventeen O O
mutated O O
T B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
PLL I B_DISEASE/I_GENE
samples O O
had O O
a O O
previously O O
reported O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele O O
. O O

In O O
contrast O O
, O O
no O O
mutations O O
were O O
detected O O
in O O
the O O
p53 O O
gene O O
, O O
suggesting O O
that O O
this O O
tumour B B_DISEASE/B_GENE
suppressor O O
is O O
not O O
frequently O O
altered O O
in O O
this O O
leukaemia B B_DISEASE/B_PERSON
. O O

Occasional O O
missense O O
mutations O O
in O O
ATM O O
were O O
also O O
found O O
in O O
tumour B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O O
from O O
patients O O
with O O
B B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
cell I I_DISEASE/I_GENE
non I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Hodgkins I I_DISEASE/I_GENE
lymphomas I I_DISEASE/I_GENE
( O O
B B B_DISEASE
- I I_DISEASE
NHL I I_DISEASE
) O O
and O O
a O O
B B B_DISEASE
- I I_DISEASE
NHL I I_DISEASE
cell O O
line O O
. O O

The O O
evidence O O
of O O
a O O
significant O O
proportion O O
of O O
loss O O
- O O
of O O
- O O
function O O
mutations O O
and O O
a O O
complete O O
absence O O
of O O
the O O
normal O O
copy O O
of O O
ATM O O
in O O
the O O
majority O O
of O O
mutated O O
tumours B B_DISEASE/B_BIO
establishes O O
somatic O O
inactivation O O
of O O
this O O
gene O O
in O O
the O O
pathogenesis O O
of O O
sporadic B B_DISEASE
T I I_DISEASE
- I I_DISEASE
PLL I I_DISEASE
and O O
suggests O O
that O O
ATM O O
acts O O
as O O
a O O
tumour B B_DISEASE
suppressor O O
. O O

As O O
constitutional O O
DNA O O
was O O
not O O
available O O
, O O
a O O
putative O O
hereditary O O
predisposition O O
to O O
T B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
PLL I I_DISEASE/I_LOCATION
will O O
require O O
further O O
investigation O O
. O O
. O O

Myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein O O
kinase O O
is O O
involved O O
in O O
the O O
modulation O O
of O O
the O O
Ca2 O O
+ O O
homeostasis O O
in O O
skeletal O O
muscle O O
cells O O
. O O

To O O
obtain O O
clues O O
to O O
the O O
normal O O
biological O O
role O O
of O O
DMPK O O
in O O
cellular O O
ion O O
homeostasis O O
, O O
we O O
have O O
compared O O
the O O
resting O O
[ O O
Ca2 O O
+ O O
] O O
i O O
, O O
the O O
amplitude O O
and O O
shape O O
of O O
depolarization O O
- O O
induced O O
Ca2 O O
+ O O
transients O O
, O O
and O O
the O O
content O O
of O O
ATP O O
- O O
driven O O
ion O O
pumps O O
in O O
cultured O O
skeletal O O
muscle O O
cells O O
of O O
wild O O
- O O
type O O
and O O
DMPK O O
[ O O
- O O
/ O O
- O O
] O O
knockout O O
mice O O
. O O

In O O
vitro O O
- O O
differentiated O O
DMPK O O
[ O O
- O O
/ O O
- O O
] O O
myotubes O O
exhibit O O
a O O
higher O O
resting O O
[ O O
Ca2 O O
+ O O
] O O
i O O
than O O
do O O
wild O O
- O O
type O O
myotubes O O
because O O
of O O
an O O
altered O O
open O O
probability O O
of O O
voltage O O
- O O
dependent O O
l O O
- O O
type O O
Ca2 O O
+ O O
and O O
Na O O
+ O O
channels O O
. O O

The O O
mutant O O
myotubes O O
exhibit O O
smaller O O
and O O
slower O O
Ca2 O O
+ O O
responses O O
upon O O
triggering O O
by O O
acetylcholine O O
or O O
high O O
external O O
K O O
+ O O
. O O

In O O
addition O O
, O O
we O O
observed O O
that O O
these O O
Ca2 O O
+ O O
transients O O
partially O O
result O O
from O O
an O O
influx O O
of O O
extracellular O O
Ca2 O O
+ O O
through O O
the O O
l O O
- O O
type O O
Ca2 O O
+ O O
channel O O
. O O

Neither O O
the O O
content O O
nor O O
the O O
activity O O
of O O
Na O O
+ O O
/ O O
K O O
+ O O
ATPase O O
and O O
sarcoplasmic O O
reticulum O O
Ca2 O O
+ O O
- O O
ATPase O O
are O O
affected O O
by O O
DMPK O O
absence O O
. O O

In O O
conclusion O O
, O O
our O O
data O O
suggest O O
that O O
DMPK O O
is O O
involved O O
in O O
modulating O O
the O O
initial O O
events O O
of O O
excitation O O
- O O
contraction O O
coupling O O
in O O
skeletal O O
muscle O O
. O O
. O O

Constitutional O O
RB1 O O
- O O
gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE/B_GENE
retinoblastoma I I_DISEASE/I_GENE
. O O

In O O
most O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE/B_GENE
retinoblastoma I I_DISEASE/I_GENE
, O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
development O O
is O O
initiated O O
by O O
somatic O O
inactivation O O
of O O
both O O
alleles O O
of O O
the O O
RB1 O O
gene O O
. O O

However O O
, O O
some O O
of O O
these O O
patients O O
can O O
transmit O O
retinoblastoma B B_DISEASE/B_GENE
predisposition O O
to O O
their O O
offspring O O
. O O

To O O
determine O O
the O O
frequency O O
and O O
nature O O
of O O
constitutional O O
RB1 O O
- O O
gene O O
mutations O O
in O O
patients O O
with O O
isolated O O
unilateral B B_DISEASE
retinoblastoma I I_DISEASE
, O O
we O O
analyzed O O
DNA O O
from O O
peripheral O O
blood O O
and O O
from O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O O
. O O

The O O
analysis O O
of O O
tumors B B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O O
54 O O
( O O
71 O O
% O O
) O O
of O O
76 O O
informative O O
patients O O
showed O O
loss O O
of O O
constitutional O O
heterozygosity O O
( O O
LOH O O
) O O
at O O
intragenic O O
loci O O
. O O

For O O
39 O O
randomly O O
selected O O
tumors B B_DISEASE/B_PERSON
, O O
SSCP O O
, O O
hetero O O
- O O
duplex O O
analysis O O
, O O
sequencing O O
, O O
and O O
Southern O O
blot O O
analysis O O
were O O
used O O
to O O
identify O O
mutations O O
. O O

Mutations O O
were O O
detected O O
in O O
21 O O
( O O
91 O O
% O O
) O O
of O O
23 O O
tumors B B_DISEASE/B_PERSON
with O O
LOH O O
. O O

In O O
6 O O
( O O
38 O O
% O O
) O O
of O O
16 O O
tumors B B_DISEASE/B_PERSON
without O O
LOH O O
, O O
one O O
mutation O O
was O O
detected O O
, O O
and O O
in O O
9 O O
( O O
56 O O
% O O
) O O
of O O
the O O
tumors B B_DISEASE/B_MEASURE
without O O
LOH O O
, O O
both O O
mutations O O
were O O
found O O
. O O

In O O
2 O O
patients O O
without O O
a O O
detectable O O
mutation O O
in O O
peripheral O O
blood O O
, O O
mosaicism O O
was O O
suggested O O
because O O
1 O O
of O O
the O O
patients O O
showed O O
multifocal O O
tumors B B_DISEASE
and O O
the O O
other O O
later O O
developed O O
bilateral B B_DISEASE
retinoblastoma I I_DISEASE
. O O

In O O
conclusion O O
, O O
our O O
results O O
emphasize O O
that O O
the O O
manifestation O O
and O O
transmissibility O O
of O O
retinoblastoma B B_DISEASE/B_GENE
depend O O
on O O
the O O
nature O O
of O O
the O O
first O O
mutation O O
, O O
its O O
time O O
in O O
development O O
, O O
and O O
the O O
number O O
and O O
types O O
of O O
cells O O
that O O
are O O
affected O O
. O O
. O O

Hereditary B B_DISEASE
deficiency I I_DISEASE
of I I_DISEASE
the I I_DISEASE
fifth I I_DISEASE
component I I_DISEASE
of I I_DISEASE
complement I I_DISEASE
in O O
man O O
. O O

I O O
. O O

Clinical O O
, O O
immunochemical O O
, O O
and O O
family O O
studies O O
. O O

The O O
first O O
recognized O O
human O O
kindred O O
with O O
hereditary B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
fifth I I_DISEASE/I_GENE
component I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
complement I I_DISEASE/I_GENE
( O O
C5 O O
) O O
is O O
described O O
. O O

The O O
proband O O
, O O
a O O
20 O O
- O O
year O O
- O O
old O O
black O O
female O O
with O O
systemic B B_DISEASE/B_LOCATION
lupus I I_DISEASE/I_LOCATION
erythematosus I I_DISEASE/I_LOCATION
since O O
age O O
11 O O
, O O
lacked O O
serum O O
hemolytic O O
complement O O
activity O O
, O O
even O O
during O O
remission O O
. O O

By O O
hemolytic O O
assay O O
, O O
she O O
exhibited O O
1 O O
- O O
2 O O
% O O
of O O
the O O
normal O O
serum O O
C5 O O
level O O
and O O
normal O O
concentrations O O
of O O
other O O
complement O O
components O O
. O O

C5 O O
levels O O
of O O
other O O
family O O
members O O
were O O
either O O
normal O O
or O O
approximately O O
half O O
- O O
normal O O
, O O
consistent O O
with O O
autosomal O O
codominant O O
inheritance O O
of O O
the O O
gene O O
determining O O
C5 B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
. O O

Normal O O
hemolytic O O
titers O O
were O O
restored O O
to O O
both O O
homozygous O O
C5 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
deficient I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
C5D B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
sera O O
by O O
addition O O
of O O
highly O O
purified O O
human O O
C5 O O
. O O

In O O
specific O O
C5 O O
titrations O O
, O O
however O O
, O O
it O O
was O O
noted O O
that O O
when O O
limited O O
amounts O O
of O O
C5 O O
were O O
assayed O O
in O O
the O O
presence O O
of O O
low O O
dilutions O O
of O O
either O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
serum O O
, O O
curving O O
rather O O
than O O
linear O O
dose O O
- O O
response O O
plots O O
were O O
consistently O O
obtained O O
, O O
suggesting O O
some O O
inhibitory O O
effect O O
. O O

Further O O
studies O O
suggested O O
that O O
low O O
dilutions O O
of O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
serum O O
contain O O
a O O
factor O O
( O O
or O O
factors O O
) O O
interfering O O
at O O
some O O
step O O
in O O
the O O
hemolytic O O
assay O O
of O O
C5 O O
, O O
rather O O
than O O
a O O
true O O
C5 O O
inhibitor O O
or O O
inactivator O O
. O O

Of O O
clinical O O
interest O O
are O O
( O O
a O O
) O O
the O O
documentation O O
of O O
membranous O O
glomerulonephritis B B_DISEASE
, O O
vasculitis B B_DISEASE
, O O
and O O
arthritis B B_DISEASE
in O O
an O O
individual O O
lacking O O
C5 O O
( O O
and O O
its O O
biologic O O
functions O O
) O O
, O O
and O O
( O O
b O O
) O O
a O O
remarkable O O
propensity O O
to O O
bacterial B B_DISEASE_ADJECTIVE[DISEASE]
infections I I_DISEASE_ADJECTIVE[DISEASE]
in O O
the O O
proband O O
, O O
even O O
during O O
periods O O
of O O
low O O
- O O
dose O O
or O O
alternate O O
- O O
day O O
corticosteroid O O
therapy O O
. O O

Other O O
observations O O
indicate O O
that O O
the O O
C5D B B_DISEASE_ADJECTIVE[DISEASE]
state O O
is O O
compatible O O
with O O
normal O O
coagulation O O
function O O
and O O
the O O
capacity O O
to O O
mount O O
a O O
neutrophilic O O
leukocytosis O O
during O O
pyogenic B B_DISEASE
infection I I_DISEASE
. O O
. O O

Susceptibility O O
to O O
ankylosing B B_DISEASE
spondylitis I I_DISEASE
in O O
twins O O
: O O
the O O
role O O
of O O
genes O O
, O O
HLA O O
, O O
and O O
the O O
environment O O
. O O

OBJECTIVE O O
To O O
determine O O
the O O
relative O O
effects O O
of O O
genetic O O
and O O
environmental O O
factors O O
in O O
susceptibility O O
to O O
ankylosing B B_DISEASE
spondylitis I I_DISEASE
( O O
AS B B_DISEASE/B_LOCATION
) O O
. O O

METHODS O O
Twins O O
with O O
AS B B_DISEASE/B_LOCATION
were O O
identified O O
from O O
the O O
Royal O O
National O O
Hospital O O
for O O
Rheumatic B B_DISEASE/B_PERSON
Diseases I I_DISEASE/I_PERSON
database O O
. O O

Clinical O O
and O O
radiographic O O
examinations O O
were O O
performed O O
to O O
establish O O
diagnoses O O
, O O
and O O
disease O O
severity O O
was O O
assessed O O
using O O
a O O
combination O O
of O O
validated O O
scoring O O
systems O O
. O O

HLA O O
typing O O
for O O
HLA O O
- O O
B27 O O
, O O
HLA O O
- O O
B60 O O
, O O
and O O
HLA O O
- O O
DR1 O O
was O O
performed O O
by O O
polymerase O O
chain O O
reaction O O
with O O
sequence O O
- O O
specific O O
primers O O
, O O
and O O
zygosity O O
was O O
assessed O O
using O O
microsatellite O O
markers O O
. O O

Genetic O O
and O O
environmental O O
variance O O
components O O
were O O
assessed O O
with O O
the O O
program O O
Mx O O
, O O
using O O
data O O
from O O
this O O
and O O
previous O O
studies O O
of O O
twins O O
with O O
AS B B_DISEASE/B_LOCATION
. O O

RESULTS O O
Six O O
of O O
8 O O
monozygotic O O
( O O
MZ O O
) O O
twin O O
pairs O O
were O O
disease O O
concordant O O
, O O
compared O O
with O O
4 O O
of O O
15 O O
B27 O O
- O O
positive O O
dizygotic O O
( O O
DZ O O
) O O
twin O O
pairs O O
( O O
27 O O
% O O
) O O
and O O
4 O O
of O O
32 O O
DZ O O
twin O O
pairs O O
overall O O
( O O
12 O O
. O O
5 O O
% O O
) O O
. O O

Additive O O
genetic O O
effects O O
were O O
estimated O O
to O O
contribute O O
97 O O
% O O
of O O
the O O
population O O
variance O O
. O O

CONCLUSION O O
Susceptibility O O
to O O
AS B B_DISEASE/B_LOCATION
is O O
largely O O
genetically O O
determined O O
, O O
and O O
the O O
environmental O O
trigger O O
for O O
the O O
disease O O
is O O
probably O O
ubiquitous O O
. O O

HLA O O
- O O
B27 O O
accounts O O
for O O
a O O
minority O O
of O O
the O O
overall O O
genetic O O
susceptibility O O
to O O
AS B B_DISEASE/B_LOCATION
. O O

Germ O O
- O O
line O O
mutations O O
of O O
the O O
BRCA1 O O
gene O O
predispose O O
women O O
to O O
early O O
- O O
onset O O
breast B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
ovarian I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
by O O
compromising O O
the O O
genes O O
presumptive O O
function O O
as O O
a O O
tumor B B_DISEASE
suppressor O O
. O O

Although O O
the O O
biochemical O O
properties O O
of O O
BRCA1 O O
polypeptides O O
are O O
not O O
understood O O
, O O
their O O
expression O O
pattern O O
and O O
subcellular O O
localization O O
suggest O O
a O O
role O O
in O O
cell O O
- O O
cycle O O
regulation O O
. O O

When O O
resting O O
cells O O
are O O
induced O O
to O O
proliferate O O
, O O
the O O
steady O O
- O O
state O O
levels O O
of O O
BRCA1 O O
increase O O
in O O
late O O
G1 O O
and O O
reach O O
a O O
maximum O O
during O O
S O O
phase O O
. O O

" O O
BRCA1 O O
associates O O
in O O
vivo O O
with O O
a O O
structurally O O
related O O
protein O O
termed O O
BARD1 O O
. O O

Here O O
we O O
show O O
that O O
the O O
steady O O
- O O
state O O
levels O O
of O O
BARD1 O O
, O O
unlike O O
those O O
of O O
BRCA1 O O
, O O
remain O O
relatively O O
constant O O
during O O
cell O O
cycle O O
progression O O
. O O

However O O
, O O
immunostaining O O
revealed O O
that O O
BARD1 O O
resides O O
within O O
BRCA1 O O
nuclear O O
dots O O
during O O
S O O
phase O O
of O O
the O O
cell O O
cycle O O
, O O
but O O
not O O
during O O
the O O
G1 O O
phase O O
. O O

Nevertheless O O
, O O
BARD1 O O
polypeptides O O
are O O
found O O
exclusively O O
in O O
the O O
nuclear O O
fractions O O
of O O
both O O
G1 O O
- O O
and O O
S O O
- O O
phase O O
cells O O
. O O

This O O
cell O O
cycle O O
- O O
dependent O O
colocalization O O
of O O
BARD1 O O
and O O
BRCA1 O O
indicates O O
a O O
role O O
for O O
BARD1 O O
in O O
BRCA1 O O
- O O
mediated O O
tumor B B_DISEASE/B_GENE
suppression O O
. O O

Ethnic O O
differences O O
in O O
the O O
HFE O O
codon O O
282 O O
( O O
Cys O O
/ O O
Tyr O O
) O O
polymorphism O O
. O O

Recent O O
studies O O
have O O
shown O O
that O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
( O O
HH B B_PROTEIN[GENE]/B_DISEASE
) O O
is O O
likely O O
to O O
be O O
caused O O
by O O
homozygosity O O
for O O
a O O
Cys282Tyr O O
mutation O O
in O O
the O O
HFE O O
gene O O
located O O
4 O O
. O O

5 O O
Mb O O
telomeric O O
to O O
HLA O O
- O O
A O O
. O O

We O O
have O O
studied O O
the O O
codon O O
282 O O
( O O
Cys O O
/ O O
Tyr O O
) O O
polymorphism O O
in O O
different O O
ethnic O O
groups O O
. O O

In O O
agreement O O
with O O
previous O O
observations O O
the O O
Tyr O O
allele O O
appeared O O
to O O
be O O
rare O O
or O O
absent O O
in O O
Asiatic O O
( O O
Indian O O
, O O
Chinese O O
) O O
populations O O
. O O

The O O
highest O O
allele O O
frequency O O
( O O
7 O O
. O O
5 O O
% O O
) O O
was O O
found O O
in O O
Swedes O O
. O O

Comparisons O O
with O O
allele O O
frequencies O O
based O O
on O O
prevalence O O
estimates O O
of O O
HH B B_DISEASE/B_GENE
showed O O
some O O
disagreements O O
with O O
the O O
RFLP O O
data O O
, O O
particularly O O
in O O
Finns O O
. O O

The O O
newly O O
described O O
HFE O O
marker O O
provides O O
a O O
new O O
approach O O
to O O
the O O
screening O O
of O O
HH B B_DISEASE/B_PERSON
as O O
well O O
as O O
studies O O
of O O
the O O
relationship O O
between O O
the O O
HFE O O
Tyr O O
allele O O
and O O
different O O
disorders O O
including O O
cancer B B_DISEASE

Autosomal B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dominant I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
neurohypophyseal I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
diabetes I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
insipidus I I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
associated O O
with O O
a O O
missense O O
mutation O O
encoding O O
Gly23 O O
- O O
- O O
> O O
Val O O
in O O
neurophysin O O
II O O
. O O

Autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
neurohypophyseal I I_DISEASE/I_GENE
diabetes I I_DISEASE/I_GENE
insipidus I I_DISEASE/I_GENE
( O O
ADNDI B B_DISEASE
) O O
is O O
an O O
inherited B B_DISEASE
disease I I_DISEASE
caused O O
by O O
progressive O O
degeneration O O
of O O
the O O
magnocellular O O
neurons O O
of O O
the O O
hypothalamus O O
leading O O
to O O
decreased O O
ability O O
to O O
produce O O
the O O
hormone O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
. O O

Affected O O
individuals O O
are O O
not O O
symptomatic O O
at O O
birth O O
, O O
but O O
usually O O
develop O O
diabetes B B_DISEASE_ADJECTIVE[DISEASE]
insipidus I I_DISEASE_ADJECTIVE[DISEASE]
at O O
1 O O
- O O
6 O O
yr O O
of O O
age O O
. O O

The O O
genetic O O
locus O O
of O O
the O O
disease O O
is O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
NPII O O
) O O
gene O O
, O O
and O O
mutations O O
that O O
cause O O
ADNDI B B_DISEASE/B_GENE
have O O
been O O
found O O
in O O
both O O
the O O
signal O O
peptide O O
of O O
the O O
prepro O O
- O O
AVP O O
- O O
NPII O O
precursor O O
and O O
within O O
NPII O O
itself O O
. O O

An O O
affected O O
girl O O
who O O
presented O O
at O O
9 O O
months O O
of O O
age O O
and O O
her O O
similarly O O
affected O O
younger O O
brother O O
and O O
father O O
were O O
all O O
found O O
to O O
have O O
a O O
novel O O
missense O O
mutation O O
( O O
G1758 O O
- O O
- O O
> O O
T O O
) O O
encoding O O
the O O
amino O O
acid O O
substitution O O
Gly23 O O
- O O
- O O
> O O
Val O O
within O O
NPII O O
. O O

This O O
mutation O O
may O O
be O O
valuable O O
for O O
developing O O
models O O
of O O
dominantly B B_DISEASE
inherited I I_DISEASE
neurodegeneration I I_DISEASE
, O O
as O O
the O O
early O O
age O O
of O O
onset O O
of O O
symptoms O O
suggests O O
that O O
this O O
mutation O O
may O O
be O O
particularly O O
deleterious O O
to O O
the O O
magnocellular O O
neuron O O
. O O
. O O

Frequent O O
inactivation O O
of O O
PTEN O O
/ O O
MMAC1 O O
in O O
primary O O
prostate B B_DISEASE
cancer I I_DISEASE
. O O

Sporadic B B_DISEASE
prostate I I_DISEASE
carcinoma I I_DISEASE
is O O
the O O
most O O
common O O
male B B_DISEASE
cancer I I_DISEASE
in O O
the O O
Western O O
world O O
, O O
yet O O
many O O
of O O
the O O
major O O
genetic O O
events O O
involved O O
in O O
the O O
progression O O
of O O
this O O
often O O
fatal O O
cancer B B_DISEASE
remain O O
to O O
be O O
elucidated O O
. O O

Numerous O O
cytogenetic O O
and O O
allelotype O O
studies O O
have O O
reported O O
frequent O O
loss O O
of O O
heterozygosity O O
on O O
chromosomal O O
arm O O
10q O O
in O O
sporadic B B_DISEASE
prostate I I_DISEASE
cancer I I_DISEASE
. O O

A O O
new O O
tumor B B_DISEASE/B_GENE
suppressor O O
gene O O
, O O
PTEN O O
/ O O
MMAC1 O O
, O O
was O O
isolated O O
recently O O
at O O
this O O
region O O
of O O
chromosome O O
10q23 O O
and O O
found O O
to O O
be O O
inactivated O O
by O O
mutation O O
in O O
three O O
prostate B B_DISEASE
cancer I I_DISEASE
cell O O
lines O O
. O O

We O O
screened O O
80 O O
prostate B B_DISEASE/B_PERSON
tumors I I_DISEASE/I_PERSON
by O O
microsatellite O O
analysis O O
and O O
found O O
chromosome O O
10q23 O O
to O O
be O O
deleted O O
in O O
23 O O
cases O O
. O O

The O O
identification O O
of O O
the O O
second O O
mutational O O
event O O
in O O
10 O O
( O O
43 O O
% O O
) O O
tumors B B_DISEASE/B_PERSON
establishes O O
PTEN O O
/ O O
MMAC1 O O
as O O
a O O
main O O
inactivation O O
target O O
of O O
10q O O
loss O O
in O O
sporadic B B_DISEASE/B_GENE
prostate I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
. O O
. O O

Risk O O
reversals O O
in O O
predictive O O
testing O O
for O O
Huntington B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

The O O
first O O
predictive O O
testing O O
for O O
Huntington B B_DISEASE
disease I I_DISEASE
( O O
HD B B_DISEASE/B_PROTEIN[GENE]
) O O
was O O
based O O
on O O
analysis O O
of O O
linked O O
polymorphic O O
DNA O O
markers O O
to O O
estimate O O
the O O
likelihood O O
of O O
inheriting O O
the O O
mutation O O
for O O
HD B B_DISEASE/B_PROTEIN[GENE]
. O O

Limits O O
to O O
accuracy O O
included O O
recombination O O
between O O
the O O
DNA O O
markers O O
and O O
the O O
mutation O O
, O O
pedigree O O
structure O O
, O O
and O O
whether O O
DNA O O
samples O O
were O O
available O O
from O O
family O O
members O O
. O O

With O O
direct O O
tests O O
for O O
the O O
HD B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O O
, O O
we O O
have O O
assessed O O
the O O
accuracy O O
of O O
results O O
obtained O O
by O O
linkage O O
approaches O O
when O O
requested O O
to O O
do O O
so O O
by O O
the O O
test O O
individuals O O
. O O

For O O
six O O
such O O
individuals O O
, O O
there O O
was O O
significant O O
disparity O O
between O O
the O O
tests O O
. O O

Three O O
went O O
from O O
a O O
decreased O O
risk O O
to O O
an O O
increased O O
risk O O
, O O
while O O
in O O
another O O
three O O
the O O
risk O O
was O O
decreased O O
. O O

A O O
novel O O
common O O
missense O O
mutation O O
G301C O O
in O O
the O O
N O O
- O O
acetylgalactosamine O O
- O O
6 O O
- O O
sulfate O O
sulfatase O O
gene O O
in O O
mucopolysaccharidosis B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
IVA I B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O O

In O O
previous O O
studies O O
, O O
we O O
have O O
found O O
two O O
common O O
mutations O O
in O O
Caucasians O O
and O O
Japanese O O
, O O
respectively O O
. O O

To O O
characterize O O
the O O
mutational O O
spectrum O O
in O O
various O O
ethnic O O
groups O O
, O O
mutations O O
in O O
the O O
GALNS O O
gene O O
in O O
Colombian O O
MPS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
were O O
investigated O O
, O O
and O O
genetic O O
backgrounds O O
were O O
extensively O O
analyzed O O
to O O
identify O O
racial O O
origin O O
, O O
based O O
on O O
mitochondrial O O
DNA O O
( O O
mtDNA O O
) O O
lineages O O
. O O

Three O O
novel O O
missense O O
mutations O O
never O O
identified O O
previously O O
in O O
other O O
populations O O
and O O
found O O
in O O
16 O O
out O O
of O O
19 O O
Colombian O O
MPS B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
IVA I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
unrelated O O
alleles O O
account O O
for O O
84 O O
. O O

2 O O
% O O
of O O
the O O
alleles O O
in O O
this O O
study O O
. O O

The O O
G301C O O
and O O
S162F O O
mutations O O
account O O
for O O
68 O O
. O O

4 O O
% O O
and O O
10 O O
. O O

5 O O
% O O
of O O
mutations O O
, O O
respectively O O
, O O
whereas O O
the O O
remaining O O
F69V O O
is O O
limited O O
to O O
a O O
single O O
allele O O
. O O

Low O O
frequency O O
of O O
BRCA1 O O
germline O O
mutations O O
in O O
45 O O
German O O
breast B B_DISEASE/B_PERSON
/ I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
. O O

In O O
this O O
study O O
we O O
investigated O O
45 O O
German O O
breast B B_DISEASE
/ I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
families O O
for O O
germline O O
mutations O O
in O O
the O O
BRCA1 O O
gene O O
. O O

We O O
identified O O
four O O
germline O O
mutations O O
in O O
three O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
families O O
and O O
in O O
one O O
breast B B_DISEASE
- I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
family O O
. O O
among O O
these O O
were O O
one O O
frameshift O O
mutation O O
, O O
one O O
nonsense O O
mutation O O
, O O
one O O
novel O O
splice O O
site O O
mutation O O
, O O
and O O
one O O
missense O O
mutation O O
. O O

The O O
missense O O
mutation O O
was O O
also O O
found O O
in O O
2 O O
. O O

8 O O
% O O
of O O
the O O
general O O
population O O
, O O
suggesting O O
that O O
it O O
is O O
not O O
disease O O
associated O O
. O O

3 O O
and O O
37 O O
. O O

4 O O
years O O
, O O
whereas O O
the O O
family O O
harbouring O O
the O O
missense O O
mutation O O
had O O
an O O
average O O
age O O
of O O
onset O O
of O O
51 O O
. O O

2 O O
years O O
. O O

These O O
findings O O
show O O
that O O
BRCA1 O O
is O O
implicated O O
in O O
a O O
small O O
fraction O O
of O O
breast B B_DISEASE/B_GENE
/ I I_DISEASE/I_GENE
ovarian I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
families O O
suggesting O O
the O O
involvement O O
of O O
another O O
susceptibility O O
gene O O
( O O
s O O
) O O

Paternal O O
transmission O O
of O O
congenital B B_DISEASE
myotonic I I_DISEASE
dystrophy I I_DISEASE
. O O

We O O
report O O
a O O
rare O O
case O O
of O O
paternally O O
transmitted O O
congenital B B_DISEASE
myotonic I I_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_DISEASE/B_GENE
) O O
. O O

The O O
proband O O
is O O
a O O
23 O O
year O O
old O O
, O O
mentally B B_PERSON/B_DISEASE
retarded I I_PERSON/I_DISEASE
male O O
who O O
suffers O O
severe O O
muscular B B_DISEASE
weakness I I_DISEASE
. O O

His O O
two O O
sibs O O
suffer O O
from O O
childhood O O
onset O O
DM B B_DISEASE
. O O

Their O O
late O O
father O O
had O O
the O O
adult O O
type O O
of O O
DM B B_DISEASE/B_GENE
, O O
with O O
onset O O
around O O
30 O O
years O O
. O O

Only O O
six O O
other O O
cases O O
of O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
have O O
been O O
reported O O
recently O O
. O O

We O O
review O O
the O O
sex O O
related O O
effects O O
on O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
. O O

Decreased O O
fertility O O
of O O
males O O
with O O
adult O O
onset O O
DM B B_DISEASE/B_GENE
and O O
contraction O O
of O O
the O O
repeat O O
upon O O
male O O
transmission O O
contribute O O
to O O
the O O
almost O O
absent O O
occurrence O O
of O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE/B_GENE
DM I I_DISEASE/I_GENE
. O O

Also O O
the O O
fathers O O
of O O
the O O
reported O O
congenitally O O
affected O O
children O O
showed O O
, O O
on O O
average O O
, O O
shorter O O
CTG O O
repeat O O
lengths O O
and O O
hence O O
less O O
severe O O
clinical O O
symptoms O O
than O O
the O O
mothers O O
of O O
children O O
with O O
congenital B B_DISEASE/B_PERSON
DM I I_DISEASE/I_PERSON
. O O

We O O
conclude O O
that O O
paternal O O
transmission O O
of O O
congenital B B_DISEASE
DM I I_DISEASE
is O O
rare O O
and O O
preferentially O O
occurs O O
with O O
onset O O
of O O
DM B B_DISEASE
past O O
30 O O
years O O
in O O
the O O
father O O
. O O
. O O

The O O
RB1 O O
gene O O
mutation O O
in O O
a O O
child O O
with O O
ectopic B B_DISEASE
intracranial I I_DISEASE
retinoblastoma I I_DISEASE
. O O

The O O
RB1 O O
gene O O
mutation O O
was O O
investigated O O
in O O
a O O
child O O
with O O
ectopic B B_DISEASE
intracranial I I_DISEASE
retinoblastoma I I_DISEASE
using O O
DNA O O
obtained O O
from O O
both O O
the O O
pineal B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
retinal I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
tumours I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O O
the O O
patient O O
. O O

A O O
nonsense O O
mutation O O
in O O
exon O O
17 O O
( O O
codon O O
556 O O
) O O
of O O
the O O
RB1 O O
gene O O
was O O
found O O
to O O
be O O
present O O
homozygously O O
in O O
both O O
the O O
retinal B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
the I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pineal I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tumours I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O

The O O
mutation O O
is O O
in O O
an O O
area O O
of O O
the O O
gene O O
that O O
encodes O O
the O O
protein O O
- O O
binding O O
region O O
known O O
as O O
the O O
pocket O O
region O O
and O O
has O O
been O O
detected O O
in O O
other O O
cases O O
of O O
retinoblastoma B B_DISEASE
. O O
. O O

Low O O
levels O O
of O O
beta O O
hexosaminidase O O
A O O
in O O
healthy O O
individuals O O
with O O
apparent O O
deficiency O O
of O O
this O O
enzyme O O
. O O

Appreciable O O
beta O O
hexosaminidase O O
A O O
( O O
hex O O
A O O
) O O
activity O O
has O O
been O O
detected O O
in O O
cultured O O
skin O O
fibroblasts O O
and O O
melanoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O O
from O O
healthy O O
individuals O O
previously O O
reported O O
as O O
having O O
deficiency B B_ENZYME[GENE]/B_DISEASE
of I I_ENZYME[GENE]/I_DISEASE
hex I I_ENZYME[GENE]/I_DISEASE
A I I_ENZYME[GENE]/I_DISEASE
activity O O
indistinguishable O O
from O O
that O O
of O O
patients O O
with O O
Tay B B_DISEASE
- I I_DISEASE
Sachs I I_DISEASE
disease I I_DISEASE
( O O
TSD B B_MEASURE/B_DISEASE
) O O
. O O

Identification O O
and O O
quantitation O O
of O O
hex O O
A O O
, O O
amounting O O
to O O
3 O O
. O O

5 O O
% O O
- O O
6 O O
. O O

9 O O
% O O
of O O
total O O
beta O O
hexosaminidase O O
activity O O
, O O
has O O
been O O
obtained O O
by O O
cellulose O O
acetate O O
gel O O
electrophoresis O O
, O O
DEAE O O
- O O
cellulose O O
ion O O
- O O
exchange O O
chromatography O O
, O O
radial O O
immunodiffusion O O
, O O
and O O
radioimmunoassay O O
. O O

Previous O O
family O O
studies O O
suggested O O
that O O
these O O
individuals O O
may O O
be O O
compound O O
heterozygotes O O
for O O
the O O
common O O
mutant O O
TSD B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
and O O
a O O
rare O O
( O O
allelic O O
) O O
mutant O O
gene O O
. O O

Thus O O
, O O
the O O
postulated O O
rate O O
mutant O O
gene O O
appears O O
to O O
code O O
for O O
the O O
expression O O
of O O
low O O
amounts O O
of O O
hex O O
A O O
. O O

Heterozygotes O O
for O O
the O O
rare O O
mutant O O
may O O
be O O
indistinguishable O O
from O O
heterozygotes O O
for O O
the O O
common O O
TSD B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant O O
. O O

However O O
, O O
direct O O
visualization O O
and O O
quantitation O O
of O O
hex O O
A O O
by O O
the O O
methods O O
described O O
may O O
prevent O O
false O O
- O O
positive O O
prenatal O O
diagnosis O O
of O O
TSD B B_DISEASE
in O O
fetuses O O
having O O
the O O
incomplete O O
hex B B_DISEASE/B_GENE
A I I_DISEASE/I_GENE
deficiency I I_DISEASE/I_GENE
of O O
the O O
type O O
described O O
in O O
the O O
four O O
healthy O O
individuals O O

The O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
suppressor O O
gene O O
Smad4 O O
/ O O
Dpc4 O O
is O O
required O O
for O O
gastrulation O O
and O O
later O O
for O O
anterior O O
development O O
of O O
the O O
mouse O O
embryo O O
. O O

Mutations O O
in O O
the O O
SMAD4 O O
/ O O
DPC4 O O
tumor B B_DISEASE/B_GENE
suppressor O O
gene O O
, O O
a O O
key O O
signal O O
transducer O O
in O O
most O O
TGFbeta O O
- O O
related O O
pathways O O
, O O
are O O
involved O O
in O O
50 O O
% O O
of O O
pancreatic B B_DISEASE/B_PERSON
cancers I I_DISEASE/I_PERSON
. O O

Homozygous O O
Smad4 O O
mutant O O
mice O O
die O O
before O O
day O O
7 O O
. O O

5 O O
of O O
embryogenesis O O
. O O

Growth B B_DISEASE_ADJECTIVE[DISEASE]
retardation I I_DISEASE_ADJECTIVE[DISEASE]
of O O
the O O
Smad4 O O
- O O
deficient O O
embryos O O
results O O
from O O
reduced O O
cell O O
proliferation O O
rather O O
than O O
increased O O
apoptosis O O
. O O

Aggregation O O
of O O
mutant O O
Smad4 O O
ES O O
cells O O
with O O
wild O O
- O O
type O O
tetraploid O O
morulae O O
rescues O O
the O O
gastrulation B B_DISEASE_ADJECTIVE[DISEASE]
defect I I_DISEASE_ADJECTIVE[DISEASE]
. O O

These O O
results O O
indicate O O
that O O
Smad4 O O
is O O
initially O O
required O O
for O O
the O O
differentiation O O
of O O
the O O
visceral O O
endoderm O O
and O O
that O O
the O O
gastrulation B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O O
the O O
epiblast O O
is O O
secondary O O
and O O
non O O
- O O
cell O O
autonomous O O
. O O

Prevalence O O
of O O
p16 O O
and O O
CDK4 O O
germline O O
mutations O O
in O O
48 O O
melanoma B B_DISEASE
- O O
prone O O
families O O
in O O
France O O
. O O

The O O
French O O
Familial B B_DISEASE/B_LOCATION
Melanoma I I_DISEASE/I_LOCATION
Study O O
Group O O
. O O

Germline O O
mutations O O
in O O
the O O
p16 O O
and O O
CDK4 O O
genes O O
have O O
been O O
reported O O
in O O
a O O
subset O O
of O O
melanoma B B_DISEASE/B_LOCATION
pedigrees O O
, O O
but O O
their O O
prevalence O O
is O O
not O O
well O O
known O O
. O O

We O O
searched O O
for O O
such O O
germline O O
mutations O O
in O O
48 O O
French O O
melanoma B B_DISEASE/B_LOCATION
- O O
prone O O
families O O
selected O O
according O O
to O O
two O O
major O O
criteria O O
families O O
with O O
at O O
least O O
three O O
affected O O
members O O
( O O
n O O
= O O
20 O O
) O O
or O O
families O O
with O O
two O O
affected O O
members O O
, O O
one O O
of O O
them O O
affected O O
before O O
the O O
age O O
of O O
50 O O
( O O
n O O
= O O
28 O O
) O O
, O O
and O O
one O O
additional O O
minor O O
criterion O O
. O O

In O O
summary O O
, O O
our O O
results O O
show O O
frequent O O
involvement O O
of O O
the O O
p16 O O
gene O O
in O O
familial B B_DISEASE
melanoma I I_DISEASE
and O O
confirm O O
the O O
role O O
of O O
the O O
CDK4 O O
gene O O
as O O
a O O
melanoma B B_DISEASE
- O O
predisposing O O
gene O O
. O O
. O O

Progression O O
of O O
somatic O O
CTG O O
repeat O O
length O O
heterogeneity O O
in O O
the O O
blood O O
cells O O
of O O
myotonic B B_DISEASE/B_LOCATION
dystrophy I I_DISEASE/I_LOCATION
patients O O
. O O

One O O
of O O
the O O
principal O O
features O O
of O O
the O O
DM B B_DISEASE/B_GENE
mutation O O
is O O
an O O
extraordinarily O O
high O O
level O O
of O O
somatic O O
mosaicism O O
, O O
due O O
to O O
an O O
extremely O O
high O O
degree O O
of O O
somatic O O
instability O O
both O O
within O O
and O O
between O O
different O O
tissues O O
. O O

In O O
order O O
to O O
further O O
characterize O O
the O O
dynamics O O
of O O
DM B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
CTG O O
repeat O O
somatic O O
instability O O
, O O
we O O
have O O
studied O O
repeat O O
length O O
changes O O
over O O
time O O
in O O
111 O O
myotonic B B_DISEASE
dystrophy I I_DISEASE
patients O O
with O O
varying O O
clinical O O
severity O O
and O O
CTG O O
repeat O O
size O O
over O O
time O O
intervals O O
of O O
1 O O
- O O
7 O O
years O O
. O O

We O O
have O O
found O O
a O O
direct O O
progression O O
of O O
the O O
size O O
heterogeneity O O
over O O
time O O
related O O
to O O
initial O O
CTG O O
repeat O O
size O O
and O O
the O O
time O O
interval O O
and O O
always O O
biased O O
towards O O
further O O
expansion O O
. O O

Aspartylglucosaminuria B B_DISEASE
among O O
Palestinian O O
Arabs O O
. O O

AGU B B_DISEASE
is O O
inherited O O
as O O
an O O
autosomal O O
recessive O O
trait O O
and O O
occurs O O
with O O
a O O
high O O
frequency O O
in O O
Finland O O
because O O
of O O
a O O
founder O O
effect O O
. O O

While O O
very O O
few O O
patients O O
with O O
AGU B B_DISEASE/B_LOCATION
have O O
been O O
reported O O
from O O
non O O
- O O
Finnish O O
origin O O
, O O
we O O
diagnosed O O
the O O
disorder O O
in O O
8 O O
patients O O
originating O O
from O O
3 O O
unrelated O O
families O O
, O O
all O O
Palestinian O O
Arabs O O
from O O
the O O
region O O
of O O
Jerusalem O O
. O O

The O O
clinical O O
diagnosis O O
of O O
AGU B B_DISEASE/B_LOCATION
is O O
often O O
difficult O O
, O O
in O O
particular O O
early O O
in O O
the O O
course O O
of O O
the O O
disease O O
, O O
and O O
most O O
of O O
the O O
patients O O
are O O
diagnosed O O
after O O
the O O
age O O
of O O
5 O O
years O O
. O O

However O O
, O O
since O O
these O O
patients O O
excrete O O
early O O
large O O
amounts O O
of O O
aspartylglucosamine O O
in O O
urine O O
, O O
biochemical O O
screening O O
is O O
easy O O
by O O
urine O O
chromatography O O
. O O
. O O

Detection O O
of O O
heterozygous O O
carriers O O
of O O
the O O
ataxia B B_DISEASE/B_GENE
- I B_DISEASE/I_GENE
telangiectasia I B_DISEASE/I_GENE
( O O
ATM O O
) O O
gene O O
by O O
G2 O O
phase O O
chromosomal O O
radiosensitivity O O
of O O
peripheral O O
blood O O
lymphocytes O O
. O O

Heterozygotes O O
for O O
the O O
ATM O O
gene O O
have O O
no O O
clinical O O
expression O O
of O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O O
may O O
be O O
cancer B B_DISEASE/B_GENE
prone O O
with O O
a O O
moderate O O
increase O O
in O O
in O O
vitro O O
radiosensitivity O O
. O O

In O O
combination O O
with O O
molecular O O
genetic O O
analyses O O
, O O
this O O
test O O
may O O
be O O
of O O
value O O
in O O
studies O O
of O O
familial B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
sporadic I I_DISEASE/I_LOCATION
cancers I I_DISEASE/I_LOCATION
aimed O O
at O O
determination O O
of O O
the O O
potential O O
involvement O O
of O O
ATM O O
mutations O O
in O O
tumor B B_DISEASE/B_LOCATION
risk O O
or O O
development O O
. O O
. O O

Ataxia B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O O
identification O O
and O O
detection O O
of O O
founder O O
- O O
effect O O
mutations O O
in O O
the O O
ATM O O
gene O O
in O O
ethnic O O
populations O O
. O O

Both O O
genomic O O
mutations O O
and O O
their O O
effects O O
on O O
cDNA O O
were O O
characterized O O
. O O

Assays O O
requiring O O
minimal O O
amounts O O
of O O
genomic O O
DNA O O
were O O
designed O O
to O O
allow O O
rapid O O
screening O O
for O O
common O O
ethnic O O
mutations O O
. O O

Additional O O
mutations O O
were O O
observed O O
in O O
Japanese O O
, O O
Utah O O
Mormon O O
, O O
and O O
African O O
American O O
patients O O
. O O

These O O
assays O O
should O O
facilitate O O
screening O O
for O O
A B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O O
in O O
the O O
populations O O
studied O O
. O O
. O O

The O O
von B B_DISEASE/B_GENE
Hippel I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Lindau I I_DISEASE/I_GENE
tumor I I_DISEASE/I_GENE
suppressor O O
gene O O
is O O
required O O
for O O
cell O O
cycle O O
exit O O
upon O O
serum O O
withdrawal O O
. O O

VHL O O
- O O
negative O O
786 O O
- O O
0 O O
RCC B B_DISEASE
cells O O
are O O
tumorigenic O O
in O O
nude O O
mice O O
which O O
is O O
suppressed O O
by O O
the O O
reintroduction O O
of O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O O

Remarkably O O
, O O
this O O
occurs O O
without O O
affecting O O
the O O
growth O O
rate O O
and O O
cell O O
cycle O O
profile O O
of O O
these O O
cells O O
in O O
culture O O
. O O

The O O
786 O O
- O O
0 O O
cell O O
line O O
, O O
like O O
many O O
cancer B B_DISEASE
cells O O
, O O
fails O O
to O O
exit O O
the O O
cell O O
cycle O O
upon O O
serum O O
withdrawal O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
reintroduction O O
of O O
the O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
restores O O
the O O
ability O O
of O O
VHL O O
- O O
negative O O
RCC B B_DISEASE
cancer I I_DISEASE
cells O O
to O O
exit O O
the O O
cell O O
cycle O O
and O O
enter O O
G0 O O
/ O O
quiescence O O
in O O
low O O
serum O O
. O O

Both O O
VHL O O
- O O
positive O O
and O O
VHL O O
- O O
negative O O
RCC B B_DISEASE
cells O O
exit O O
the O O
cell O O
cycle O O
by O O
contact O O
inhibition O O
. O O

The O O
cyclin O O
- O O
dependent O O
kinase O O
inhibitor O O
, O O
p27 O O
, O O
accumulates O O
upon O O
serum O O
withdrawal O O
, O O
only O O
in O O
the O O
presence O O
of O O
VHL B B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
as O O
a O O
result O O
of O O
the O O
stabilization O O
of O O
the O O
protein O O
. O O

We O O
propose O O
that O O
the O O
loss O O
of O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
results O O
in O O
a O O
specific O O
cellular O O
defect O O
in O O
serum O O
- O O
dependent O O
growth O O
control O O
, O O
which O O
may O O
initiate O O
tumor B B_DISEASE
formation O O
. O O

This O O
is O O
corrected O O
by O O
the O O
reintroduction O O
of O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O O
implicating O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O O
the O O
first O O
tumor B B_DISEASE/B_GENE
suppressor O O
involved O O
in O O
the O O
regulation O O
of O O
cell O O
cycle O O
exit O O
, O O
which O O
is O O
consistent O O
with O O
its O O
gatekeeper O O
function O O
in O O
the O O
kidney O O
. O O
. O O

Piebaldism B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
with O O
deafness B B_DISEASE
: O O
molecular O O
evidence O O
for O O
an O O
expanded O O
syndrome O O
. O O

In O O
a O O
South O O
African O O
girl O O
of O O
Xhosa O O
stock O O
with O O
severe O O
piebaldism B B_DISEASE
and O O
profound O O
congenital O O
sensorineural B B_DISEASE
deafness I I_DISEASE
we O O
identified O O
a O O
novel O O
missense O O
substitution O O
at O O
a O O
highly O O
conserved O O
residue O O
in O O
the O O
intracellular O O
kinase O O
domain O O
of O O
the O O
KIT O O
proto O O
- O O
oncogene O O
, O O
R796G O O
. O O

Though O O
auditory B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anomalies I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O O
been O O
observed O O
in O O
mice O O
with O O
dominant O O
white O O
spotting O O
( O O
W O O
) O O
due O O
to O O
KIT O O
mutations O O
, O O
deafness B B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O O
not O O
typical O O
in O O
human O O
piebaldism B B_DISEASE/B_PERSON
. O O

Thus O O
, O O
the O O
occurrence O O
of O O
sensorineural B B_DISEASE/B_GENE
deafness I I_DISEASE/I_GENE
in O O
this O O
patient O O
extends O O
considerably O O
the O O
phenotypic O O
range O O
of O O
piebaldism B B_DISEASE/B_MEASURE
due O O
to O O
KIT O O
gene O O
mutation O O
in O O
humans O O
and O O
tightens O O
the O O
clinical O O
similarity O O
between O O
piebaldism B B_DISEASE/B_PERSON
and O O
the O O
various O O
forms O O
of O O
Waardenburg B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
. O O
. O O

Cycloheximide O O
facilitates O O
the O O
identification O O
of O O
aberrant O O
transcripts O O
resulting O O
from O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
. O O

Patients O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
often O O
show O O
decreased O O
expression O O
of O O
type O O
XVII O O
collagen O O
, O O
a O O
transmembrane O O
hemidesmosomal O O
protein O O
encoded O O
by O O
COL17A1 O O
. O O

This O O
report O O
documents O O
a O O
novel O O
splice O O
- O O
site O O
mutation O O
in O O
COL17A1 O O
in O O
a O O
patient O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
, O O
and O O
applies O O
a O O
new O O
methodology O O
to O O
define O O
and O O
characterize O O
the O O
resulting O O
mRNA O O
splice O O
variants O O
. O O

Mutational O O
analysis O O
of O O
COL17A1 O O
identified O O
a O O
maternally O O
inherited O O
G O O
- O O
to O O
- O O
T O O
transversion O O
at O O
the O O
- O O
1 O O
position O O
of O O
exon O O
32 O O
. O O

This O O
acceptor O O
splice O O
- O O
site O O
mutation O O
led O O
to O O
the O O
formation O O
of O O
aberrant O O
transcripts O O
present O O
at O O
extremely O O
low O O
levels O O
. O O

5 O O
h O O
in O O
the O O
presence O O
or O O
absence O O
of O O
10 O O
microg O O
cycloheximide O O
per O O
ml O O
. O O

Using O O
this O O
approach O O
, O O
an O O
abnormally O O
spliced O O
transcript O O
was O O
identified O O
that O O
contains O O
an O O
extra O O
264 O O
bases O O
upstream O O
from O O
exon O O
32 O O
, O O
resulting O O
in O O
a O O
premature O O
termination O O
codon O O
27 O O
bp O O
downstream O O
from O O
the O O
cryptic O O
splice O O
site O O
. O O

Three O O
other O O
splice O O
variants O O
, O O
including O O
one O O
derived O O
from O O
the O O
skipping O O
of O O
exon O O
32 O O
, O O
were O O
also O O
identified O O
. O O

A O O
deletion O O
mutation O O
in O O
COL17A1 O O
in O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B B_DISEASE/B_GENE
benign I I_DISEASE/I_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
represents O O
propagation O O
of O O
an O O
ancestral O O
allele O O
. O O

Patients O O
with O O
generalized O O
atrophic B B_DISEASE
benign I I_DISEASE
epidermolysis I I_DISEASE
bullosa I I_DISEASE
, O O
a O O
usually O O
nonlethal O O
form O O
of O O
junctional B B_DISEASE/B_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
, O O
have O O
generalized O O
blistering B B_DISEASE
, O O
nail B B_DISEASE
dystrophy I I_DISEASE
, O O
patchy B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
alopecia I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
dental B B_DISEASE
abnormalities I I_DISEASE
. O O

Skin B B_DISEASE/B_GENE
fragility I I_DISEASE/I_GENE
in O O
most O O
cases O O
is O O
due O O
to O O
mutations O O
in O O
the O O
gene O O
encoding O O
type O O
XVII O O
collagen O O
( O O
COL17A1 O O
) O O
. O O

Recently O O
, O O
we O O
reported O O
five O O
Austrian O O
families O O
with O O
generalized O O
atrophic B B_DISEASE/B_GENE
benign I I_DISEASE/I_GENE
epidermolysis I I_DISEASE/I_GENE
bullosa I I_DISEASE/I_GENE
who O O
share O O
the O O
same O O
COL17A1 O O
mutation O O
. O O

Affected O O
individuals O O
in O O
three O O
families O O
are O O
homozygous O O
for O O
4003delTC O O
, O O
whereas O O
those O O
in O O
two O O
others O O
are O O
compound O O
heterozygotes O O
. O O

Five O O
intragenic O O
polymorphisms O O
were O O
chosen O O
based O O
on O O
their O O
informativeness O O
. O O

One O O
of O O
these O O
, O O
not O O
previously O O
reported O O
, O O
was O O
2988 O O
A O O
or O O
C O O
that O O
introduces O O
a O O
new O O
restriction O O
site O O
for O O
Eco0109 O O
I O O
. O O

All O O
the O O
4003delTC O O
alleles O O
showed O O
the O O
same O O
haplotype O O
for O O
these O O
five O O
polymorphic O O
markers O O
. O O

Fourteen O O
microsatellite O O
polymorphisms O O
were O O
selected O O
based O O
on O O
their O O
high O O
heterozygosity O O
and O O
their O O
location O O
within O O
10q23 O O
- O O
q25 O O
near O O
COL17A1 O O
. O O

These O O
results O O
indicate O O
that O O
4003delTC O O
occurs O O
on O O
a O O
single O O
ancestral O O
allele O O
. O O
. O O

The O O
haptoglobin O O
- O O
gene O O
deletion O O
responsible O O
for O O
anhaptoglobinemia B B_DISEASE
. O O

We O O
have O O
found O O
an O O
allelic O O
deletion O O
of O O
the O O
haptoglobin O O
( O O
Hp O O
) O O
gene O O
from O O
an O O
individual O O
with O O
anhaptoglobinemia B B_DISEASE/B_LOCATION
. O O

The O O
Hp O O
gene O O
cluster O O
consists O O
of O O
coding O O
regions O O
of O O
the O O
alpha O O
chain O O
and O O
beta O O
chain O O
of O O
the O O
haptoglobin O O
gene O O
( O O
Hp O O
) O O
and O O
of O O
the O O
alpha O O
chain O O
and O O
beta O O
chain O O
of O O
the O O
haptoglobin O O
- O O
related O O
gene O O
( O O
Hpr O O
) O O
, O O
in O O
tandem O O
from O O
the O O
5 O O
side O O
. O O

Southern O O
blot O O
and O O
PCR O O
analyses O O
have O O
indicated O O
that O O
the O O
individual O O
with O O
anhaptoglobinemia B B_DISEASE
was O O
homozygous O O
for O O
the O O
gene O O
deletion O O
and O O
that O O
the O O
gene O O
deletion O O
was O O
included O O
at O O
least O O
from O O
the O O
promoter O O
region O O
of O O
Hp O O
to O O
Hpr O O
alpha O O
but O O
not O O
to O O
Hpr O O
beta O O
( O O
Hpdel O O
) O O
. O O

In O O
addition O O
, O O
we O O
found O O
seven O O
individuals O O
with O O
hypohaptoglobinemia B B_DISEASE
in O O
three O O
families O O
, O O
and O O
the O O
genotypes O O
of O O
six O O
of O O
the O O
seven O O
individuals O O
were O O
found O O
to O O
be O O
Hp2 O O
/ O O
Hpdel O O
. O O

The O O
phenotypes O O
and O O
genotypes O O
in O O
one O O
of O O
these O O
three O O
families O O
showed O O
the O O
father O O
to O O
be O O
hypohaptoglobinemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
the O O
mother O O
to O O
be O O
Hp2 O O
- O O
1 O O
and O O
Hp1 O O
/ O O
Hp2 O O
, O O
one O O
of O O
the O O
two O O
children O O
to O O
be O O
hypohaptoglobinemic B B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O O
Hp2 O O
) O O
and O O
Hp2 O O
/ O O
Hpdel O O
, O O
and O O
the O O
other O O
child O O
to O O
be O O
Hp1 O O
and O O
Hp1 O O
/ O O
Hpdel O O
, O O
showing O O
an O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
in O O
the O O
child O O
with O O
Hp1 O O
. O O

50 O O
mg O O
/ O O
ml O O
, O O
which O O
was O O
approximately O O
half O O
the O O
level O O
of O O
Hp O O
in O O
control O O
sera O O
from O O
the O O
Hp1 O O
phenotype O O
( O O
1 O O
. O O
26 O O
+ O O
/ O O
- O O
0 O O
. O O
33 O O
mg O O
/ O O
ml O O
; O O
n O O
= O O
9 O O
) O O
, O O
showing O O
a O O
gene O O
- O O
dosage O O
effect O O
. O O

On O O
the O O
basis O O
of O O
the O O
present O O
study O O
, O O
the O O
mechanism O O
of O O
anhaptoglobinemia B B_DISEASE/B_GENE
and O O
the O O
mechanism O O
of O O
anomalous O O
inheritance O O
of O O
Hp O O
phenotypes O O
were O O
well O O
explained O O
. O O

However O O
, O O
the O O
mechanism O O
of O O
hypohaptoglobinemia B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O O
unknown O O

ATM O O
mutations O O
and O O
phenotypes O O
in O O
ataxia B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
telangiectasia I B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O O
in O O
the O O
British O O
Isles O O
: O O
expression O O
of O O
mutant O O
ATM O O
and O O
the O O
risk O O
of O O
leukemia B B_DISEASE
, O O
lymphoma B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
breast B B_DISEASE
cancer I I_DISEASE
. O O

Of O O
51 O O
ATM O O
mutations O O
identified O O
in O O
families O O
native O O
to O O
the O O
British O O
Isles O O
, O O
11 O O
were O O
founder O O
mutations O O
, O O
and O O
2 O O
of O O
these O O
11 O O
conferred O O
a O O
milder O O
clinical O O
phenotype O O
with O O
respect O O
to O O
both O O
cerebellar B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degeneration I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
cellular O O
features O O
. O O

In O O
addition O O
, O O
we O O
have O O
studied O O
18 O O
A B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
T I I_DISEASE/I_MEASURE
patients O O
, O O
in O O
15 O O
families O O
, O O
who O O
developed O O
leukemia B B_DISEASE
, O O
lymphoma B B_DISEASE
, O O
preleukemic O O
T O O
- O O
cell O O
proliferation O O
, O O
or O O
Hodgkin B B_DISEASE
lymphoma I I_DISEASE
, O O
mostly O O
in O O
childhood O O
. O O

We O O
also O O
show O O
that O O
25 O O
% O O
of O O
all O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
carried O O
in O O
- O O
frame O O
deletions O O
or O O
missense O O
mutations O O
, O O
many O O
of O O
which O O
were O O
also O O
associated O O
with O O
expression O O
of O O
mutant O O
ATM O O
protein O O
. O O

The O O
DMPK O O
gene O O
of O O
severely O O
affected O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
patients O O
is O O
hypermethylated O O
proximal O O
to O O
the O O
largely O O
expanded O O
CTG O O
repeat O O
. O O

Using O O
methylation O O
- O O
sensitive O O
restriction O O
enzymes O O
, O O
we O O
characterized O O
the O O
methylation O O
pattern O O
on O O
the O O
5 O O
side O O
of O O
the O O
CTG O O
repeat O O
in O O
the O O
DMPK O O
gene O O
of O O
normal O O
individuals O O
and O O
of O O
patients O O
affected O O
with O O
myotonic B B_DISEASE/B_GENE
dystrophy I I_DISEASE/I_GENE
, O O
showing O O
expansions O O
of O O
the O O
repetitive O O
sequence O O
. O O

The O O
gene O O
segment O O
analyzed O O
corresponds O O
to O O
the O O
genomic O O
SacI O O
- O O
HindIII O O
fragment O O
carrying O O
exons O O
11 O O
- O O
15 O O
. O O

There O O
is O O
constitutive O O
methylation O O
in O O
intron O O
12 O O
at O O
restriction O O
sites O O
of O O
SacII O O
and O O
HhaI O O
, O O
localized O O
1 O O
, O O
159 O O
- O O
1 O O
, O O
232 O O
bp O O
upstream O O
of O O
the O O
CTG O O
repeat O O
, O O
whereas O O
most O O
, O O
if O O
not O O
all O O
, O O
of O O
the O O
other O O
sites O O
of O O
SacII O O
, O O
HhaI O O
, O O
and O O
HpaII O O
in O O
this O O
region O O
are O O
unmethylated O O
, O O
in O O
normal O O
individuals O O
and O O
most O O
of O O
the O O
patients O O
. O O

In O O
a O O
number O O
of O O
young O O
and O O
severely O O
affected O O
patients O O
, O O
however O O
, O O
complete O O
methylation O O
of O O
these O O
restriction O O
sites O O
was O O
found O O
in O O
the O O
mutated O O
allele O O
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O O
product O O
complexes O O
with O O
the O O
transferrin O O
receptor O O
and O O
lowers O O
its O O
affinity O O
for O O
ligand O O
binding O O
. O O

We O O
recently O O
reported O O
the O O
positional O O
cloning O O
of O O
a O O
candidate O O
gene O O
for O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
called O O
HFE O O
. O O

This O O
mutation O O
eliminates O O
the O O
ability O O
of O O
HFE O O
to O O
associate O O
with O O
beta2 O O
- O O
microglobulin O O
( O O
beta2m O O
) O O
and O O
prevents O O
cell O O
- O O
surface O O
expression O O
. O O

The O O
C282Y O O
mutation O O
nearly O O
completely O O
prevents O O
the O O
association O O
of O O
the O O
mutant O O
HFE O O
protein O O
with O O
the O O
TfR O O
. O O

Studies O O
on O O
cell O O
- O O
associated O O
transferrin O O
at O O
37 O O
degrees O O
C O O
suggest O O
that O O
the O O
overexpressed O O
wild O O
- O O
type O O
HFE O O
protein O O
decreases O O
the O O
affinity O O
of O O
the O O
TfR O O
for O O
transferrin O O
. O O

Addition O O
of O O
soluble O O
wild O O
- O O
type O O
HFE O O
/ O O
beta2m O O
heterodimers O O
to O O
cultured O O
cells O O
also O O
decreased O O
the O O
apparent O O
affinity O O
of O O
the O O
TfR O O
for O O
its O O
ligand O O
under O O
steady O O
- O O
state O O
conditions O O
, O O
both O O
in O O
293 O O
cells O O
and O O
in O O
HeLa O O
cells O O
. O O

Furthermore O O
, O O
at O O
4 O O
degrees O O
C O O
, O O
the O O
added O O
soluble O O
complex O O
of O O
HFE O O
/ O O
beta2m O O
inhibited O O
binding O O
of O O
transferrin O O
to O O
HeLa O O
cell O O
TfR O O
in O O
a O O
concentration O O
- O O
dependent O O
manner O O
. O O

Scatchard O O
plots O O
of O O
these O O
data O O
indicate O O
that O O
the O O
added O O
heterodimer O O
substantially O O
reduced O O
the O O
affinity O O
of O O
TfR O O
for O O
transferrin O O
. O O

These O O
results O O
establish O O
a O O
molecular O O
link O O
between O O
HFE O O
and O O
a O O
key O O
protein O O
involved O O
in O O
iron O O
transport O O
, O O
the O O
TfR O O
, O O
and O O
raise O O
the O O
possibility O O
that O O
alterations O O
in O O
this O O
regulatory O O
mechanism O O
may O O
play O O
a O O
role O O
in O O
the O O
pathogenesis O O
of O O
hereditary B B_DISEASE
hemochromatosis I I_DISEASE
. O O
. O O

Genomic O O
organization O O
of O O
the O O
UBE3A O O
/ O O
E6 O O
- O O
AP O O
gene O O
and O O
related O O
pseudogenes O O
. O O

The O O
UBE3A O O
gene O O
encodes O O
the O O
E6 O O
- O O
AP O O
ubiquitin O O
- O O
protein O O
ligase O O
and O O
has O O
recently O O
been O O
shown O O
to O O
be O O
mutated O O
in O O
Angelman B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patients O O
who O O
lack O O
15q11 O O
- O O
q13 O O
deletions O O
or O O
chromosome O O
15 O O
paternal O O
uniparental B B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
disomy I I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O O

Previous O O
UBE3A O O
cDNA O O
analysis O O
has O O
shown O O
a O O
coding O O
region O O
of O O
approximately O O
2 O O
. O O

6 O O
kb O O
and O O
a O O
3 O O
- O O
untranslated O O
region O O
( O O
UTR O O
) O O
of O O
< O O
50 O O
bp O O
, O O
whereas O O
Northern O O
analysis O O
has O O
indicated O O
mRNA O O
sizes O O
of O O
5 O O
- O O
8 O O
kb O O
. O O

We O O
have O O
analyzed O O
additional O O
cDNA O O
clones O O
and O O
provide O O
evidence O O
for O O
an O O
additional O O
0 O O
. O O

5 O O
kb O O
of O O
5 O O
- O O
UTR O O
and O O
> O O
2 O O
kb O O
of O O
3 O O
- O O
UTR O O
. O O

We O O
have O O
established O O
the O O
genomic O O
organization O O
of O O
UBE3A O O
and O O
the O O
sequence O O
of O O
intron O O
- O O
exon O O
borders O O
. O O

We O O
have O O
also O O
mapped O O
two O O
highly O O
homologous O O
processed O O
pseudogenes O O
, O O
UBE3AP1 O O
and O O
UBE3AP2 O O
, O O
to O O
chromosomes O O
2 O O
and O O
21 O O
, O O
respectively O O
, O O
and O O
determined O O
their O O
genomic O O
organization O O
. O O

These O O
results O O
will O O
form O O
the O O
basis O O
for O O
studies O O
of O O
mutation O O
and O O
imprinting O O
of O O
UBE3A O O
. O O

Mutation O O
spectrum O O
and O O
genotype O O
- O O
phenotype O O
analyses O O
in O O
Cowden B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
and O O
Bannayan B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Zonana I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
, O O
two O O
hamartoma B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndromes I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O O
germline O O
PTEN O O
mutation O O
. O O

The O O
tumour B B_DISEASE/B_GENE
suppressor O O
gene O O
PTEN O O
, O O
which O O
maps O O
to O O
10q23 O O
. O O

3 O O
and O O
encodes O O
a O O
403 O O
amino O O
acid O O
dual O O
specificity O O
phosphatase O O
( O O
protein O O
tyrosine O O
phosphatase O O
; O O
PTPase O O
) O O
, O O
was O O
shown O O
recently O O
to O O
play O O
a O O
broad O O
role O O
in O O
human O O
malignancy B B_DISEASE
. O O

Somatic O O
PTEN O O
deletions O O
and O O
mutations O O
were O O
observed O O
in O O
sporadic B B_DISEASE
breast I I_DISEASE
, I I_DISEASE
brain I I_DISEASE
, I I_DISEASE
prostate I I_DISEASE
and I I_DISEASE
kidney I I_DISEASE
cancer I I_DISEASE
cell O O
lines O O
and O O
in O O
several O O
primary O O
tumours B B_DISEASE/B_LOCATION
such O O
as O O
endometrial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
malignant B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
melanoma I I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O O
thyroid B B_DISEASE
tumours I I_DISEASE
. O O

In O O
addition O O
, O O
PTEN O O
was O O
identified O O
as O O
the O O
susceptibility O O
gene O O
for O O
two O O
hamartoma B B_DISEASE
syndromes I I_DISEASE
Cowden B I_DISEASE
disease I I_DISEASE
( O O
CD B B_LOCATION/B_DISEASE
; O O
MIM O O
158350 O O
) O O
and O O
Bannayan B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Zonana I I_DISEASE/I_GENE
( I I_DISEASE/I_GENE
BZS I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
or I I_DISEASE/I_GENE
Ruvalcaba I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Riley I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
Smith I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
( O O
MIM O O
153480 O O
) O O
. O O

Constitutive O O
DNA O O
from O O
37 O O
CD B B_DISEASE
families O O
and O O
seven O O
BZS B B_DISEASE/B_LOCATION
families O O
was O O
screened O O
for O O
germline O O
PTEN O O
mutations O O
. O O

PTEN O O
mutations O O
were O O
identified O O
in O O
30 O O
of O O
37 O O
( O O
81 O O
% O O
) O O
CD B B_DISEASE
families O O
, O O
including O O
missense O O
and O O
nonsense O O
point O O
mutations O O
, O O
deletions O O
, O O
insertions O O
, O O
a O O
deletion O O
/ O O
insertion O O
and O O
splice O O
site O O
mutations O O
. O O

A O O
hot O O
spot O O
for O O
PTEN O O
mutation O O
in O O
CD B B_DISEASE/B_LOCATION
was O O
identified O O
in O O
exon O O
5 O O
that O O
contains O O
the O O
PTPase O O
core O O
motif O O
, O O
with O O
13 O O
of O O
30 O O
( O O
43 O O
% O O
) O O
CD B B_DISEASE/B_GENE
mutations O O
identified O O
in O O
this O O
exon O O
. O O

Seven O O
of O O
30 O O
( O O
23 O O
% O O
) O O
were O O
within O O
the O O
core O O
motif O O
, O O
the O O
majority O O
( O O
five O O
of O O
seven O O
) O O
of O O
which O O
were O O
missense O O
mutations O O
, O O
possibly O O
pointing O O
to O O
the O O
functional O O
significance O O
of O O
this O O
region O O
. O O

Germline O O
PTEN O O
mutations O O
were O O
identified O O
in O O
four O O
of O O
seven O O
( O O
57 O O
% O O
) O O
BZS B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O O
studied O O
. O O

It O O
is O O
also O O
worthy O O
of O O
note O O
that O O
a O O
single O O
nonsense O O
point O O
mutation O O
, O O
R233X O O
, O O
was O O
observed O O
in O O
the O O
germline O O
DNA O O
from O O
two O O
unrelated O O
CD B B_DISEASE/B_LOCATION
families O O
and O O
one O O
BZS B B_LOCATION/B_DISEASE
family O O
. O O

However O O
, O O
genotype O O
- O O
phenotype O O
analysis O O
inthe O O
group O O
of O O
CD B B_DISEASE/B_NUMBER[MEASURE]
families O O
revealed O O
two O O
possible O O
associations O O
worthy O O
of O O
follow O O
- O O
up O O
in O O
independent O O
analyses O O
. O O

Specifically O O
and O O
more O O
directly O O
, O O
an O O
association O O
was O O
also O O
observed O O
between O O
the O O
presence O O
of O O
a O O
PTEN O O
mutation O O
and O O
malignant B B_DISEASE/B_GENE
breast I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
. O O

However O O
, O O
these O O
observations O O
would O O
need O O
to O O
be O O
confirmed O O
by O O
studying O O
a O O
larger O O
number O O
of O O
CD B B_DISEASE/B_LOCATION
families O O
. O O

Molecular O O
defects O O
leading O O
to O O
human O O
complement B B_DISEASE
component I I_DISEASE
C6 I I_DISEASE
deficiency I I_DISEASE
in O O
an O O
African O O
- O O
American O O
family O O
. O O

Complement B B_DISEASE
component I I_DISEASE
C6 I I_DISEASE
deficiency I I_DISEASE
( O O
C6D B B_DISEASE/B_LOCATION
) O O
was O O
diagnosed O O
in O O
a O O
16 O O
- O O
year O O
- O O
old O O
African O O
- O O
American O O
male O O
with O O
meningococcal B B_DISEASE/B_GENE
meningitis I I_DISEASE/I_GENE
. O O

The O O
patients O O
father O O
and O O
two O O
brothers O O
also O O
had O O
C6D B B_DISEASE
, O O
but O O
gave O O
no O O
history O O
of O O
meningitis B B_DISEASE
or O O
other O O
neisserial B B_DISEASE_ADJECTIVE[DISEASE]
infection I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
first O O
, O O
1195delC O O
located O O
in O O
exon O O
7 O O
, O O
is O O
a O O
novel O O
mutation O O
, O O
while O O
the O O
second O O
, O O
1936delG O O
in O O
exon O O
12 O O
, O O
has O O
been O O
described O O
before O O
to O O
cause O O
C6D B B_DISEASE/B_GENE
in O O
an O O
unrelated O O
African O O
- O O
American O O
individual O O
. O O

PAX6 O O
mutations O O
reviewed O O
. O O

Mutations O O
in O O
PAX6 O O
are O O
responsible O O
for O O
human O O
aniridia B B_DISEASE/B_SPECIES[BIO]
and O O
have O O
also O O
been O O
found O O
in O O
patients O O
with O O
Peters B B_DISEASE
anomaly I I_DISEASE
, O O
with O O
congenital B B_DISEASE
cataracts I I_DISEASE
, O O
with O O
autosomal B B_DISEASE
dominant I I_DISEASE
keratitis I I_DISEASE
, O O
and O O
with O O
isolated B B_DISEASE
foveal I I_DISEASE
hypoplasia I I_DISEASE
. O O

No O O
locus O O
other O O
than O O
chromosome O O
11p13 O O
has O O
been O O
implicated O O
in O O
aniridia B B_DISEASE/B_SPECIES[BIO]
, O O
and O O
PAX6 O O
is O O
clearly O O
the O O
major O O
, O O
if O O
not O O
only O O
, O O
gene O O
responsible O O
. O O

Increased O O
mutation O O
in O O
the O O
homeodomain O O
is O O
accounted O O
for O O
by O O
the O O
hypermutable O O
CpG O O
dinucleotide O O
in O O
codon O O
240 O O
. O O

In O O
a O O
gene O O
with O O
such O O
extraordinarily O O
high O O
sequence O O
conservation O O
throughout O O
evolution O O
, O O
there O O
are O O
presumed O O
undiscovered O O
missense O O
mutations O O
, O O
these O O
are O O
hypothesized O O
to O O
exist O O
in O O
as O O
- O O
yet O O
unidentified O O
phenotypes O O
. O O
. O O

Genetic O O
heterogeneity O O
and O O
penetrance O O
analysis O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
genes O O
in O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cancer I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O O
. O O

The O O
contribution O O
of O O
BRCA1 O O
and O O
BRCA2 O O
to O O
inherited B B_DISEASE/B_GENE
breast I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
was O O
assessed O O
by O O
linkage O O
and O O
mutation O O
analysis O O
in O O
237 O O
families O O
, O O
each O O
with O O
at O O
least O O
four O O
cases O O
of O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
, O O
collected O O
by O O
the O O
Breast B B_DISEASE/B_LOCATION
Cancer I B_DISEASE/I_LOCATION
Linkage O O
Consortium O O
. O O

Families O O
were O O
included O O
without O O
regard O O
to O O
the O O
occurrence O O
of O O
ovarian B B_DISEASE
or I I_DISEASE
other I I_DISEASE
cancers I I_DISEASE
. O O

The O O
majority O O
( O O
81 O O
% O O
) O O
of O O
the O O
breast B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
ovarian I I_DISEASE_ADJECTIVE[DISEASE]
cancer I I_DISEASE_ADJECTIVE[DISEASE]
families O O
were O O
due O O
to O O
BRCA1 O O
, O O
with O O
most O O
others O O
( O O
14 O O
% O O
) O O
due O O
to O O
BRCA2 O O
. O O

Conversely O O
, O O
the O O
majority O O
of O O
families O O
with O O
male B B_DISEASE/B_LOCATION
and I I_DISEASE/I_LOCATION
female I I_DISEASE/I_LOCATION
breast I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
were O O
due O O
to O O
BRCA2 O O
( O O
76 O O
% O O
) O O
. O O

The O O
largest O O
proportion O O
( O O
67 O O
% O O
) O O
of O O
families O O
due O O
to O O
other O O
genes O O
was O O
found O O
in O O
families O O
with O O
four O O
or O O
five O O
cases O O
of O O
female O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
only O O
. O O

The O O
estimated O O
sensitivity O O
was O O
identical O O
for O O
direct O O
sequencing O O
and O O
other O O
techniques O O
. O O

The O O
estimated O O
cumulative O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
reached O O
28 O O
% O O
( O O
95 O O
% O O
CI O O
9 O O
% O O
- O O
44 O O
% O O
) O O
by O O
age O O
50 O O
years O O
and O O
84 O O
% O O
( O O
95 O O
% O O
CI O O
43 O O
% O O
- O O
95 O O
% O O
) O O
by O O
age O O
70 O O
years O O
. O O

The O O
corresponding O O
ovarian B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cancer I B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
risks O O
were O O
0 O O
. O O

4 O O
% O O
( O O
95 O O
% O O
CI O O
0 O O
% O O
- O O
1 O O
% O O
) O O
by O O
age O O
50 O O
years O O
and O O
27 O O
% O O
( O O
95 O O
% O O
CI O O
0 O O
% O O
- O O
47 O O
% O O
) O O
by O O
age O O
70 O O
years O O
. O O

The O O
lifetime O O
risk O O
of O O
breast B B_DISEASE
cancer I I_DISEASE
appears O O
similar O O
to O O
the O O
risk O O
in O O
BRCA1 O O
carriers O O
, O O
but O O
there O O
was O O
some O O
suggestion O O
of O O
a O O
lower O O
risk O O
in O O
BRCA2 O O
carriers O O
< O O
50 O O
years O O
of O O
age O O
. O O

Eye B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
movement I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
abnormalities I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
correlate O O
with O O
genotype O O
in O O
autosomal O O
dominant O O
cerebellar B B_DISEASE/B_PERSON
ataxia I I_DISEASE/I_PERSON
type I I_DISEASE/I_PERSON
I I I_DISEASE/I_PERSON
. O O

In O O
SCA1 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O O
saccade O O
amplitude O O
was O O
significantly O O
increased O O
, O O
resulting O O
in O O
hypermetria B B_DISEASE
. O O

In O O
SCA2 B B_DISEASE/B_TIME[MEASURE]
, O O
saccade O O
velocity O O
was O O
markedly O O
decreased O O
. O O

The O O
percentage O O
of O O
errors O O
in O O
antisaccades O O
was O O
greatly O O
increased O O
and O O
was O O
significantly O O
correlated O O
with O O
age O O
at O O
disease O O
onset O O
. O O

Three O O
major O O
criteria O O
, O O
saccade O O
amplitude O O
, O O
saccade O O
velocity O O
, O O
and O O
presence O O
of O O
gaze B B_DISEASE
- I I_DISEASE
evoked I I_DISEASE
nystagmus I I_DISEASE
, O O
permitted O O
the O O
correct O O
assignment O O
of O O
90 O O
% O O
of O O
the O O
SCA1 B B_DISEASE/B_PERSON
, O O
90 O O
% O O
of O O
the O O
SCA2 B B_DISEASE/B_PERSON
, O O
and O O
93 O O
% O O
of O O
the O O
patients O O
with O O
SCA3 B B_DISEASE/B_GENE
to O O
their O O
genetically O O
confirmed O O
patient O O
group O O
and O O
, O O
therefore O O
, O O
may O O
help O O
orient O O
diagnoses O O
of O O
SCA1 B B_DISEASE/B_GENE
, O O
SCA2 B B_DISEASE/B_GENE
, O O
and O O
SCA3 B B_DISEASE/B_PERSON
at O O
early O O
clinical O O
stages O O
of O O
the O O
diseases O O
. O O
. O O

Genetic O O
basis O O
and O O
molecular O O
mechanism O O
for O O
idiopathic B B_DISEASE
ventricular I I_DISEASE
fibrillation I I_DISEASE
. O O

Ventricular B B_DISEASE
fibrillation I I_DISEASE
causes O O
more O O
than O O
300 O O
, O O
000 O O
sudden O O
deaths O O
each O O
year O O
in O O
the O O
USA O O
alone O O
. O O

A O O
distinct O O
group O O
of O O
IVF B B_DISEASE/B_PERSON
patients O O
has O O
been O O
found O O
to O O
present O O
with O O
a O O
characteristic O O
electrocardiographic O O
pattern O O
. O O

Because O O
of O O
the O O
small O O
size O O
of O O
most O O
pedigrees O O
and O O
the O O
high O O
incidence O O
of O O
sudden B B_DISEASE
death I I_DISEASE
, O O
however O O
, O O
molecular O O
genetic O O
studies O O
of O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O O
not O O
yet O O
been O O
done O O
. O O

Because O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O O
cardiac O O
rhythm O O
disturbance O O
, O O
we O O
investigated O O
whether O O
malfunction O O
of O O
ion O O
channels O O
could O O
cause O O
the O O
disorder O O
by O O
studying O O
mutations O O
in O O
the O O
cardiac O O
sodium O O
channel O O
gene O O
SCN5A O O
. O O

We O O
have O O
now O O
identified O O
a O O
missense O O
mutation O O
, O O
a O O
splice O O
- O O
donor O O
mutation O O
, O O
and O O
a O O
frameshift O O
mutation O O
in O O
the O O
coding O O
region O O
of O O
SCN5A O O
in O O
three O O
IVF B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
families O O
. O O

Our O O
results O O
indicate O O
that O O
mutations O O
in O O
cardiac O O
ion O O
- O O
channel O O
genes O O
contribute O O
to O O
the O O
risk O O
of O O
developing O O
IVF B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O
. O O

Molecular O O
heterogeneity O O
in O O
mucopolysaccharidosis B B_DISEASE/B_LOCATION
IVA I I_DISEASE/I_LOCATION
in O O
Australia O O
and O O
Northern O O
Ireland O O
: O O
nine O O
novel O O
mutations O O
including O O
T312S O O
, O O
a O O
common O O
allele O O
that O O
confers O O
a O O
mild O O
phenotype O O
. O O

We O O
studied O O
mutations O O
in O O
the O O
GALNS O O
gene O O
from O O
23 O O
additional O O
MPS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
( O O
15 O O
from O O
Australia O O
, O O
8 O O
from O O
Northern O O
Ireland O O
) O O
, O O
with O O
various O O
clinical O O
phenotypes O O
( O O
severe O O
, O O
16 O O
cases O O
; O O
intermediate O O
, O O
4 O O
cases O O
; O O
mild O O
, O O
3 O O
cases O O
) O O
. O O

One O O
is O O
the O O
T312S O O
mutation O O
, O O
a O O
novel O O
mutation O O
found O O
exclusively O O
in O O
milder O O
patients O O
. O O

The O O
other O O
is O O
the O O
previously O O
described O O
I113F O O
that O O
produces O O
a O O
severe O O
phenotype O O
. O O

The O O
other O O
9 O O
novel O O
mutations O O
identified O O
in O O
these O O
23 O O
patients O O
were O O
each O O
limited O O
to O O
a O O
single O O
family O O
. O O

These O O
data O O
provide O O
further O O
evidence O O
for O O
extensive O O
allelic O O
heterogeneity O O
in O O
MPS B B_DISEASE/B_GENE
IVA I B_DISEASE/I_GENE
in O O
British O O
- O O
Irish O O
patients O O
and O O
provide O O
evidence O O
for O O
their O O
transmission O O
to O O
Australia O O
by O O
British O O
- O O
Irish O O
migrants O O
. O O
. O O

Identification O O
of O O
constitutional O O
WT1 O O
mutations O O
, O O
in O O
patients O O
with O O
isolated O O
diffuse B B_DISEASE/B_GENE
mesangial I I_DISEASE/I_GENE
sclerosis I I_DISEASE/I_GENE
, O O
and O O
analysis O O
of O O
genotype O O
/ O O
phenotype O O
correlations O O
by O O
use O O
of O O
a O O
computerized O O
mutation O O
database O O
. O O

Most O O
mutations O O
in O O
DDS B B_DISEASE/B_PERSON
patients O O
lie O O
in O O
exon O O
8 O O
or O O
exon O O
9 O O
, O O
encoding O O
zinc O O
finger O O
2 O O
or O O
zinc O O
finger O O
3 O O
, O O
respectively O O
, O O
with O O
a O O
hot O O
spot O O
( O O
R394W O O
) O O
in O O
exon O O
9 O O
. O O

We O O
analyzed O O
a O O
series O O
of O O
24 O O
patients O O
, O O
10 O O
with O O
isolated B B_DISEASE/B_GENE
DMS I I_DISEASE/I_GENE
( O O
IDMS B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
, O O
10 O O
with O O
DDS B B_DISEASE/B_LOCATION
, O O
and O O
4 O O
with O O
urogenital B B_DISEASE/B_PROTEIN[GENE]
abnormalities I B_DISEASE/I_PROTEIN[GENE]
and O O
/ O O
or O O
WT B B_DISEASE/B_GENE
. O O

We O O
report O O
WT1 O O
heterozygous O O
mutations O O
in O O
16 O O
patients O O
, O O
4 O O
of O O
whom O O
presented O O
with O O
IDMS B B_DISEASE
. O O

One O O
male O O
and O O
two O O
female O O
IDMS B B_DISEASE/B_PERSON
patients O O
with O O
WT1 O O
mutations O O
underwent O O
normal O O
puberty O O
. O O

Two O O
mutations O O
associated O O
with O O
IDMS B B_DISEASE
are O O
different O O
from O O
those O O
described O O
in O O
DDS B B_DISEASE/B_MEASURE
patients O O
. O O

No O O
WT1 O O
mutations O O
were O O
detected O O
in O O
the O O
six O O
other O O
IDMS B B_DISEASE/B_NUMBER[MEASURE]
patients O O
, O O
suggesting O O
genetic O O
heterogeneity O O
of O O
this O O
disease O O
. O O

This O O
demonstrated O O
( O O
1 O O
) O O
the O O
association O O
between O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
and O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O O
( O O
2 O O
) O O
among O O
patients O O
with O O
DMS B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
a O O
higher O O
frequency O O
of O O
exon O O
8 O O
mutations O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
female O O
phenotype O O
than O O
among O O
46 O O
, O O
XY O O
patients O O
with O O
sexual O O
ambiguity O O
or O O
male O O
phenotype O O
; O O
and O O
( O O
3 O O
) O O
statistically O O
significant O O
evidence O O
that O O
mutations O O
in O O
exons O O
8 O O
and O O
9 O O
preferentially O O
affect O O
amino O O
acids O O
with O O
different O O
functions O O
. O O
. O O

All O O
tested O O
Ashkenazi O O
mutation O O
carriers O O
share O O
the O O
same O O
allelic O O
pattern O O
at O O
the O O
BRCA1 O O
locus O O
. O O

We O O
extended O O
our O O
analysis O O
to O O
other O O
non O O
- O O
Ashkenazi O O
subsets O O
354 O O
of O O
Moroccan O O
origin O O
, O O
200 O O
Yemenites O O
and O O
150 O O
Iranian O O
Jews O O
. O O

Heteroduplex O O
analysis O O
complemented O O
by O O
direct O O
DNA O O
sequencing O O
of O O
abnormally O O
migrating O O
bands O O
were O O
employed O O
. O O

Four O O
of O O
Moroccan O O
origin O O
( O O
1 O O
. O O
1 O O
% O O
) O O
and O O
none O O
of O O
the O O
Yemenites O O
or O O
Iranians O O
was O O
a O O
carrier O O
of O O
the O O
185delAG O O
mutation O O
. O O

BRCA1 O O
allelic O O
patterns O O
were O O
determined O O
for O O
four O O
of O O
these O O
individuals O O
and O O
for O O
12 O O
additional O O
non O O
- O O
Ashkenazi O O
185delAG O O
mutation O O
carriers O O
who O O
had O O
breast B B_DISEASE
/ I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

We O O
conclude O O
that O O
the O O
185delAG O O
BRCA1 O O
mutation O O
occurs O O
in O O
some O O
non O O
- O O
Ashkenazi O O
populations O O
at O O
rates O O
comparable O O
with O O
that O O
of O O
Ashkenazim O O
. O O

The O O
majority O O
of O O
Jewish O O
185delAG O O
mutation O O
carriers O O
have O O
a O O
common O O
allelic O O
pattern O O
, O O
supporting O O
the O O
founder O O
effect O O
notion O O
, O O
but O O
dating O O
the O O
mutations O O
origin O O
to O O
an O O
earlier O O
date O O
than O O
currently O O
estimated O O
. O O

Crystal O O
structure O O
of O O
the O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O O
HFE O O
and O O
characterization O O
of O O
its O O
interaction O O
with O O
transferrin O O
receptor O O
. O O

HFE O O
is O O
an O O
MHC O O
- O O
related O O
protein O O
that O O
is O O
mutated O O
in O O
the O O
iron B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
overload I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hereditary B I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hemochromatosis I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

The O O
2 O O
. O O

6 O O
A O O
crystal O O
structure O O
of O O
HFE O O
reveals O O
the O O
locations O O
of O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O O
and O O
a O O
patch O O
of O O
histidines O O
that O O
could O O
be O O
involved O O
in O O
pH O O
- O O
dependent O O
interactions O O
. O O

We O O
also O O
demonstrate O O
that O O
soluble O O
TfR O O
and O O
HFE O O
bind O O
tightly O O
at O O
the O O
basic O O
pH O O
of O O
the O O
cell O O
surface O O
, O O
but O O
not O O
at O O
the O O
acidic O O
pH O O
of O O
intracellular O O
vesicles O O
. O O

TfR O O
HFE O O
stoichiometry O O
( O O
2 O O
1 O O
) O O
differs O O
from O O
TfR O O
transferrin O O
stoichiometry O O
( O O
2 O O
2 O O
) O O
, O O
implying O O
a O O
different O O
mode O O
of O O
binding O O
for O O
HFE O O
and O O
transferrin O O
to O O
TfR O O
, O O
consistent O O
with O O
our O O
demonstration O O
that O O
HFE O O
, O O
transferrin O O
, O O
and O O
TfR O O
form O O
a O O
ternary O O
complex O O
. O O

Identification O O
of O O
three O O
novel O O
mutations O O
and O O
a O O
high O O
frequency O O
of O O
the O O
Arg778Leu O O
mutation O O
in O O
Korean O O
patients O O
with O O
Wilson B B_DISEASE/B_GENE
disease I I_DISEASE/I_GENE
. O O

Four O O
mutations O O
- O O
- O O
R778L O O
, O O
A874V O O
, O O
L1083F O O
, O O
and O O
2304delC O O
- O O
- O O
in O O
the O O
copper O O
- O O
transporting O O
enzyme O O
, O O
P O O
- O O
type O O
ATPase O O
( O O
ATP7B O O
) O O
, O O
were O O
identified O O
in O O
Korean O O
Patients O O
with O O
Wilson B B_DISEASE
disease I I_DISEASE
. O O

5 O O
% O O
, O O
which O O
is O O
considerably O O
higher O O
than O O
those O O
in O O
other O O
Asian O O
populations O O
. O O

Since O O
a O O
mutation O O
at O O
cDNA O O
nucleotide O O
2302 O O
( O O
2302insC O O
) O O
had O O
been O O
previously O O
described O O
, O O
this O O
region O O
of O O
the O O
ATP7B O O
gene O O
may O O
be O O
susceptible O O
to O O
gene O O
rearrangements O O
causing O O
Wilson B B_DISEASE
disease I I_DISEASE
. O O

Disruption O O
of O O
splicing O O
regulated O O
by O O
a O O
CUG O O
- O O
binding O O
protein O O
in O O
myotonic B B_DISEASE/B_BIO
dystrophy I I_DISEASE/I_BIO
. O O

One O O
model O O
of O O
DM B B_DISEASE
pathogenesis O O
suggests O O
that O O
RNAs O O
from O O
the O O
expanded O O
allele O O
create O O
a O O
gain O O
- O O
of O O
- O O
function O O
mutation O O
by O O
the O O
inappropriate O O
binding O O
of O O
proteins O O
to O O
the O O
CUG O O
repeats O O
. O O

CUG O O
- O O
BP O O
was O O
found O O
to O O
bind O O
to O O
the O O
human O O
cardiac O O
troponin O O
T O O
( O O
cTNT O O
) O O
pre O O
- O O
messenger O O
RNA O O
and O O
regulate O O
its O O
alternative O O
splicing O O
. O O

Splicing O O
of O O
cTNT O O
was O O
disrupted O O
in O O
DM B B_DISEASE/B_MEASURE
striated O O
muscle O O
and O O
in O O
normal O O
cells O O
expressing O O
transcripts O O
that O O
contain O O
CUG O O
repeats O O
. O O

Altered O O
expression O O
of O O
genes O O
regulated O O
posttranscriptionally O O
by O O
CUG O O
- O O
BP O O
therefore O O
may O O
contribute O O
to O O
DM B B_DISEASE/B_LOCATION
pathogenesis O O
. O O
. O O

Identification O O
of O O
a O O
novel O O
nonsense O O
mutation O O
and O O
a O O
missense O O
substitution O O
in O O
the O O
vasopressin O O
- O O
neurophysin O O
II O O
gene O O
in O O
two O O
Spanish O O
kindreds O O
with O O
familial B B_DISEASE
neurohypophyseal I I_DISEASE
diabetes I I_DISEASE
insipidus I I_DISEASE
. O O

Familial B B_DISEASE/B_PERSON
neurohypophyseal I I_DISEASE/I_PERSON
diabetes I I_DISEASE/I_PERSON
insipidus I I_DISEASE/I_PERSON
( O O
FNDI B B_DISEASE
) O O
is O O
an O O
autosomal B B_DISEASE
dominant I I_DISEASE
disease I I_DISEASE
caused O O
by O O
deficiency O O
in O O
the O O
antidiuretic O O
hormone O O
arginine O O
vasopressin O O
( O O
AVP O O
) O O
encoded O O
by O O
the O O
AVP O O
- O O
neurophysin O O
II O O
( O O
AVP O O
- O O
NPII O O
) O O
gene O O
on O O
chromosome O O
20p13 O O
. O O

In O O
this O O
study O O
, O O
we O O
analyzed O O
two O O
families O O
with O O
FNDI B B_DISEASE
using O O
direct O O
automated O O
fluorescent O O
, O O
solid O O
phase O O
, O O
single O O
- O O
stranded O O
DNA O O
sequencing O O
of O O
PCR O O
- O O
amplified O O
AVP O O
- O O
NPII O O
DNA O O
. O O

In O O
the O O
second O O
family O O
, O O
a O O
G279A O O
substitution O O
at O O
position O O
- O O
1 O O
of O O
the O O
signal O O
peptide O O
was O O
observed O O
in O O
all O O
affected O O
individuals O O
. O O

This O O
missense O O
mutation O O
, O O
which O O
replaces O O
Ala O O
with O O
Thr O O
, O O
is O O
frequent O O
among O O
FNDI B B_DISEASE/B_LOCATION
patients O O
and O O
is O O
thought O O
to O O
reduce O O
the O O
efficiency O O
of O O
cleavage O O
by O O
signal O O
peptidases O O
. O O
. O O

Genetic O O
heterogeneity O O
of O O
Saethre B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Chotzen I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
, O O
due O O
to O O
TWIST O O
and O O
FGFR O O
mutations O O
. O O

Thirty O O
- O O
two O O
unrelated O O
patients O O
with O O
features O O
of O O
Saethre B B_DISEASE
- I I_DISEASE
Chotzen I I_DISEASE
syndrome I I_DISEASE
, O O
a O O
common O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dominant I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
condition I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O O
craniosynostosis B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O O
limb B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anomalies I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
were O O
screened O O
for O O
mutations O O
in O O
TWIST O O
, O O
FGFR2 O O
, O O
and O O
FGFR3 O O
. O O

Nine O O
novel O O
and O O
three O O
recurrent O O
TWIST O O
mutations O O
were O O
found O O
in O O
12 O O
families O O
. O O

Seven O O
families O O
were O O
found O O
to O O
have O O
the O O
FGFR3 O O
P250R O O
mutation O O
, O O
and O O
one O O
individual O O
was O O
found O O
to O O
have O O
an O O
FGFR2 O O
VV269 O O
- O O
270 O O
deletion O O
. O O

More O O
than O O
35 O O
different O O
TWIST O O
mutations O O
are O O
now O O
known O O
in O O
the O O
literature O O
. O O

The O O
most O O
common O O
phenotypic O O
features O O
, O O
present O O
in O O
more O O
than O O
a O O
third O O
of O O
our O O
patients O O
with O O
TWIST O O
mutations O O
, O O
are O O
coronal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
synostosis I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
brachycephaly B B_DISEASE
, O O
low B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
frontal I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hairline I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
facial B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
asymmetry I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
ptosis B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
hypertelorism B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O O
broad B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
great I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
toes I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
and O O
clinodactyly B B_DISEASE
. O O

The O O
overlap O O
in O O
clinical O O
features O O
and O O
the O O
presence O O
, O O
in O O
the O O
same O O
genes O O
, O O
of O O
mutations O O
for O O
more O O
than O O
one O O
craniosynostotic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
condition I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O O
such O O
as O O
Saethre B B_DISEASE/B_LOCATION
- I I_DISEASE/I_LOCATION
Chotzen I I_DISEASE/I_LOCATION
, I I_DISEASE/I_LOCATION
Crouzon I I_DISEASE/I_LOCATION
, I I_DISEASE/I_LOCATION
and I I_DISEASE/I_LOCATION
Pfeiffer I I_DISEASE/I_LOCATION
syndromes I I_DISEASE/I_LOCATION
- O O
support O O
the O O
hypothesis O O
that O O
TWIST O O
and O O
FGFRs O O
are O O
components O O
of O O
the O O
same O O
molecular O O
pathway O O
involved O O
in O O
the O O
modulation O O
of O O
craniofacial O O
and O O
limb O O
development O O
in O O
humans O O
. O O
. O O

Mutation O O
analysis O O
of O O
UBE3A O O
in O O
Angelman B B_DISEASE/B_NUMBER[MEASURE]
syndrome I I_DISEASE/I_NUMBER[MEASURE]
patients O O
. O O

UBE3A O O
encodes O O
a O O
ubiquitin O O
- O O
protein O O
ligase O O
and O O
shows O O
brain O O
- O O
specific O O
imprinting O O
. O O

Here O O
we O O
describe O O
UBE3A O O
coding O O
- O O
region O O
mutations O O
detected O O
by O O
SSCP O O
analysis O O
in O O
13 O O
AS B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
individuals O O
or O O
families O O
. O O

Two O O
identical O O
de O O
novo O O
5 O O
- O O
bp O O
duplications O O
in O O
exon O O
16 O O
were O O
found O O
. O O

Eight O O
of O O
the O O
cases O O
were O O
familial O O
, O O
and O O
five O O
were O O
sporadic O O
. O O

In O O
two O O
familial O O
cases O O
and O O
one O O
sporadic O O
case O O
, O O
mosaicism O O
for O O
UBE3A O O
mutations O O
was O O
detected O O
in O O
the O O
mother O O
of O O
three O O
AS B B_DISEASE
sons O O
, O O
in O O
the O O
maternal O O
grandfather O O
of O O
two O O
AS B B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
first O O
cousins O O
, O O
and O O
in O O
the O O
mother O O
of O O
an O O
AS B B_LOCATION/B_DISEASE
daughter O O
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
845 O O
G O O
- O O
- O O
> O O
A O O
and O O
187 O O
C O O
- O O
- O O
> O O
G O O
mutations O O
: O O
prevalence O O
in O O
non O O
- O O
Caucasian O O
populations O O
. O O

Hemochromatosis B B_DISEASE
, O O
the O O
inherited B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disorder I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
iron I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
metabolism I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O O
leads O O
, O O
if O O
untreated O O
, O O
to O O
progressive O O
iron B B_DISEASE
overload I I_DISEASE
and O O
premature B B_DISEASE
death I I_DISEASE
. O O

The O O
hemochromatosis B B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
gene O O
, O O
HFE O O
, O O
recently O O
has O O
been O O
identified O O
, O O
and O O
characterization O O
of O O
this O O
gene O O
has O O
shown O O
that O O
it O O
contains O O
two O O
mutations O O
that O O
result O O
in O O
amino O O
acid O O
substitutions O O
- O O
cDNA O O
nucleotides O O
845 O O
G O O
- O O
- O O
> O O
A O O
( O O
C282Y O O
) O O
and O O
187 O O
C O O
- O O
- O O
> O O
G O O
( O O
H63D O O
) O O
. O O

Although O O
hemochromatosis B B_DISEASE/B_LOCATION
is O O
common O O
in O O
Caucasians O O
, O O
affecting O O
> O O
= O O
1 O O
/ O O
300 O O
individuals O O
of O O
northern O O
European O O
origin O O
, O O
it O O
has O O
not O O
been O O
recognized O O
in O O
other O O
populations O O
. O O

The O O
present O O
study O O
used O O
PCR O O
and O O
restriction O O
- O O
enzyme O O
digestion O O
to O O
analyze O O
the O O
frequency O O
of O O
the O O
845 O O
G O O
- O O
- O O
> O O
A O O
and O O
187 O O
C O O
- O O
- O O
> O O
G O O
mutations O O
in O O
HLA O O
- O O
typed O O
samples O O
from O O
non O O
- O O
Caucasian O O
populations O O
, O O
comprising O O
Australian O O
Aboriginal O O
, O O
Chinese O O
, O O
and O O
Pacific O O
Islanders O O
. O O

68 O O
% O O
in O O
the O O
two O O
populations O O
analyzed O O
( O O
Australian O O
Aboriginal O O
and O O
Chinese O O
) O O
. O O

Genotype O O
- O O
phenotype O O
correlations O O
in O O
attenuated B B_DISEASE/B_BIO
adenomatous I I_DISEASE/I_BIO
polyposis I I_DISEASE/I_BIO
coli I I_DISEASE/I_BIO
. O O

AAPC B B_DISEASE/B_PERSON
is O O
recognized O O
by O O
the O O
occurrence O O
of O O
< O O
100 O O
colonic B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
and O O
a O O
later O O
onset O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
( O O
age O O
> O O
40 O O
years O O
) O O
. O O

Variability O O
in O O
the O O
number O O
of O O
colorectal B B_DISEASE/B_PERSON
adenomas I I_DISEASE/I_PERSON
was O O
most O O
apparent O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
and O O
upper O O
- O O
gastrointestinal O O
manifestations O O
were O O
more O O
severe O O
in O O
them O O
. O O

In O O
individuals O O
with O O
mutations O O
in O O
either O O
region O O
2 O O
or O O
region O O
3 O O
, O O
the O O
average O O
number O O
of O O
adenomas B B_DISEASE/B_BIO
tended O O
to O O
be O O
lower O O
than O O
those O O
in O O
individuals O O
with O O
mutations O O
in O O
region O O
1 O O
, O O
although O O
age O O
at O O
diagnosis O O
was O O
similar O O
. O O

No O O
desmoid B B_DISEASE/B_GENE
tumors I I_DISEASE/I_GENE
were O O
found O O
in O O
these O O
kindreds O O
. O O

This O O
should O O
help O O
in O O
the O O
design O O
of O O
tailored O O
clinical O O
- O O
management O O
protocols O O
in O O
this O O
subset O O
of O O
FAP B B_DISEASE/B_PERSON
patients O O
. O O
. O O

Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
' I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O O
and O O
Dax O O
- O O
1 O O
modulate O O
the O O
orphan O O
nuclear O O
receptor O O
SF O O
- O O
1 O O
in O O
sex O O
- O O
specific O O
gene O O
expression O O
. O O

Products O O
of O O
steroidogenic O O
factor O O
1 O O
( O O
SF O O
- O O
1 O O
) O O
and O O
Wilms B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O O
( O O
WT1 O O
) O O
genes O O
are O O
essential O O
for O O
mammalian O O
gonadogenesis O O
prior O O
to O O
sexual O O
differentiation O O
. O O

In O O
males O O
, O O
SF O O
- O O
1 O O
participates O O
in O O
sexual O O
development O O
by O O
regulating O O
expression O O
of O O
the O O
polypeptide O O
hormone O O
Mullerian O O
inhibiting O O
substance O O
( O O
MIS O O
) O O
. O O

In O O
contrast O O
, O O
WT1 O O
missense O O
mutations O O
, O O
associated O O
with O O
male B B_DISEASE/B_GENE
pseudohermaphroditism I I_DISEASE/I_GENE
in O O
Denys B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Drash I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
fail O O
to O O
synergize O O
with O O
SF O O
- O O
1 O O
. O O

Additionally O O
, O O
the O O
X O O
- O O
linked O O
, O O
candidate O O
dosage O O
- O O
sensitive O O
sex O O
- O O
reversal O O
gene O O
, O O
Dax O O
- O O
1 O O
, O O
antagonizes O O
synergy O O
between O O
SF O O
- O O
1 O O
and O O
WT1 O O
, O O
most O O
likely O O
through O O
a O O
direct O O
interaction O O
with O O
SF O O
- O O
1 O O
. O O

We O O
propose O O
that O O
WT1 O O
and O O
Dax O O
- O O
1 O O
functionally O O
oppose O O
each O O
other O O
in O O
testis O O
development O O
by O O
modulating O O
SF O O
- O O
1 O O
- O O
mediated O O
transactivation O O
. O O
. O O

A O O
mouse O O
model O O
for O O
Prader B B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
- I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
Willi I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
imprinting O O
- O O
centre O O
mutations O O
. O O

Deletion O O
of O O
this O O
IC O O
abolishes O O
local O O
paternally O O
derived O O
gene O O
expression O O
and O O
results O O
in O O
Prader B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
Willi I I_DISEASE/I_ORGANISM_FUNCTION
syndrome I I_DISEASE/I_ORGANISM_FUNCTION
( O O
PWS B B_MEASURE/B_DISEASE
) O O
. O O

We O O
have O O
created O O
two O O
deletion O O
mutations O O
in O O
mice O O
to O O
understand O O
PWS B B_DISEASE_ADJECTIVE[DISEASE]
and O O
the O O
mechanism O O
of O O
this O O
IC O O
. O O

Mice O O
harbouring O O
an O O
intragenic O O
deletion O O
in O O
Snrpn O O
are O O
phenotypically O O
normal O O
, O O
suggesting O O
that O O
mutations O O
of O O
SNRPN O O
are O O
not O O
sufficient O O
to O O
induce O O
PWS B B_DISEASE
. O O

These O O
data O O
demonstrate O O
that O O
both O O
the O O
position O O
of O O
the O O
IC O O
and O O
its O O
role O O
in O O
the O O
coordinate O O
expression O O
of O O
genes O O
is O O
conserved O O
between O O
mouse O O
and O O
human O O
, O O
and O O
indicate O O
that O O
the O O
mouse O O
is O O
a O O
suitable O O
model O O
system O O
in O O
which O O
to O O
investigate O O
the O O
molecular O O
mechanisms O O
of O O
imprinting O O
in O O
this O O
region O O
of O O
the O O
genome O O
. O O
. O O

Mutations O O
of O O
the O O
ATM O O
gene O O
detected O O
in O O
Japanese O O
ataxia B B_DISEASE
- I I_DISEASE
telangiectasia I I_DISEASE
patients O O
: O O
possible O O
preponderance O O
of O O
the O O
two O O
founder O O
mutations O O
4612del165 O O
and O O
7883del5 O O
. O O

The O O
ATM O O
( O O
A O O
- O O
T O O
, O O
mutated O O
) O O
gene O O
on O O
human O O
chromosome O O
11q22 O O
. O O

In O O
order O O
to O O
define O O
the O O
types O O
of O O
disease O O
- O O
causing O O
ATM O O
mutations O O
in O O
Japanese O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O O
as O O
well O O
as O O
to O O
look O O
for O O
possible O O
mutational O O
hotspots O O
, O O
reverse O O
- O O
transcribed O O
RNA O O
derived O O
from O O
ten O O
patients O O
belonging O O
to O O
eight O O
unrelated O O
Japanese O O
A B B_DISEASE/B_PERSON
- I I_DISEASE/I_PERSON
T I I_DISEASE/I_PERSON
families O O
was O O
analyzed O O
for O O
mutations O O
by O O
the O O
restriction O O
endonuclease O O
fingerprinting O O
method O O
. O O

Six O O
different O O
mutations O O
were O O
identified O O
on O O
12 O O
of O O
the O O
16 O O
alleles O O
examined O O
. O O

The O O
4612del165 O O
mutations O O
in O O
three O O
different O O
families O O
were O O
all O O
ascribed O O
to O O
the O O
same O O
T O O
- O O
- O O
> O O
A O O
substitution O O
at O O
the O O
splice O O
donor O O
site O O
in O O
intron O O
33 O O
. O O

Microsatellite O O
genotyping O O
around O O
the O O
ATM O O
locus O O
also O O
indicated O O
that O O
a O O
common O O
haplotype O O
was O O
shared O O
by O O
the O O
mutant O O
alleles O O
in O O
both O O
mutations O O
. O O

This O O
suggests O O
that O O
these O O
two O O
founder O O
mutations O O
may O O
be O O
predominant O O
among O O
Japanese O O
ATM O O
mutant O O
alleles O O
. O O

W474C O O
amino O O
acid O O
substitution O O
affects O O
early O O
processing O O
of O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
and O O
is O O
associated O O
with O O
subacute O O
G B B_DISEASE
( I I_DISEASE
M2 I I_DISEASE
) I I_DISEASE
gangliosidosis I I_DISEASE
. O O

Mutations O O
in O O
the O O
HEXA O O
gene O O
, O O
encoding O O
the O O
alpha O O
- O O
subunit O O
of O O
beta O O
- O O
hexosaminidase O O
A O O
( O O
Hex O O
A O O
) O O
, O O
that O O
abolish O O
Hex O O
A O O
enzyme O O
activity O O
cause O O
Tay B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Sachs I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
( O O
TSD B B_DISEASE/B_LOCATION
) O O
, O O
the O O
fatal O O
infantile B B_DISEASE_ADJECTIVE[DISEASE]
form I I_DISEASE_ADJECTIVE[DISEASE]
of I I_DISEASE_ADJECTIVE[DISEASE]
G I I_DISEASE_ADJECTIVE[DISEASE]
( I I_DISEASE_ADJECTIVE[DISEASE]
M2 I I_DISEASE_ADJECTIVE[DISEASE]
) I I_DISEASE_ADJECTIVE[DISEASE]
gangliosidosis I I_DISEASE_ADJECTIVE[DISEASE]
, I I_DISEASE_ADJECTIVE[DISEASE]
Type I I_DISEASE_ADJECTIVE[DISEASE]
1 I I_DISEASE_ADJECTIVE[DISEASE]
. O O

We O O
identified O O
a O O
1422 O O
G O O
- O O
- O O
> O O
C O O
( O O
amino O O
acid O O
W474C O O
) O O
substitution O O
in O O
the O O
first O O
position O O
of O O
exon O O
13 O O
of O O
HEXA O O
of O O
a O O
non O O
- O O
Jewish O O
proband O O
who O O
manifested O O
a O O
subacute O O
variant O O
of O O
G B B_DISEASE/B_GENE
( I I_DISEASE/I_GENE
M2 I I_DISEASE/I_GENE
) I I_DISEASE/I_GENE
gangliosidosis I I_DISEASE/I_GENE
. O O

Pulse O O
- O O
chase O O
analysis O O
using O O
proband O O
fibroblasts O O
revealed O O
that O O
the O O
W474C O O
- O O
containing O O
alpha O O
- O O
subunit O O
precursor O O
was O O
normally O O
synthesized O O
, O O
but O O
not O O
phosphorylated O O
or O O
secreted O O
, O O
and O O
the O O
mature O O
lysosomal O O
alpha O O
- O O
subunit O O
was O O
not O O
detected O O
. O O

When O O
the O O
W474C O O
- O O
containing O O
alpha O O
- O O
subunit O O
was O O
transiently O O
co O O
- O O
expressed O O
with O O
the O O
beta O O
- O O
subunit O O
to O O
produce O O
Hex O O
A O O
( O O
alphabeta O O
) O O
in O O
COS O O
- O O
7 O O
cells O O
, O O
the O O
mature O O
alpha O O
- O O
subunit O O
was O O
present O O
, O O
but O O
its O O
level O O
was O O
much O O
lower O O
than O O
that O O
from O O
normal O O
alpha O O
- O O
subunit O O
transfections O O
, O O
although O O
higher O O
than O O
in O O
those O O
cells O O
transfected O O
with O O
an O O
alpha O O
- O O
subunit O O
associated O O
with O O
infantile O O
TSD B B_DISEASE
. O O

Furthermore O O
, O O
the O O
precursor O O
level O O
of O O
the O O
W474C O O
alpha O O
- O O
subunit O O
was O O
found O O
to O O
accumulate O O
in O O
comparison O O
to O O
the O O
normal O O
alpha O O
- O O
subunit O O
precursor O O
levels O O
. O O

We O O
conclude O O
that O O
the O O
1422 O O
G O O
- O O
- O O
> O O
C O O
mutation O O
is O O
the O O
cause O O
of O O
Hex B B_DISEASE/B_GENE
A I I_DISEASE/I_GENE
enzyme I I_DISEASE/I_GENE
deficiency I I_DISEASE/I_GENE
in O O
the O O
proband O O
. O O

The O O
resulting O O
W474C O O
substitution O O
clearly O O
interferes O O
with O O
alpha O O
- O O
subunit O O
processing O O
, O O
but O O
because O O
the O O
base O O
substitution O O
falls O O
at O O
the O O
first O O
position O O
of O O
exon O O
13 O O
, O O
aberrant O O
splicing O O
may O O
also O O
contribute O O
to O O
Hex B B_DISEASE
A I I_DISEASE
deficiency I I_DISEASE
in O O
this O O
proband O O
. O O
. O O

Two O O
frequent O O
missense O O
mutations O O
in O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

Pendred B B_DISEASE/B_LOCATION
syndrome I I_DISEASE/I_LOCATION
is O O
an O O
autosomal B B_DISEASE_ADJECTIVE[DISEASE]
recessive I I_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
characterized O O
by O O
early O O
childhood O O
deafness B B_DISEASE
and O O
goiter B B_DISEASE
. O O

1 O O
and O O
, O O
recently O O
, O O
found O O
to O O
encode O O
a O O
putative O O
sulfate O O
transporter O O
. O O

We O O
performed O O
mutation O O
analysis O O
of O O
the O O
PDS B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O O
in O O
patients O O
from O O
14 O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O O
originating O O
from O O
seven O O
countries O O
and O O
identified O O
all O O
mutations O O
. O O

The O O
mutations O O
include O O
three O O
single O O
base O O
deletions O O
, O O
one O O
splice O O
site O O
mutation O O
and O O
10 O O
missense O O
mutations O O
. O O

One O O
missense O O
mutation O O
( O O
L236P O O
) O O
was O O
found O O
in O O
a O O
homozygous O O
state O O
in O O
two O O
consanguineous O O
families O O
and O O
in O O
a O O
heterozygous O O
state O O
in O O
five O O
additional O O
non O O
- O O
consanguineous O O
families O O
. O O

In O O
total O O
, O O
one O O
or O O
both O O
of O O
these O O
mutations O O
were O O
found O O
in O O
nine O O
of O O
the O O
14 O O
families O O
analyzed O O
. O O

The O O
identification O O
of O O
two O O
frequent O O
PDS B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O O
will O O
facilitate O O
the O O
molecular O O
diagnosis O O
of O O
Pendred B B_DISEASE
syndrome I I_DISEASE
. O O

Insertional O O
mutation O O
by O O
transposable O O
element O O
, O O
L1 O O
, O O
in O O
the O O
DMD B B_DISEASE/B_GENE
gene O O
results O O
in O O
X B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
linked I I_DISEASE/I_GENE
dilated I I_DISEASE/I_GENE
cardiomyopathy I I_DISEASE/I_GENE
. O O

X B B_DISEASE
- I I_DISEASE
linked I I_DISEASE
dilated I I_DISEASE
cardiomyopathy I I_DISEASE
( O O
XLDCM B B_DISEASE/B_LOCATION
) O O
is O O
a O O
clinical O O
phenotype O O
of O O
dystrophinopathy B B_DISEASE
which O O
is O O
characterized O O
by O O
preferential O O
myocardial B B_DISEASE/B_ORGANISM_FUNCTION
involvement I I_DISEASE/I_ORGANISM_FUNCTION
without O O
any O O
overt O O
clinical O O
signs O O
of O O
skeletal B B_DISEASE
myopathy I I_DISEASE
. O O

To O O
date O O
, O O
several O O
mutations O O
in O O
the O O
Duchenne B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
gene O O
, O O
DMD O O
, O O
have O O
been O O
identified O O
in O O
patients O O
with O O
XLDCM B B_DISEASE
, O O
but O O
a O O
pathogenic O O
correlation O O
of O O
these O O
cardiospecific O O
mutations O O
in O O
DMD O O
with O O
the O O
XLDCM B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O O
has O O
remained O O
to O O
be O O
elucidated O O
. O O

We O O
report O O
here O O
the O O
identification O O
of O O
a O O
unique O O
de O O
novo O O
L1 O O
insertion O O
in O O
the O O
muscle O O
exon O O
1 O O
in O O
DMD O O
in O O
three O O
XLDCM B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O O
from O O
two O O
unrelated O O
Japanese O O
families O O
. O O

The O O
insertion O O
was O O
a O O
5 O O
- O O
truncated O O
form O O
of O O
human O O
L1 O O
inversely O O
integrated O O
in O O
the O O
5 O O
- O O
untranslated O O
region O O
in O O
the O O
muscle O O
exon O O
1 O O
, O O
which O O
affected O O
the O O
transcription O O
or O O
the O O
stability O O
of O O
the O O
muscle O O
form O O
of O O
dystrophin O O
transcripts O O
but O O
not O O
that O O
of O O
the O O
brain O O
or O O
Purkinje O O
cell O O
form O O
, O O
probably O O
due O O
to O O
its O O
unique O O
site O O
of O O
integration O O
. O O

We O O
speculate O O
that O O
this O O
insertion O O
of O O
an O O
L1 O O
sequence O O
in O O
DMD O O
is O O
responsible O O
for O O
some O O
of O O
the O O
population O O
of O O
Japanese O O
patients O O
with O O
XLDCM B B_DISEASE
. O O
. O O

Severe O O
early O O
- O O
onset O O
obesity B B_DISEASE
, O O
adrenal B B_DISEASE/B_COLOR
insufficiency I I_DISEASE/I_COLOR
and O O
red O O
hair O O
pigmentation O O
caused O O
by O O
POMC O O
mutations O O
in O O
humans O O
. O O

Sequential O O
cleavage O O
of O O
the O O
precursor O O
protein O O
pre O O
- O O
pro O O
- O O
opiomelanocortin O O
( O O
POMC O O
) O O
generates O O
the O O
melanocortin O O
peptides O O
adrenocorticotrophin O O
( O O
ACTH O O
) O O
, O O
melanocyte O O
- O O
stimulating O O
hormones O O
( O O
MSH O O
) O O
alpha O O
, O O
beta O O
and O O
gamma O O
as O O
well O O
as O O
the O O
opioid O O
- O O
receptor O O
ligand O O
beta O O
- O O
endorphin O O
. O O

While O O
a O O
few O O
cases O O
of O O
isolated O O
ACTH B B_DISEASE
deficiency I I_DISEASE
have O O
been O O
reported O O
( O O
OMIM O O
201400 O O
) O O
, O O
an O O
inherited O O
POMC O O
defect O O
has O O
not O O
been O O
described O O
so O O
far O O
. O O

Recent O O
studies O O
in O O
animal O O
models O O
elucidated O O
a O O
central O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
the O O
regulation O O
of O O
food O O
intake O O
by O O
activation O O
of O O
the O O
brain O O
melanocortin O O
- O O
4 O O
- O O
receptor O O
( O O
MC4 O O
- O O
R O O
; O O
refs O O
3 O O
- O O
5 O O
) O O
and O O
the O O
linkage O O
of O O
human O O
obesity B B_DISEASE/B_GENE
to O O
chromosome O O
2 O O
in O O
close O O
proximity O O
to O O
the O O
POMC O O
locus O O
, O O
led O O
to O O
the O O
proposal O O
of O O
an O O
association O O
of O O
POMC O O
with O O
human O O
obesity B B_DISEASE/B_ORGANISM_FUNCTION
. O O

The O O
dual O O
role O O
of O O
alpha O O
- O O
MSH O O
in O O
regulating O O
food O O
intake O O
and O O
influencing O O
hair O O
pigmentation O O
predicts O O
that O O
the O O
phenotype O O
associated O O
with O O
a O O
defect O O
in O O
POMC O O
function O O
would O O
include O O
obesity B B_DISEASE
, O O
alteration O O
in O O
pigmentation O O
and O O
ACTH B B_DISEASE/B_ORGANISM_FUNCTION
deficiency I I_DISEASE/I_ORGANISM_FUNCTION
. O O

The O O
observation O O
of O O
these O O
symptoms O O
in O O
two O O
probands O O
prompted O O
us O O
to O O
search O O
for O O
mutations O O
within O O
their O O
POMC O O
genes O O
. O O

These O O
findings O O
represent O O
the O O
first O O
examples O O
of O O
a O O
genetic B B_DISEASE/B_GENE
defect I I_DISEASE/I_GENE
within O O
the O O
POMC O O
gene O O
and O O
define O O
a O O
new O O
monogenic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
endocrine I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
disorder I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
resulting O O
in O O
early O O
- O O
onset O O
obesity B B_DISEASE
, O O
adrenal B B_DISEASE
insufficiency I I_DISEASE
and O O
red O O
hair O O
pigmentation O O
. O O
. O O

A O O
European O O
multicenter O O
study O O
of O O
phenylalanine B B_DISEASE/B_LOCATION
hydroxylase I I_DISEASE/I_LOCATION
deficiency I I_DISEASE/I_LOCATION
: O O
classification O O
of O O
105 O O
mutations O O
and O O
a O O
general O O
system O O
for O O
genotype O O
- O O
based O O
prediction O O
of O O
metabolic O O
phenotype O O
. O O

Previous O O
studies O O
have O O
suggested O O
that O O
the O O
highly O O
variable O O
metabolic O O
phenotypes O O
of O O
PAH B B_DISEASE/B_BIO
deficiency I I_DISEASE/I_BIO
correlate O O
with O O
PAH O O
genotypes O O
. O O

We O O
identified O O
both O O
causative O O
mutations O O
in O O
686 O O
patients O O
from O O
seven O O
European O O
centers O O
. O O

On O O
the O O
basis O O
of O O
the O O
phenotypic O O
characteristics O O
of O O
297 O O
functionally O O
hemizygous O O
patients O O
, O O
105 O O
of O O
the O O
mutations O O
were O O
assigned O O
to O O
one O O
of O O
four O O
arbitrary O O
phenotype O O
categories O O
. O O

We O O
proposed O O
and O O
tested O O
a O O
simple O O
model O O
for O O
correlation O O
between O O
genotype O O
and O O
phenotypic O O
outcome O O
. O O

The O O
observed O O
phenotype O O
matched O O
the O O
predicted O O
phenotype O O
in O O
79 O O
% O O
of O O
the O O
cases O O
, O O
and O O
in O O
only O O
5 O O
of O O
184 O O
patients O O
was O O
the O O
observed O O
phenotype O O
more O O
than O O
one O O
category O O
away O O
from O O
that O O
expected O O
. O O

Among O O
the O O
seven O O
contributing O O
centers O O
, O O
the O O
proportion O O
of O O
patients O O
for O O
whom O O
the O O
observed O O
phenotype O O
did O O
not O O
match O O
the O O
predicted O O
phenotype O O
was O O
4 O O
% O O
- O O
23 O O
% O O
( O O
P O O
< O O
. O O
0001 O O
) O O
, O O
suggesting O O
that O O
differences O O
in O O
methods O O
used O O
for O O
mutation O O
detection O O
or O O
phenotype O O
classification O O
may O O
account O O
for O O
a O O
considerable O O
proportion O O
of O O
genotype O O
- O O
phenotype O O
inconsistencies O O
. O O

Our O O
data O O
indicate O O
that O O
the O O
PAH O O
- O O
mutation O O
genotype O O
is O O
the O O
main O O
determinant O O
of O O
metabolic O O
phenotype O O
in O O
most O O
patients O O
with O O
PAH B B_DISEASE/B_LOCATION
deficiency I I_DISEASE/I_LOCATION
. O O

In O O
the O O
present O O
study O O
, O O
the O O
classification O O
of O O
105 O O
PAH O O
mutations O O
may O O
allow O O
the O O
prediction O O
of O O
the O O
biochemical O O
phenotype O O
in O O
> O O
10 O O
, O O
000 O O
genotypes O O
, O O
which O O
may O O
be O O
useful O O
for O O
the O O
management O O
of O O
hyperphenylalaninemia B B_DISEASE
in O O
newborns O O
. O O

Somatic O O
instability O O
of O O
the O O
CTG O O
repeat O O
in O O
mice O O
transgenic O O
for O O
the O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region O O
is O O
age O O
dependent O O
but O O
not O O
correlated O O
to O O
the O O
relative O O
intertissue O O
transcription O O
levels O O
and O O
proliferative O O
capacities O O
. O O

A O O
( O O
CTG O O
) O O
nexpansion O O
in O O
the O O
3 O O
- O O
untranslated O O
region O O
( O O
UTR O O
) O O
of O O
the O O
DM O O
protein O O
kinase O O
gene O O
( O O
DMPK O O
) O O
is O O
responsible O O
for O O
causing O O
myotonic B B_DISEASE
dystrophy I I_DISEASE
( O O
DM B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O

The O O
trinucleotide O O
repeat O O
instability O O
mechanisms O O
involved O O
in O O
DM B B_DISEASE/B_LOCATION
and O O
other O O
human O O
genetic B B_DISEASE/B_GENE
diseases I I_DISEASE/I_GENE
are O O
unknown O O
. O O

We O O
studied O O
somatic O O
instability O O
by O O
measuring O O
the O O
CTG O O
repeat O O
length O O
at O O
several O O
ages O O
in O O
various O O
tissues O O
of O O
transgenic O O
mice O O
carrying O O
a O O
( O O
CTG O O
) O O
55expansion O O
surrounded O O
by O O
45 O O
kb O O
of O O
the O O
human O O
DM B B_DISEASE/B_GENE
region O O
, O O
using O O
small O O
- O O
pool O O
PCR O O
. O O

As O O
observed O O
in O O
some O O
of O O
the O O
tissues O O
of O O
DM B B_DISEASE/B_PERSON
patients O O
, O O
there O O
is O O
a O O
tendency O O
for O O
repeat O O
length O O
and O O
somatic O O
mosaicism O O
to O O
increase O O
with O O
the O O
age O O
of O O
the O O
mouse O O
. O O

The O O
somatic O O
mutation O O
rates O O
in O O
different O O
tissues O O
were O O
also O O
not O O
correlated O O
to O O
the O O
relative O O
inter O O
- O O
tissue O O
difference O O
in O O
transcriptional O O
levels O O
of O O
the O O
three O O
genes O O
( O O
DMAHP O O
, O O
DMPK O O
and O O
59 O O
) O O
surrounding O O
the O O
repeat O O
. O O
. O O

A O O
novel O O
missense O O
mutation O O
in O O
patients O O
from O O
a O O
retinoblastoma B B_DISEASE/B_LOCATION
pedigree O O
showing O O
only O O
mild O O
expression O O
of O O
the O O
tumor B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O O
. O O

We O O
have O O
used O O
single O O
strand O O
conformation O O
polymorphism O O
analysis O O
to O O
study O O
the O O
27 O O
exons O O
of O O
the O O
RB1 O O
gene O O
in O O
individuals O O
from O O
a O O
family O O
showing O O
mild O O
expression O O
of O O
the O O
retinoblastoma B B_DISEASE
phenotype O O
. O O

In O O
this O O
family O O
affected O O
individuals O O
developed O O
unilateral B B_DISEASE
tumors I I_DISEASE
and O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
, O O
unaffected O O
mutation O O
carriers O O
were O O
also O O
identified O O
within O O
the O O
pedigree O O
. O O

A O O
single O O
band O O
shift O O
using O O
SSCP O O
was O O
identified O O
in O O
exon O O
21 O O
which O O
resulted O O
in O O
a O O
missense O O
mutation O O
converting O O
a O O
cys O O
- O O
- O O
> O O
arg O O
at O O
nucleotide O O
position O O
28 O O
in O O
the O O
exon O O
. O O

Analysis O O
of O O
all O O
family O O
members O O
demonstrated O O
that O O
the O O
missense O O
mutation O O
co O O
- O O
segregated O O
with O O
patients O O
with O O
tumors B B_DISEASE/B_GENE
or O O
who O O
, O O
as O O
a O O
result O O
of O O
linkage O O
analysis O O
had O O
been O O
predicted O O
to O O
carry O O
the O O
predisposing O O
mutation O O
. O O

Maternal B B_DISEASE
uniparental I I_DISEASE
disomy I I_DISEASE
( I I_DISEASE
UPD I I_DISEASE
) I I_DISEASE
for I I_DISEASE
chromosome I I_DISEASE
15 I I_DISEASE
is O O
responsible O O
for O O
an O O
estimated O O
30 O O
% O O
of O O
cases O O
of O O
Prader B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
Willi I I_DISEASE/I_ORGANISM_FUNCTION
syndrome I I_DISEASE/I_ORGANISM_FUNCTION
( O O
PWS B B_DISEASE
) O O
. O O

We O O
report O O
on O O
an O O
unusual O O
case O O
of O O
maternal B B_DISEASE
disomy I I_DISEASE
15 I I_DISEASE
in O O
PWS B B_DISEASE/B_PERSON
that O O
is O O
most O O
consistent O O
with O O
adjacent O O
- O O
1 O O
segregation O O
of O O
a O O
paternal O O
t O O
( O O
3 O O
; O O
15 O O
) O O
( O O
p25 O O
; O O
q11 O O
. O O
2 O O
) O O
with O O
simultaneous O O
maternal O O
meiotic O O
nondisjunction O O
for O O
chromosome O O
15 O O
. O O

The O O
patient O O
( O O
J O O
. O O
B O O
. O O
) O O
, O O
a O O
17 O O
- O O
year O O
- O O
old O O
white O O
male O O
with O O
PWS B B_DISEASE/B_GENE
, O O
was O O
found O O
to O O
have O O
47 O O
chromosomes O O
with O O
a O O
supernumerary O O
, O O
paternal O O
der O O
( O O
15 O O
) O O
consisting O O
of O O
the O O
short O O
arm O O
and O O
the O O
proximal O O
long O O
arm O O
of O O
chromosome O O
15 O O
, O O
and O O
distal O O
chromosome O O
arm O O
3p O O
. O O

The O O
t O O
( O O
3 O O
; O O
15 O O
) O O
was O O
present O O
in O O
the O O
balanced O O
state O O
in O O
the O O
patients O O
father O O
and O O
a O O
sister O O
. O O

Fluorescent O O
in O O
situ O O
hybridization O O
analysis O O
demonstrated O O
that O O
the O O
PWS B B_DISEASE/B_PROTEIN[GENE]
critical O O
region O O
resided O O
on O O
the O O
derivative O O
chromosome O O
3 O O
and O O
that O O
there O O
was O O
no O O
deletion O O
of O O
the O O
PWS B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region O O
on O O
the O O
normal O O
pair O O
of O O
15s O O
present O O
in O O
J O O
. O O

B O O
. O O

B O O
. O O

Maternal B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disomy I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O O
confirmed O O
by O O
polymerase O O
chain O O
reaction O O
analysis O O
of O O
microsatellite O O
repeats O O
at O O
the O O
gamma O O
- O O
aminobutyric O O
acid O O
receptor O O
beta3 O O
subunit O O
( O O
GABRB3 O O
) O O
locus O O
. O O

Uniparental B B_DISEASE/B_GENE
disomy I I_DISEASE/I_GENE
associated O O
with O O
unbalanced O O
segregation O O
of O O
non O O
- O O
Robertsonian O O
translocations O O
has O O
been O O
reported O O
previously O O
but O O
has O O
not O O
, O O
to O O
our O O
knowledge O O
, O O
been O O
observed O O
in O O
a O O
case O O
of O O
PWS B B_DISEASE/B_GENE
. O O

Schwartz B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Jampel I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
type I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
Stuve B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
Wiedemann I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
: O O
a O O
case O O
for O O
" O O
lumping O O
" O O
. O O

Recent O O
studies O O
demonstrated O O
the O O
existence O O
of O O
a O O
genetically O O
distinct O O
, O O
usually O O
lethal O O
form O O
of O O
the O O
Schwartz B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
Jampel I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
( O O
SJS B B_DISEASE/B_LOCATION
) O O
of O O
myotonia B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
skeletal B B_DISEASE
dysplasia I I_DISEASE
, O O
which O O
we O O
called O O
SJS B B_DISEASE/B_PERSON
type I I_DISEASE/I_PERSON
2 I I_DISEASE/I_PERSON
. O O

This O O
disorder O O
is O O
reminiscent O O
of O O
another O O
rare O O
condition O O
, O O
the O O
Stuve B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Wiedemann I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
SWS B B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
which O O
comprises O O
campomelia B B_DISEASE/B_BIO
at O O
birth O O
with O O
skeletal B B_DISEASE
dysplasia I I_DISEASE
, O O
contractures B B_DISEASE
, O O
and O O
early B B_DISEASE
death I I_DISEASE
. O O

To O O
test O O
for O O
possible O O
nosologic O O
identity O O
between O O
these O O
disorders O O
, O O
we O O
reviewed O O
the O O
literature O O
and O O
obtained O O
a O O
follow O O
- O O
up O O
of O O
the O O
only O O
two O O
surviving O O
patients O O
, O O
one O O
with O O
SJS B B_DISEASE
type I I_DISEASE
2 I I_DISEASE
at O O
age O O
10 O O
years O O
and O O
another O O
with O O
SWS B B_DISEASE
at O O
age O O
7 O O
years O O
. O O

Patients O O
reported O O
as O O
having O O
either O O
neonatal O O
SJS B B_DISEASE
or O O
SWS B B_DISEASE
presented O O
a O O
combination O O
of O O
a O O
severe O O
, O O
prenatal O O
- O O
onset O O
neuromuscular B B_DISEASE
disorder I I_DISEASE
( O O
with O O
congenital B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joint I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
contractures I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O O
respiratory O O
and O O
feeding O O
difficulties O O
, O O
tendency O O
to O O
hyperthermia B B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O O
and O O
frequent O O
death O O
in O O
infancy O O
) O O
with O O
a O O
distinct O O
campomelic B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
metaphyseal I I_DISEASE_ADJECTIVE[DISEASE]
skeletal I I_DISEASE_ADJECTIVE[DISEASE]
dysplasia I I_DISEASE_ADJECTIVE[DISEASE]
. O O

The O O
follow O O
- O O
up O O
observation O O
of O O
an O O
identical O O
and O O
unique O O
pattern O O
of O O
progressive O O
bone B B_DISEASE
dysplasia I I_DISEASE
in O O
the O O
two O O
patients O O
( O O
one O O
with O O
SJS B B_DISEASE/B_GENE
type I I_DISEASE/I_GENE
2 I I_DISEASE/I_GENE
, O O
one O O
with O O
SWS B B_DISEASE/B_GENE
) O O
surviving O O
beyond O O
infancy O O
adds O O
to O O
the O O
evidence O O
in O O
favor O O
of O O
identity O O
. O O

A O O
mouse O O
model O O
of O O
severe O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
: O O
defects O O
in O O
hemostasis O O
and O O
thrombosis B B_DISEASE
. O O

von B B_DISEASE/B_LOCATION
Willebrand I I_DISEASE/I_LOCATION
factor I I_DISEASE/I_LOCATION
( I I_DISEASE/I_LOCATION
vWf I I_DISEASE/I_LOCATION
) I I_DISEASE/I_LOCATION
deficiency I I_DISEASE/I_LOCATION
causes O O
severe O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
in O O
humans O O
. O O

Neither O O
vWf O O
nor O O
vWf O O
propolypeptide O O
( O O
von B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Willebrand I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigen O O
II O O
) O O
were O O
detectable O O
in O O
plasma O O
, O O
platelets O O
, O O
or O O
endothelial O O
cells O O
of O O
the O O
homozygous O O
mutant O O
mice O O
. O O

Defective O O
thrombosis B B_DISEASE
in O O
mutant O O
mice O O
was O O
also O O
evident O O
in O O
an O O
in O O
vivo O O
model O O
of O O
vascular B B_DISEASE/B_LOCATION
injury I I_DISEASE/I_LOCATION
. O O

We O O
conclude O O
that O O
these O O
mice O O
very O O
closely O O
mimic O O
severe O O
human O O
von B B_DISEASE
Willebrand I I_DISEASE
disease I I_DISEASE
and O O
will O O
be O O
very O O
useful O O
for O O
investigating O O
the O O
role O O
of O O
vWf O O
in O O
normal O O
physiology O O
and O O
in O O
disease O O
models O O
. O O
. O O

Oral O O
contraceptives O O
and O O
the O O
risk O O
of O O
hereditary B B_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

BACKGROUND O O
Women O O
with O O
mutations O O
in O O
either O O
the O O
BRCA1 O O
or O O
the O O
BRCA2 O O
gene O O
have O O
a O O
high O O
lifetime O O
risk O O
of O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

Oral O O
contraceptives O O
protect O O
against O O
ovarian B B_DISEASE/B_ORGANISM_FUNCTION
cancer I I_DISEASE/I_ORGANISM_FUNCTION
in O O
general O O
, O O
but O O
it O O
is O O
not O O
known O O
whether O O
they O O
also O O
protect O O
against O O
hereditary B B_DISEASE
forms I I_DISEASE
of I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O

METHODS O O
We O O
enrolled O O
207 O O
women O O
with O O
hereditary B B_DISEASE/B_LOCATION
ovarian I I_DISEASE/I_LOCATION
cancer I I_DISEASE/I_LOCATION
and O O
161 O O
of O O
their O O
sisters O O
as O O
controls O O
in O O
a O O
case O O
- O O
control O O
study O O
. O O

The O O
control O O
women O O
were O O
enrolled O O
regardless O O
of O O
whether O O
or O O
not O O
they O O
had O O
either O O
mutation O O
. O O

Lifetime O O
histories O O
of O O
oral O O
- O O
contraceptive O O
use O O
were O O
obtained O O
by O O
interview O O
or O O
by O O
written O O
questionnaire O O
and O O
were O O
compared O O
between O O
patients O O
and O O
control O O
women O O
, O O
after O O
adjustment O O
for O O
year O O
of O O
birth O O
and O O
parity O O
. O O

RESULTS O O
The O O
adjusted O O
odds O O
ratio O O
for O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
associated O O
with O O
any O O
past O O
use O O
of O O
oral O O
contraceptives O O
was O O
0 O O
. O O

5 O O
( O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
3 O O
to O O
0 O O
. O O
8 O O
) O O
. O O

Oral O O
- O O
contraceptive O O
use O O
protected O O
against O O
ovarian B B_DISEASE
cancer I I_DISEASE
both O O
for O O
carriers O O
of O O
the O O
BRCA1 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
5 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
3 O O
to O O
0 O O
. O O
9 O O
) O O
and O O
for O O
carriers O O
of O O
the O O
BRCA2 O O
mutation O O
( O O
odds O O
ratio O O
, O O
0 O O
. O O
4 O O
; O O
95 O O
percent O O
confidence O O
interval O O
, O O
0 O O
. O O
2 O O
to O O
1 O O
. O O
1 O O
) O O
. O O

CONCLUSIONS O O
Oral O O
- O O
contraceptive O O
use O O
may O O
reduce O O
the O O
risk O O
of O O
ovarian B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
in O O
women O O
with O O
pathogenic O O
mutations O O
in O O
the O O
BRCA1 O O
or O O
BRCA2 O O
gene O O

A O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B B_DISEASE/B_GENE
with O O
a O O
codon O O
291 O O
deletion O O
: O O
a O O
clinical O O
, O O
biochemical O O
, O O
pathological O O
, O O
and O O
genetic O O
report O O
. O O

We O O
report O O
a O O
Japanese O O
family O O
with O O
adrenoleukodystrophy B B_DISEASE
( O O
ALD B B_DISEASE/B_PROTEIN[GENE]
) O O
with O O
a O O
three O O
base O O
pair O O
deletion O O
( O O
delGAG O O
291 O O
) O O
in O O
the O O
ALD B B_DISEASE/B_GENE
gene O O
. O O

A O O
variety O O
of O O
phenotypes O O
were O O
observed O O
within O O
this O O
family O O
. O O

While O O
the O O
proband O O
( O O
patient O O
1 O O
) O O
was O O
classified O O
as O O
having O O
a O O
rare O O
intermediate O O
type O O
of O O
adult O O
cerebral O O
and O O
cerebello O O
- O O
brain O O
stem O O
forms O O
, O O
his O O
younger O O
brother O O
( O O
patient O O
2 O O
) O O
and O O
nephew O O
( O O
patient O O
3 O O
) O O
had O O
a O O
childhood O O
ALD B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
type O O
. O O

The O O
tau O O
level O O
in O O
the O O
cerebrospinal O O
fluid O O
( O O
CSF O O
) O O
in O O
patient O O
1 O O
was O O
as O O
high O O
as O O
that O O
of O O
patients O O
with O O
Alzheimers B B_DISEASE
disease I I_DISEASE
( O O
AD B B_DISEASE
) O O
. O O

His O O
brain O O
magnetic O O
resonance O O
image O O
( O O
MRI O O
) O O
showed O O
abnormalities B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
bilateral I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cerebellar I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hemispheres I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
brain O O
stem O O
, O O
but O O
not O O
in O O
the O O
cerebral O O
white O O
matter O O
, O O
where O O
marked O O
reductions O O
of O O
the O O
cerebral O O
blood O O
flow O O
and O O
oxygen O O
metabolism O O
were O O
clearly O O
demonstrated O O
by O O
positron O O
emission O O
tomography O O
( O O
PET O O
) O O
. O O

In O O
patients O O
2 O O
and O O
3 O O
, O O
the O O
autopsy O O
findings O O
showed O O
massive O O
demyelination B B_DISEASE
of I I_DISEASE
the I I_DISEASE
cerebral I I_DISEASE
white I I_DISEASE
matter I I_DISEASE
with O O
sparing O O
of O O
the O O
U O O
- O O
fibers O O
, O O
compatible O O
with O O
the O O
findings O O
of O O
childhood O O
ALD B B_DISEASE/B_LOCATION
. O O

Oleic O O
and O O
erucic O O
acids O O
( O O
Lorenzos O O
Oil O O
) O O
were O O
administered O O
to O O
patients O O
1 O O
and O O
4 O O
, O O
but O O
sufficient O O
effectiveness O O
was O O
not O O
obtained O O
. O O

The O O
findings O O
in O O
this O O
family O O
suggest O O
that O O
delGAG291 O O
is O O
part O O
of O O
the O O
cause O O
of O O
Japanese O O
ALD B B_DISEASE/B_PERSON
with O O
phenotypic O O
variations O O
. O O

Moreover O O
, O O
although O O
the O O
scale O O
of O O
the O O
study O O
is O O
limited O O
, O O
there O O
is O O
a O O
possibility O O
that O O
PET O O
can O O
detect O O
an O O
insidious B B_DISEASE/B_GENE
lesion I I_DISEASE/I_GENE
which O O
is O O
undetectable O O
by O O
computed O O
tomogram O O
( O O
CT O O
) O O
or O O
MRI O O
analysis O O
, O O
and O O
that O O
the O O
higher O O
level O O
of O O
tau O O
reflects O O
the O O
process O O
of O O
neuronal B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degeneration I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O O
ALD B B_DISEASE/B_LOCATION
. O O

Lorenzos O O
Oil O O
should O O
be O O
given O O
in O O
the O O
early O O
stage O O
. O O
. O O

Nonsense O O
mutation O O
in O O
exon O O
4 O O
of O O
human O O
complement O O
C9 O O
gene O O
is O O
the O O
major O O
cause O O
of O O
Japanese O O
complement B B_DISEASE/B_PERSON
C9 I I_DISEASE/I_PERSON
deficiency I I_DISEASE/I_PERSON
. O O

Deficiency B B_DISEASE/B_PROTEIN[GENE]
of I B_DISEASE/I_PROTEIN[GENE]
the I B_DISEASE/I_PROTEIN[GENE]
ninth I B_DISEASE/I_PROTEIN[GENE]
component I B_DISEASE/I_PROTEIN[GENE]
of I B_DISEASE/I_PROTEIN[GENE]
human I B_DISEASE/I_PROTEIN[GENE]
complement I B_DISEASE/I_PROTEIN[GENE]
( O O
C9 O O
) O O
is O O
the O O
most O O
common O O
complement B B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_DISEASE_ADJECTIVE[DISEASE]
in O O
Japan O O
but O O
is O O
rare O O
in O O
other O O
countries O O
. O O

Direct O O
sequencing O O
of O O
amplified O O
C9 O O
cDNA O O
and O O
DNA O O
revealed O O
a O O
nonsense O O
substitution O O
( O O
CGA O O
- O O
- O O
> O O
TGA O O
) O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
in O O
the O O
four O O
C9 B B_DISEASE_ADJECTIVE[DISEASE]
- I I_DISEASE_ADJECTIVE[DISEASE]
deficient I I_DISEASE_ADJECTIVE[DISEASE]
individuals O O
. O O

The O O
common O O
mutation O O
at O O
codon O O
95 O O
in O O
exon O O
4 O O
might O O
be O O
responsible O O
for O O
most O O
Japanese O O
C9 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O O
. O O

The O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ovarian I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
susceptibility O O
gene O O
BRCA1 O O
encodes O O
a O O
zinc O O
finger O O
protein O O
of O O
unknown O O
function O O
. O O

Here O O
, O O
it O O
is O O
shown O O
that O O
mouse O O
embryonic O O
stem O O
cells O O
deficient B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
BRCA1 I I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O O
defective O O
in O O
the O O
ability O O
to O O
carry O O
out O O
transcription O O
- O O
coupled O O
repair O O
of O O
oxidative O O
DNA O O
damage O O
, O O
and O O
are O O
hypersensitive O O
to O O
ionizing O O
radiation O O
and O O
hydrogen O O
peroxide O O
. O O

PAX6 O O
is O O
a O O
transcription O O
factor O O
with O O
two O O
DNA O O
- O O
binding O O
domains O O
( O O
paired O O
box O O
and O O
homeobox O O
) O O
and O O
a O O
proline O O
- O O
serine O O
- O O
threonine O O
( O O
PST O O
) O O
- O O
rich O O
transactivation O O
domain O O
. O O

PAX6 O O
regulates O O
eye O O
development O O
in O O
animals O O
ranging O O
from O O
jellyfish O O
to O O
Drosophila O O
to O O
humans O O
. O O

Heterozygous O O
mutations O O
in O O
the O O
human O O
PAX6 O O
gene O O
result O O
in O O
various O O
phenotypes O O
, O O
including O O
aniridia B B_DISEASE/B_SPECIES[BIO]
, O O
Peters B B_DISEASE
anomaly I I_DISEASE
, O O
autosomal B B_DISEASE
dominant I I_DISEASE
keratitis I I_DISEASE
, O O
and O O
familial B B_DISEASE
foveal I I_DISEASE
dysplasia I I_DISEASE
. O O

It O O
is O O
believed O O
that O O
the O O
mutated O O
allele O O
of O O
PAX6 O O
produces O O
an O O
inactive O O
protein O O
and O O
aniridia B B_DISEASE/B_SPECIES[BIO]
is O O
caused O O
due O O
to O O
genetic O O
haploinsufficiency O O
. O O

However O O
, O O
several O O
truncation O O
mutations O O
have O O
been O O
found O O
to O O
occur O O
in O O
the O O
C O O
- O O
terminal O O
half O O
of O O
PAX6 O O
in O O
patients O O
with O O
Aniridia B B_DISEASE/B_SPECIES[BIO]
resulting O O
in O O
mutant O O
proteins O O
that O O
retain O O
the O O
DNA O O
- O O
binding O O
domains O O
but O O
have O O
lost O O
most O O
of O O
the O O
transactivation O O
domain O O
. O O

It O O
is O O
not O O
clear O O
whether O O
such O O
mutants O O
really O O
behave O O
as O O
loss O O
- O O
of O O
- O O
function O O
mutants O O
as O O
predicted O O
by O O
haploinsufficiency O O
. O O

Kinetic O O
studies O O
of O O
binding O O
and O O
dissociation O O
revealed O O
that O O
various O O
truncation O O
mutants O O
have O O
3 O O
- O O
5 O O
- O O
fold O O
higher O O
affinity O O
to O O
various O O
DNA O O
- O O
binding O O
sites O O
when O O
compared O O
with O O
the O O
wild O O
- O O
type O O
PAX6 O O
. O O

These O O
results O O
provide O O
a O O
new O O
insight O O
into O O
the O O
role O O
of O O
mutant O O
PAX6 O O
in O O
causing O O
aniridia B B_DISEASE/B_SPECIES[BIO]
. O O
. O O

Reversal O O
of O O
severe O O
hypertrophic B B_DISEASE
cardiomyopathy I I_DISEASE
and O O
excellent O O
neuropsychologic O O
outcome O O
in O O
very B B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
long I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chain I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
acyl I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
A I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O O

Very B B_DISEASE
- I I_DISEASE
long I I_DISEASE
- I I_DISEASE
chain I I_DISEASE
acyl I I_DISEASE
- I I_DISEASE
coenzyme I I_DISEASE
A I I_DISEASE
dehydrogenase I I_DISEASE
( I I_DISEASE
VLCAD I I_DISEASE
) I I_DISEASE
deficiency I I_DISEASE
is O O
a O O
disorder O O
of O O
fatty O O
acid O O
beta O O
oxidation O O
that O O
reportedly O O
has O O
high O O
rates O O
of O O
morbidity O O
and O O
mortality O O
. O O

We O O
describe O O
the O O
outcome O O
of O O
a O O
5 O O
- O O
year O O
- O O
old O O
girl O O
with O O
VLCAD B B_DISEASE
deficiency I I_DISEASE
who O O
was O O
first O O
seen O O
at O O
5 O O
months O O
of O O
age O O
with O O
severe O O
hypertrophic B B_DISEASE
cardiomyopathy I I_DISEASE
, O O
hepatomegaly B B_DISEASE
, O O
encephalopathy B B_DISEASE
, O O
and O O
hypotonia B B_DISEASE
. O O

Biochemical O O
studies O O
indicated O O
VLCAD B B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_DISEASE_ADJECTIVE[DISEASE]
caused O O
by O O
a O O
stable O O
yet O O
inactive O O
enzyme O O
. O O

After O O
initial O O
treatment O O
with O O
intravenous O O
glucose O O
and O O
carnitine O O
, O O
the O O
patient O O
has O O
thrived O O
on O O
a O O
low O O
- O O
fat O O
diet O O
supplemented O O
with O O
medium O O
- O O
chain O O
triglyceride O O
oil O O
and O O
carnitine O O
and O O
avoidance O O
of O O
fasting O O
. O O

Clinical O O
recognition O O
of O O
VLCAD B B_DISEASE
deficiency I I_DISEASE
is O O
important O O
because O O
it O O
is O O
one O O
of O O
the O O
few O O
directly O O
treatable O O
causes O O
of O O
cardiomyopathy B B_DISEASE
in O O
children O O
. O O
. O O

Cloning O O
of O O
a O O
novel O O
member O O
of O O
the O O
low O O
- O O
density O O
lipoprotein O O
receptor O O
family O O
. O O

A O O
gene O O
encoding O O
a O O
novel O O
transmembrane O O
protein O O
was O O
identified O O
by O O
DNA O O
sequence O O
analysis O O
within O O
the O O
insulin B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
dependent I I_DISEASE/I_GENE
diabetes I I_DISEASE/I_GENE
mellitus I I_DISEASE/I_GENE
( O O
IDDM B B_DISEASE/B_GENE
) O O
locus O O
IDDM4 O O
on O O
chromosome O O
11q13 O O
. O O

Based O O
on O O
its O O
chromosomal O O
position O O
, O O
this O O
gene O O
is O O
a O O
candidate O O
for O O
conferring O O
susceptibility O O
to O O
diabetes B B_DISEASE/B_LOCATION
. O O

The O O
gene O O
, O O
termed O O
low O O
- O O
density O O
lipoprotein O O
receptor O O
related O O
protein O O
5 O O
( O O
LRP5 O O
) O O
, O O
encodes O O
a O O
protein O O
of O O
1615 O O
amino O O
acids O O
that O O
contains O O
conserved O O
modules O O
which O O
are O O
characteristic O O
of O O
the O O
low O O
- O O
density O O
lipoprotein O O
( O O
LDL O O
) O O
receptor O O
family O O
. O O

These O O
modules O O
include O O
a O O
putative O O
signal O O
peptide O O
for O O
protein O O
export O O
, O O
four O O
epidermal O O
growth O O
factor O O
( O O
EGF O O
) O O
repeats O O
with O O
associated O O
spacer O O
domains O O
, O O
three O O
LDL O O
- O O
receptor O O
( O O
LDLR O O
) O O
repeats O O
, O O
a O O
single O O
transmembrane O O
spanning O O
domain O O
, O O
and O O
a O O
cytoplasmic O O
domain O O
. O O

The O O
encoded O O
protein O O
has O O
a O O
unique O O
organization O O
of O O
EGF O O
and O O
LDLR O O
repeats O O
; O O
therefore O O
, O O
LRP5 O O
likely O O
represents O O
a O O
new O O
category O O
of O O
the O O
LDLR O O
family O O
. O O

Both O O
human O O
and O O
mouse O O
LRP5 O O
cDNAs O O
have O O
been O O
isolated O O
and O O
the O O
encoded O O
mature O O
proteins O O
are O O
95 O O
% O O
identical O O
, O O
indicating O O
a O O
high O O
degree O O
of O O
evolutionary O O
conservation O O
. O O
. O O

Four O O
patients O O
had O O
a O O
germ O O
- O O
line O O
E1317Q O O
missense O O
variant O O
of O O
APC O O
that O O
was O O
not O O
present O O
in O O
controls O O
; O O
one O O
of O O
these O O
individuals O O
had O O
an O O
unusually O O
large O O
number O O
of O O
metaplastic B B_DISEASE/B_GENE
polyps I I_DISEASE/I_GENE
of I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
colorectum I I_DISEASE/I_GENE
. O O

Genomic O O
structure O O
of O O
the O O
human O O
congenital B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloride I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
diarrhea I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O O
CLD B B_DISEASE/B_LOCATION
) O O
gene O O
. O O

We O O
report O O
here O O
the O O
complete O O
genomic O O
organization O O
of O O
the O O
human O O
CLD B B_GENE/B_DISEASE
gene O O
which O O
spans O O
approximately O O
39kb O O
, O O
and O O
comprises O O
21 O O
exons O O
. O O

All O O
exon O O
/ O O
intron O O
boundaries O O
conform O O
to O O
the O O
GT O O
/ O O
AG O O
rule O O
. O O

An O O
analysis O O
of O O
the O O
putative O O
promoter O O
region O O
sequence O O
shows O O
a O O
putative O O
TATA O O
box O O
and O O
predicts O O
multiple O O
transcription O O
factor O O
binding O O
sites O O
. O O

The O O
genomic O O
structure O O
was O O
determined O O
using O O
DNA O O
from O O
several O O
sources O O
including O O
multiple O O
large O O
- O O
insert O O
libaries O O
and O O
genomic O O
DNA O O
from O O
Finnish O O
CLD B B_DISEASE/B_LOCATION
patients O O
and O O
controls O O
. O O

Genomic O O
sequencing O O
of O O
a O O
BAC O O
clone O O
H O O
_ O O
RG364P16 O O
revealed O O
the O O
presence O O
of O O
another O O
, O O
highly O O
homologous O O
gene O O
3 O O
of O O
the O O
CLD B B_DISEASE/B_GENE
gene O O
, O O
with O O
a O O
similar O O
genomic O O
structure O O
, O O
recently O O
identified O O
as O O
the O O
Pendred B B_DISEASE_ADJECTIVE[DISEASE]
syndrome I I_DISEASE_ADJECTIVE[DISEASE]
gene O O
( O O
PDS B B_DISEASE/B_PROTEIN[GENE]
) O O
. O O
. O O

The O O
APCI1307K O O
allele O O
and O O
cancer B B_DISEASE/B_LOCATION
risk O O
in O O
a O O
community O O
- O O
based O O
study O O
of O O
Ashkenazi O O
Jews O O
. O O

Mutations O O
in O O
APC O O
are O O
classically O O
associated O O
with O O
familial B B_DISEASE
adenomatous I I_DISEASE
polyposis I I_DISEASE
( O O
FAP B B_DISEASE/B_PROTEIN[GENE]
) O O
, O O
a O O
highly O O
penetrant O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
characterized O O
by O O
multiple O O
intestinal O O
polyps B B_DISEASE
and O O
, O O
without O O
surgical O O
intervention O O
, O O
the O O
development O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
( O O
CRC B B_DISEASE/B_LOCATION
) O O
. O O

The O O
I1307K O O
allele O O
was O O
found O O
in O O
6 O O
. O O

1 O O
% O O
of O O
unselected O O
Ashkenazi O O
Jews O O
and O O
higher O O
proportions O O
of O O
Ashkenazim O O
with O O
family O O
or O O
personal O O
histories O O
of O O
CRC B B_DISEASE/B_LOCATION
( O O
ref O O
. O O
2 O O
) O O
. O O

To O O
evaluate O O
the O O
role O O
of O O
I1307K O O
in O O
cancer B B_DISEASE/B_LOCATION
, O O
we O O
genotyped O O
5 O O
, O O
081 O O
Ashkenazi O O
volunteers O O
in O O
a O O
community O O
survey O O
. O O

Risk O O
of O O
developing O O
colorectal B B_DISEASE
, I I_DISEASE
breast I I_DISEASE
and I I_DISEASE
other I I_DISEASE
cancers I I_DISEASE
were O O
compared O O
between O O
genotyped O O
I1307K O O
carriers O O
and O O
non O O
- O O
carriers O O
and O O
their O O
first O O
- O O
degree O O
relatives O O
. O O

Sperm O O
DNA O O
analysis O O
in O O
a O O
Friedreich B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ataxia I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
premutation O O
carrier O O
suggests O O
both O O
meiotic O O
and O O
mitotic O O
expansion O O
in O O
the O O
FRDA B B_DISEASE/B_GENE
gene O O
. O O

Friedreich B B_DISEASE
ataxia I I_DISEASE
is O O
usually O O
caused O O
by O O
an O O
expansion O O
of O O
a O O
GAA O O
trinucleotide O O
repeat O O
in O O
intron O O
1 O O
of O O
the O O
FRDA B B_DISEASE/B_GENE
gene O O
. O O

Occasionally O O
, O O
a O O
fully O O
expanded O O
allele O O
has O O
been O O
found O O
to O O
arise O O
from O O
a O O
premutation O O
of O O
100 O O
or O O
less O O
triplet O O
repeats O O
. O O

We O O
have O O
examined O O
the O O
sperm O O
DNA O O
of O O
a O O
premutation O O
carrier O O
. O O

This O O
mans O O
leucocyte O O
DNA O O
showed O O
one O O
normal O O
allele O O
and O O
one O O
allele O O
of O O
approximately O O
100 O O
repeats O O
. O O

His O O
sperm O O
showed O O
an O O
expanded O O
allele O O
in O O
a O O
tight O O
range O O
centering O O
on O O
a O O
size O O
of O O
approximately O O
320 O O
trinucleotide O O
repeats O O
. O O

His O O
affected O O
son O O
has O O
repeat O O
sizes O O
of O O
1040 O O
and O O
540 O O
. O O

We O O
also O O
show O O
that O O
in O O
all O O
informative O O
carrier O O
father O O
to O O
affected O O
child O O
transmissions O O
, O O
with O O
the O O
notable O O
exception O O
of O O
the O O
premutation O O
carrier O O
, O O
the O O
expansion O O
size O O
decreases O O
. O O
. O O

The O O
R496H O O
mutation O O
of O O
arylsulfatase O O
A O O
does O O
not O O
cause O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
. O O

Deficiency B B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
arylsulfatase I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
A I I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
ARSA O O
) O O
enzyme O O
activity O O
causes O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
( O O
MLD B B_DISEASE
) O O
. O O

A O O
number O O
of O O
ARSA O O
gene O O
mutations O O
responsible O O
for O O
MLD B B_DISEASE
have O O
been O O
identified O O
. O O

Recently O O
, O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
was O O
proposed O O
to O O
be O O
a O O
cause O O
of O O
MLD B B_DISEASE
( O O
Draghia O O
et O O
al O O
. O O
, O O
1997 O O
) O O
. O O

It O O
is O O
therefore O O
concluded O O
that O O
the O O
R496H O O
mutation O O
of O O
ARSA O O
does O O
not O O
negatively O O
influence O O
the O O
activity O O
of O O
ARSA O O
and O O
is O O
not O O
a O O
cause O O
of O O
MLD B B_DISEASE

Down O O
- O O
regulation O O
of O O
transmembrane O O
carbonic O O
anhydrases O O
in O O
renal B B_DISEASE
cell I I_DISEASE
carcinoma I I_DISEASE
cell O O
lines O O
by O O
wild O O
- O O
type O O
von B B_DISEASE/B_GENE
Hippel I B_DISEASE/I_GENE
- I B_DISEASE/I_GENE
Lindau I B_DISEASE/I_GENE
transgenes O O
. O O

To O O
discover O O
genes O O
involved O O
in O O
von B B_DISEASE/B_VIRUS[BIO]
Hippel I B_DISEASE/I_VIRUS[BIO]
- I B_DISEASE/I_VIRUS[BIO]
Lindau I B_DISEASE/I_VIRUS[BIO]
( O O
VHL B B_DISEASE/B_GENE
) O O
- O O
mediated O O
carcinogenesis O O
, O O
we O O
used O O
renal B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O O
lines O O
stably O O
transfected O O
with O O
wild O O
- O O
type O O
VHL O O
- O O
expressing O O
transgenes O O
. O O

Large O O
- O O
scale O O
RNA O O
differential O O
display O O
technology O O
applied O O
to O O
these O O
cell O O
lines O O
identified O O
several O O
differentially O O
expressed O O
genes O O
, O O
including O O
an O O
alpha O O
carbonic O O
anhydrase O O
gene O O
, O O
termed O O
CA12 O O
. O O

The O O
deduced O O
protein O O
sequence O O
was O O
classified O O
as O O
a O O
one O O
- O O
pass O O
transmembrane O O
CA O O
possessing O O
an O O
apparently O O
intact O O
catalytic O O
domain O O
in O O
the O O
extracellular O O
CA O O
module O O
. O O

Reintroduced O O
wild O O
- O O
type O O
VHL B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
strongly O O
inhibited O O
the O O
overexpression O O
of O O
the O O
CA12 O O
gene O O
in O O
the O O
parental O O
renal B B_DISEASE
cell I I_DISEASE
carcinoma I I_DISEASE
cell O O
lines O O
. O O

Similar O O
results O O
were O O
obtained O O
with O O
CA9 O O
, O O
encoding O O
another O O
transmembrane O O
CA O O
with O O
an O O
intact O O
catalytic O O
domain O O
. O O

Although O O
both O O
domains O O
of O O
the O O
VHL B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
protein O O
contribute O O
to O O
regulation O O
of O O
CA12 O O
expression O O
, O O
the O O
elongin O O
binding O O
domain O O
alone O O
could O O
effectively O O
regulate O O
CA9 O O
expression O O
. O O

We O O
mapped O O
CA12 O O
and O O
CA9 O O
loci O O
to O O
chromosome O O
bands O O
15q22 O O
and O O
17q21 O O
. O O

2 O O
respectively O O
, O O
regions O O
prone O O
to O O
amplification O O
in O O
some O O
human O O
cancers B B_DISEASE/B_BIO
. O O

Additional O O
experiments O O
are O O
needed O O
to O O
define O O
the O O
role O O
of O O
CA O O
IX O O
and O O
CA O O
XII O O
enzymes O O
in O O
the O O
regulation O O
of O O
pH O O
in O O
the O O
extracellular O O
microenvironment O O
and O O
its O O
potential O O
impact O O
on O O
cancer B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell O O
growth O O
. O O

A O O
gene O O
encoding O O
a O O
transmembrane O O
protein O O
is O O
mutated O O
in O O
patients O O
with O O
diabetes B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mellitus I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
optic B B_DISEASE
atrophy I I_DISEASE
( O O
Wolfram B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
syndrome I I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O O
. O O

Wolfram B B_DISEASE/B_GENE
syndrome I I_DISEASE/I_GENE
( O O
WFS B B_DISEASE/B_PROTEIN[GENE]
; O O
OMIM O O
222300 O O
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
neurodegenerative I I_DISEASE/I_GENE
disorder I I_DISEASE/I_GENE
defined O O
by O O
young O O
- O O
onset O O
non O O
- O O
immune O O
insulin B B_DISEASE
- I I_DISEASE
dependent I I_DISEASE
diabetes I I_DISEASE
mellitus I I_DISEASE
and O O
progressive O O
optic B B_DISEASE
atrophy I I_DISEASE
. O O

On O O
the O O
basis O O
of O O
meiotic O O
recombinants O O
and O O
disease O O
- O O
associated O O
haplotypes O O
, O O
the O O
WFS B B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gene O O
was O O
localized O O
to O O
a O O
BAC O O
/ O O
P1 O O
contig O O
of O O
less O O
than O O
250 O O
kb O O
. O O

Mutations O O
in O O
a O O
novel O O
gene O O
( O O
WFS1 O O
) O O
encoding O O
a O O
putative O O
transmembrane O O
protein O O
were O O
found O O
in O O
all O O
affected O O
individuals O O
in O O
six O O
WFS B B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
families O O
, O O
and O O
these O O
mutations O O
were O O
associated O O
with O O
the O O
disease O O
phenotype O O
. O O

WFS1 O O
appears O O
to O O
function O O
in O O
survival O O
of O O
islet O O
beta O O
- O O
cells O O
and O O
neurons O O
. O O
. O O

Stable O O
interaction O O
between O O
the O O
products O O
of O O
the O O
BRCA1 O O
and O O
BRCA2 O O
tumor B B_DISEASE
suppressor O O
genes O O
in O O
mitotic O O
and O O
meiotic O O
cells O O
. O O

BRCA1 O O
and O O
BRCA2 O O
account O O
for O O
most O O
cases O O
of O O
familial O O
, O O
early O O
onset O O
breast B B_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
and O O
encode O O
products O O
that O O
each O O
interact O O
with O O
hRAD51 O O
. O O

Results O O
presented O O
here O O
show O O
that O O
BRCA1 O O
and O O
BRCA2 O O
coexist O O
in O O
a O O
biochemical O O
complex O O
and O O
colocalize O O
in O O
subnuclear O O
foci O O
in O O
somatic O O
cells O O
and O O
on O O
the O O
axial O O
elements O O
of O O
developing O O
synaptonemal O O
complexes O O
. O O

Like O O
BRCA1 O O
and O O
RAD51 O O
, O O
BRCA2 O O
relocates O O
to O O
PCNA O O
+ O O
replication O O
sites O O
following O O
exposure O O
of O O
S O O
phase O O
cells O O
to O O
hydroxyurea O O
or O O
UV O O
irradiation O O
. O O

Dysfunction O O
of O O
this O O
pathway O O
may O O
be O O
a O O
general O O
phenomenon O O
in O O
the O O
majority O O
of O O
cases O O
of O O
hereditary B B_DISEASE
breast I I_DISEASE
and I I_DISEASE
/ I I_DISEASE
or I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
. O O
. O O

A O O
novel O O
Arg362Ser O O
mutation O O
in O O
the O O
sterol O O
27 O O
- O O
hydroxylase O O
gene O O
( O O
CYP27 O O
) O O
: O O
its O O
effects O O
on O O
pre O O
- O O
mRNA O O
splicing O O
and O O
enzyme O O
activity O O
. O O

A O O
novel O O
C O O
to O O
A O O
mutation O O
in O O
the O O
sterol O O
27 O O
- O O
hydroxylase O O
gene O O
( O O
CYP27 O O
) O O
was O O
identified O O
by O O
sequencing O O
amplified O O
CYP27 O O
gene O O
products O O
from O O
a O O
patient O O
with O O
cerebrotendinous B B_DISEASE
xanthomatosis I I_DISEASE
( O O
CTX B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O O
. O O

Quantitative O O
analysis O O
showed O O
that O O
the O O
expression O O
of O O
CYP27 O O
gene O O
mRNA O O
in O O
the O O
patient O O
represented O O
52 O O
. O O

5 O O
% O O
of O O
the O O
normal O O
level O O
. O O

Our O O
data O O
suggest O O
that O O
the O O
C O O
to O O
A O O
mutation O O
at O O
the O O
penultimate O O
nucleotide O O
of O O
exon O O
6 O O
of O O
the O O
CYP27 O O
gene O O
not O O
only O O
causes O O
the O O
deficiency B B_DISEASE/B_GENE
in I I_DISEASE/I_GENE
the I I_DISEASE/I_GENE
sterol I I_DISEASE/I_GENE
27 I I_DISEASE/I_GENE
- I I_DISEASE/I_GENE
hydroxylase I I_DISEASE/I_GENE
activity I I_DISEASE/I_GENE
, O O
but O O
also O O
partially O O
leads O O
to O O
alternative O O
pre O O
- O O
mRNA O O
splicing O O
of O O
the O O
gene O O
. O O

ATM O O
germline O O
mutations O O
in O O
classical O O
ataxia B B_DISEASE/B_GENE
- I I_DISEASE/I_GENE
telangiectasia I I_DISEASE/I_GENE
patients O O
in O O
the O O
Dutch O O
population O O
. O O

In O O
our O O
study O O
, O O
we O O
have O O
determined O O
the O O
ATM O O
mutation O O
spectrum O O
in O O
19 O O
classical O O
A B B_DISEASE/B_LOCATION
- I B_DISEASE/I_LOCATION
T I B_DISEASE/I_LOCATION
patients O O
, O O
including O O
some O O
immigrant O O
populations O O
, O O
as O O
well O O
as O O
12 O O
of O O
Dutch O O
ethnic O O
origin O O
. O O

Both O O
the O O
protein O O
truncation O O
test O O
( O O
PTT O O
) O O
and O O
the O O
restriction O O
endonuclease O O
fingerprinting O O
( O O
REF O O
) O O
method O O
were O O
used O O
and O O
compared O O
for O O
their O O
detection O O
efficiency O O
, O O
identifying O O
76 O O
% O O
and O O
60 O O
% O O
of O O
the O O
mutations O O
, O O
respectively O O
. O O

Most O O
patients O O
were O O
found O O
to O O
be O O
compound O O
heterozygote O O
. O O

Seventeen O O
mutations O O
were O O
distinct O O
, O O
of O O
which O O
10 O O
were O O
not O O
reported O O
previously O O
. O O

Moreover O O
, O O
a O O
16 O O
. O O

7 O O
- O O
kb O O
genomic O O
deletion O O
of O O
the O O
3 O O
end O O
of O O
the O O
gene O O
, O O
most O O
likely O O
a O O
result O O
of O O
recombination O O
between O O
two O O
LINE O O
elements O O
, O O
was O O
identified O O
. O O

The O O
presence O O
of O O
a O O
founder O O
mutation O O
among O O
relatively O O
small O O
ethnic O O
population O O
groups O O
in O O
Western O O
Europe O O
could O O
indicate O O
a O O
high O O
carrier O O
frequency O O
in O O
such O O
communities O O
. O O

The O O
observed O O
genetic O O
heterogeneity O O
including O O
the O O
relative O O
high O O
percentage O O
of O O
splice O O
- O O
site O O
mutations O O
had O O
no O O
reflection O O
on O O
the O O
phenotype O O
. O O

All O O
patients O O
manifested O O
classical O O
A B B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O O
increased O O
cellular O O
radioresistant O O
DNA O O
synthesis O O
. O O

Determination O O
of O O
the O O
genomic O O
structure O O
of O O
the O O
COL4A4 O O
gene O O
and O O
of O O
novel O O
mutations O O
causing O O
autosomal B B_DISEASE/B_GENE
recessive I I_DISEASE/I_GENE
Alport I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
. O O

Autosomal B B_DISEASE
recessive I I_DISEASE
Alport I I_DISEASE
syndrome I I_DISEASE
is O O
a O O
progressive O O
hematuric B B_DISEASE
glomerulonephritis I I_DISEASE
characterized O O
by O O
glomerular B B_DISEASE
basement I I_DISEASE
membrane I I_DISEASE
abnormalities I I_DISEASE
and O O
associated O O
with O O
mutations O O
in O O
either O O
the O O
COL4A3 O O
or O O
the O O
COL4A4 O O
gene O O
, O O
which O O
encode O O
the O O
alpha3 O O
and O O
alpha4 O O
type O O
IV O O
collagen O O
chains O O
, O O
respectively O O
. O O

To O O
date O O
, O O
mutation O O
screening O O
in O O
the O O
two O O
genes O O
has O O
been O O
hampered O O
by O O
the O O
lack O O
of O O
genomic O O
structure O O
information O O
. O O

We O O
report O O
here O O
the O O
complete O O
characterization O O
of O O
the O O
48 O O
exons O O
of O O
the O O
COL4A4 O O
gene O O
, O O
a O O
comprehensive O O
gene O O
screen O O
, O O
and O O
the O O
subsequent O O
detection O O
of O O
10 O O
novel O O
mutations O O
in O O
eight O O
patients O O
diagnosed O O
with O O
autosomal B B_DISEASE
recessive I I_DISEASE
Alport I I_DISEASE
syndrome I I_DISEASE
. O O

Furthermore O O
, O O
we O O
identified O O
a O O
glycine O O
to O O
alanine O O
substitution O O
in O O
the O O
collagenous O O
domain O O
that O O
is O O
apparently O O
silent O O
in O O
the O O
heterozygous O O
carriers O O
, O O
in O O
11 O O
. O O

5 O O
% O O
of O O
all O O
control O O
individuals O O
, O O
and O O
in O O
one O O
control O O
individual O O
homozygous O O
for O O
this O O
glycine O O
substitution O O
. O O

Founder O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_PERSON
and I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
. O O

We O O
have O O
identified O O
four O O
mutations O O
in O O
each O O
of O O
the O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
- O O
susceptibility O O
genes O O
, O O
BRCA1 O O
and O O
BRCA2 O O
, O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
and O O
breast B B_DISEASE/B_PERSON
/ I I_DISEASE/I_PERSON
ovarian I I_DISEASE/I_PERSON
cancer I I_DISEASE/I_PERSON
families O O
from O O
Quebec O O
. O O

To O O
identify O O
founder O O
effects O O
, O O
we O O
examined O O
independently O O
ascertained O O
French O O
Canadian O O
cancer B B_DISEASE/B_LOCATION
families O O
for O O
the O O
distribution O O
of O O
these O O
eight O O
mutations O O
. O O

Six O O
of O O
eight O O
mutations O O
were O O
observed O O
at O O
least O O
twice O O
. O O

The O O
BRCA1 O O
C4446T O O
mutation O O
was O O
the O O
most O O
common O O
mutation O O
found O O
, O O
followed O O
by O O
the O O
BRCA2 O O
8765delAG O O
mutation O O
. O O

7x O O
greater O O
if O O
one O O
or O O
more O O
cases O O
of O O
ovarian B B_DISEASE
cancer I I_DISEASE
were O O
also O O
present O O
in O O
the O O
family O O
. O O

3x O O
greater O O
if O O
there O O
were O O
at O O
least O O
five O O
cases O O
of O O
breast B B_DISEASE/B_GENE
cancer I I_DISEASE/I_GENE
in O O
the O O
family O O
. O O

Interestingly O O
, O O
the O O
presence O O
of O O
a O O
breast B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
case O O
< O O
36 O O
years O O
of O O
age O O
was O O
strongly O O
predictive O O
of O O
the O O
presence O O
of O O
any O O
of O O
the O O
eight O O
mutations O O
screened O O
. O O

The O O
identification O O
of O O
common O O
BRCA1 O O
and O O
BRCA2 O O
mutations O O
will O O
facilitate O O
carrier O O
detection O O
in O O
French O O
Canadian O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
breast B B_DISEASE/B_GENE
/ I I_DISEASE/I_GENE
ovarian I I_DISEASE/I_GENE
cancer I I_DISEASE/I_GENE
families O O
. O O

Are O O
Dp71 O O
and O O
Dp140 O O
brain O O
dystrophin O O
isoforms O O
related O O
to O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
in O O
Duchenne B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON

Molecular O O
study O O
and O O
neuropsychological O O
analysis O O
were O O
performed O O
concurrently O O
on O O
49 O O
patients O O
with O O
Duchenne B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscular I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
dystrophy I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O O
DMD B B_DISEASE
) O O
in O O
order O O
to O O
find O O
a O O
molecular O O
explanation O O
for O O
the O O
cognitive B B_DISEASE_ADJECTIVE[DISEASE]
impairment I I_DISEASE_ADJECTIVE[DISEASE]
observed O O
in O O
most O O
DMD B B_DISEASE/B_MEASURE
patients O O
. O O

Complete O O
analysis O O
of O O
the O O
dystrophin O O
gene O O
was O O
performed O O
to O O
define O O
the O O
localization O O
of O O
deletions O O
and O O
duplications O O
in O O
relation O O
to O O
the O O
different O O
DMD B B_DISEASE/B_GENE
promoters O O
. O O

Qualitative O O
analysis O O
of O O
the O O
Dp71 O O
transcript O O
and O O
testing O O
for O O
the O O
specific O O
first O O
exon O O
of O O
Dp140 O O
were O O
also O O
carried O O
out O O
. O O

Neuropsychological O O
analysis O O
assessed O O
verbal O O
and O O
visuospatial O O
intelligence O O
, O O
verbal O O
memory O O
, O O
and O O
reading O O
skills O O
. O O

Comparison O O
of O O
molecular O O
and O O
psychometric O O
findings O O
demonstrated O O
that O O
deletions O O
and O O
duplications O O
that O O
were O O
localized O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
seemed O O
to O O
be O O
preferentially O O
associated O O
with O O
cognitive B B_DISEASE
impairment I I_DISEASE
. O O

Two O O
altered O O
Dp71 O O
transcripts O O
and O O
two O O
deleted O O
Dp140 O O
DNA O O
sequences O O
were O O
found O O
in O O
four O O
patients O O
with O O
severe O O
cerebral B B_DISEASE
dysfunction I I_DISEASE
. O O

These O O
findings O O
suggest O O
that O O
some O O
sequences O O
located O O
in O O
the O O
distal O O
part O O
of O O
the O O
gene O O
and O O
, O O
in O O
particular O O
, O O
some O O
DMD B B_DISEASE/B_GENE
isoforms O O
expressed O O
in O O
the O O
brain O O
may O O
be O O
related O O
to O O
the O O
cognitive B B_DISEASE/B_GENE
impairment I I_DISEASE/I_GENE
associated O O
with O O
DMD B B_DISEASE
. O O
. O O

I1307K O O
APC O O
and O O
hMLH1 O O
mutations O O
in O O
a O O
non O O
- O O
Jewish O O
family O O
with O O
hereditary B B_DISEASE
non I I_DISEASE
- I I_DISEASE
polyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
. O O

We O O
describe O O
a O O
French O O
Canadian O O
hereditary B B_DISEASE
non I I_DISEASE
- I I_DISEASE
polyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
( O O
HNPCC B B_DISEASE/B_GENE
) O O
kindred O O
which O O
carries O O
a O O
novel O O
truncating O O
mutation O O
in O O
hMLH1 O O
. O O

Interestingly O O
, O O
the O O
I1307K O O
APC O O
polymorphism O O
, O O
associated O O
with O O
an O O
increased O O
risk O O
of O O
colorectal B B_DISEASE
cancer I I_DISEASE
, O O
is O O
also O O
present O O
in O O
this O O
family O O
. O O

In O O
addition O O
, O O
in O O
this O O
family O O
, O O
there O O
appears O O
to O O
be O O
no O O
relationship O O
between O O
the O O
I1307K O O
polymorphism O O
and O O
the O O
presence O O
or O O
absence O O
of O O
cancer B B_DISEASE
. O O
. O O

Identification O O
of O O
a O O
novel O O
mutation O O
of O O
the O O
CPO O O
gene O O
in O O
a O O
Japanese O O
hereditary B B_DISEASE/B_BIO
coproporphyria I I_DISEASE/I_BIO
family O O
. O O

Hereditary B B_DISEASE
coproporphyria I I_DISEASE
( O O
HCP B B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O O
is O O
an O O
autosomal B B_DISEASE/B_GENE
dominant I I_DISEASE/I_GENE
disease I I_DISEASE/I_GENE
characterized O O
by O O
a O O
deficiency B B_DISEASE
of I I_DISEASE
coproporphyrinogen I I_DISEASE
oxidase I I_DISEASE
( O O
CPO O O
) O O
caused O O
by O O
a O O
mutation O O
in O O
the O O
CPO O O
gene O O
. O O

Only O O
11 O O
mutations O O
of O O
the O O
gene O O
have O O
been O O
reported O O
in O O
HCP B B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O O
. O O

We O O
report O O
another O O
mutation O O
in O O
a O O
Japanese O O
family O O
. O O

Polymerase O O
chain O O
reaction O O
- O O
single O O
strand O O
conformational O O
polymorphism O O
and O O
direct O O
sequence O O
analyses O O
demonstrated O O
a O O
C O O
to O O
T O O
substitution O O
in O O
exon O O
1 O O
of O O
the O O
CPO O O
gene O O
at O O
nucleotide O O
position O O
85 O O
, O O
which O O
lies O O
in O O
the O O
putative O O
presequence O O
for O O
targeting O O
to O O
mitochondria O O
. O O

This O O
mutation O O
changes O O
the O O
codon O O
for O O
glutamine O O
to O O
a O O
termination O O
codon O O
at O O
amino O O
acid O O
position O O
29 O O
. O O

The O O
C O O
- O O
T O O
mutation O O
is O O
located O O
within O O
a O O
recently O O
proposed O O
putative O O
alternative O O
translation O O
initiation O O
codon O O
( O O
TIC O O
- O O
1 O O
) O O
, O O
supporting O O
that O O
TIC O O
- O O
1 O O
is O O
the O O
real O O
TIC O O
rather O O
than O O
TIC O O
- O O
2 O O
. O O
. O O

Human B B_DISEASE/B_PERSON
complement I I_DISEASE/I_PERSON
factor I I_DISEASE/I_PERSON
H I I_DISEASE/I_PERSON
deficiency I I_DISEASE/I_PERSON
associated O O
with O O
hemolytic B B_DISEASE/B_GENE
uremic I I_DISEASE/I_GENE
syndrome I I_DISEASE/I_GENE
. O O

This O O
study O O
reports O O
on O O
six O O
cases O O
of O O
deficiency B B_DISEASE
in I I_DISEASE
the I I_DISEASE
human I I_DISEASE
complement I I_DISEASE
regulatory I I_DISEASE
protein I I_DISEASE
Factor I I_DISEASE
H I I_DISEASE
( O O
FH O O
) O O
in O O
the O O
context O O
of O O
an O O
acute B B_DISEASE
renal I I_DISEASE
disease I I_DISEASE
. O O

Five O O
of O O
the O O
cases O O
were O O
observed O O
in O O
children O O
presenting O O
with O O
idiopathic O O
hemolytic B B_DISEASE
uremic I I_DISEASE
syndrome I I_DISEASE
( O O
HUS B B_DISEASE/B_LOCATION
) O O
. O O

Factor B B_DISEASE/B_PROTEIN[GENE]
H I B_DISEASE/I_PROTEIN[GENE]
deficiency I B_DISEASE/I_PROTEIN[GENE]
is O O
the O O
only O O
complement B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficiency I I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
associated O O
with O O
HUS B B_DISEASE
. O O

These O O
observations O O
suggest O O
a O O
role O O
for O O
FH O O
and O O
/ O O
or O O
FH O O
receptors O O
in O O
the O O
pathogenesis O O
of O O
idiopathic O O
HUS B B_DISEASE
. O O
. O O

Further O O
evidence O O
for O O
a O O
major O O
ancient O O
mutation O O
underlying O O
myotonic B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O O
linkage O O
disequilibrium O O
studies O O
in O O
the O O
Japanese O O
population O O
. O O

Previous O O
findings O O
in O O
Caucasian O O
populations O O
of O O
a O O
DM B B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
founder O O
chromosome O O
raise O O
a O O
question O O
about O O
the O O
molecular O O
events O O
involved O O
in O O
the O O
expansion O O
mutation O O
. O O

To O O
investigate O O
whether O O
a O O
founder O O
chromosome O O
for O O
the O O
DM B B_DISEASE/B_GENE
mutation O O
exists O O
in O O
the O O
Japanese O O
population O O
, O O
we O O
genotyped O O
families O O
using O O
polymorphic O O
markers O O
near O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
region O O
and O O
constructed O O
haplotypes O O
. O O

To O O
find O O
an O O
origin O O
of O O
the O O
( O O
CTG O O
) O O
n O O
repeat O O
mutation O O
and O O
to O O
investigate O O
the O O
mechanism O O
of O O
the O O
expansion O O
mutation O O
in O O
the O O
Japanese O O
population O O
we O O
have O O
studied O O
90 O O
Japanese O O
DM B B_DISEASE/B_PERSON
families O O
comprising O O
190 O O
affected O O
and O O
130 O O
unaffected O O
members O O
. O O

The O O
results O O
suggest O O
that O O
a O O
few O O
common O O
ancestral O O
mutations O O
in O O
both O O
Caucasian O O
and O O
Japanese O O
populations O O
have O O
originated O O
by O O
expansion O O
of O O
an O O
ancestral O O
n O O
= O O
5 O O
repeat O O
to O O
n O O
= O O
19 O O
- O O
37 O O
copies O O
. O O

These O O
data O O
support O O
multistep O O
models O O
of O O
triplet O O
repeat O O
expansion O O
that O O
have O O
been O O
proposed O O
for O O
both O O
DM B B_DISEASE/B_GENE
and O O
Friedreichs B B_DISEASE/B_LOCATION
ataxia I B_DISEASE/I_LOCATION
. O O
. O O

The O O
molecular O O
basis O O
of O O
C6 B B_DISEASE
deficiency I I_DISEASE
in O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Deficiency B B_DISEASE
of I I_DISEASE
the I I_DISEASE
sixth I I_DISEASE
component I I_DISEASE
of I I_DISEASE
human I I_DISEASE
complement I I_DISEASE
( O O
C6 O O
) O O
has O O
been O O
reported O O
in O O
a O O
number O O
of O O
families O O
from O O
the O O
western O O
Cape O O
, O O
South O O
Africa O O
. O O

Meningococcal B B_DISEASE/B_PROTEIN[GENE]
disease I B_DISEASE/I_PROTEIN[GENE]
is O O
endemic O O
in O O
the O O
Cape O O
and O O
almost O O
all O O
pedigrees O O
of O O
total O O
C6 B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O O
C6Q0 O O
) O O
have O O
been O O
ascertained O O
because O O
of O O
recurrent O O
disease O O
. O O

The O O
1936delG O O
defect O O
was O O
observed O O
only O O
once O O
in O O
the O O
Cape O O
, O O
but O O
its O O
associated O O
haplotype O O
could O O
be O O
deduced O O
. O O

The O O
data O O
from O O
the O O
haplotypes O O
indicate O O
that O O
these O O
three O O
molecular O O
defects O O
account O O
for O O
the O O
defects O O
in O O
all O O
the O O
38 O O
unrelated O O
C6Q0 O O
individuals O O
we O O
have O O
studied O O
from O O
the O O
Cape O O
. O O

Seven O O
further O O
molecular O O
bases O O
of O O
C7 B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O O
described O O
. O O

They O O
are O O
distributed O O
along O O
the O O
C7 O O
gene O O
, O O
but O O
predominantly O O
towards O O
the O O
3 O O
end O O
. O O

All O O
were O O
found O O
in O O
compound O O
heterozygous O O
individuals O O
. O O

The O O
C6 O O
/ O O
C7 O O
marker O O
haplotypes O O
associated O O
with O O
most O O
C7 B B_DISEASE/B_GENE
defects I I_DISEASE/I_GENE
are O O
tabulated O O
. O O
. O O

A O O
genome O O
- O O
wide O O
search O O
for O O
chromosomal O O
loci O O
linked O O
to O O
mental O O
health O O
wellness O O
in O O
relatives O O
at O O
high O O
risk O O
for O O
bipolar B B_DISEASE
affective I I_DISEASE
disorder I I_DISEASE
among O O
the O O
Old O O
Order O O
Amish O O
. O O

Compelling O O
evidence O O
supports O O
a O O
significant O O
genetic O O
component O O
in O O
the O O
susceptibility O O
to O O
develop O O
BPAD B B_DISEASE/B_GENE
. O O

To O O
date O O
, O O
however O O
, O O
linkage O O
studies O O
have O O
attempted O O
only O O
to O O
identify O O
chromosomal O O
loci O O
that O O
cause O O
or O O
increase O O
the O O
risk O O
of O O
developing O O
BPAD B B_DISEASE
. O O

To O O
determine O O
whether O O
there O O
could O O
be O O
protective O O
alleles O O
that O O
prevent O O
or O O
reduce O O
the O O
risk O O
of O O
developing O O
BPAD B B_DISEASE
, O O
similar O O
to O O
what O O
is O O
observed O O
in O O
other O O
genetic B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disorders I I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O O
we O O
used O O
mental O O
health O O
wellness O O
( O O
absence O O
of O O
any O O
psychiatric B B_DISEASE_ADJECTIVE[DISEASE]
disorder I I_DISEASE_ADJECTIVE[DISEASE]
) O O
as O O
the O O
phenotype O O
in O O
our O O
genome O O
- O O
wide O O
linkage O O
scan O O
of O O
several O O
large O O
multigeneration O O
Old O O
Order O O
Amish O O
pedigrees O O
exhibiting O O
an O O
extremely O O
high O O
incidence O O
of O O
BPAD B B_DISEASE
. O O

We O O
have O O
found O O
strong O O
evidence O O
for O O
a O O
locus O O
on O O
chromosome O O
4p O O
at O O
D4S2949 O O
( O O
maximum O O
GENEHUNTER O O
- O O
PLUS O O
nonparametric O O
linkage O O
score O O
= O O
4 O O
. O O
05 O O
, O O
P O O
= O O
5 O O
. O O
22 O O
x O O
10 O O
( O O
- O O
4 O O
) O O
; O O
SIBPAL O O
Pempirical O O
value O O
< O O
3 O O
x O O
10 O O
( O O
- O O
5 O O
) O O
) O O
and O O
suggestive O O
evidence O O
for O O
a O O
locus O O
on O O
chromosome O O
4q O O
at O O
D4S397 O O
( O O
maximum O O
GENEHUNTER O O
- O O
PLUS O O
nonparametric O O
linkage O O
score O O
= O O
3 O O
. O O
29 O O
, O O
P O O
= O O
2 O O
. O O
57 O O
x O O
10 O O
( O O
- O O
3 O O
) O O
; O O
SIBPAL O O
Pempirical O O
value O O
< O O
1 O O
x O O
10 O O
( O O
- O O
3 O O
) O O
) O O
that O O
are O O
linked O O
to O O
mental O O
health O O
wellness O O
. O O

These O O
findings O O
are O O
consistent O O
with O O
the O O
hypothesis O O
that O O
certain O O
alleles O O
could O O
prevent O O
or O O
modify O O
the O O
clinical O O
manifestations O O
of O O
BPAD B B_DISEASE
and O O
perhaps O O
other O O
related O O
affective B B_DISEASE/B_GENE
disorders I I_DISEASE/I_GENE
. O O

Segregation O O
distortion O O
in O O
myotonic B B_DISEASE/B_PERSON
dystrophy I I_DISEASE/I_PERSON
. O O

This O O
results O O
in O O
infertility B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O O
congenital B B_DISEASE/B_ORGANISM_FUNCTION
myotonic I I_DISEASE/I_ORGANISM_FUNCTION
dystrophy I I_DISEASE/I_ORGANISM_FUNCTION
( O O
CDM B B_DISEASE/B_LOCATION
) O O
with O O
the O O
disappearance O O
of O O
DM B B_DISEASE/B_PERSON
in O O
that O O
pedigree O O
. O O

The O O
concept O O
of O O
segregation O O
distortion O O
, O O
where O O
there O O
is O O
preferential O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B B_DISEASE/B_GENE
locus O O
, O O
has O O
been O O
put O O
forward O O
to O O
explain O O
partially O O
the O O
maintenance O O
of O O
DM B B_DISEASE/B_PROTEIN[GENE]
in O O
the O O
population O O
. O O

Sibships O O
where O O
the O O
status O O
of O O
all O O
the O O
members O O
had O O
been O O
identified O O
were O O
examined O O
to O O
determine O O
the O O
transmission O O
of O O
the O O
DM B B_DISEASE/B_PERSON
expansion O O
from O O
affected O O
parents O O
to O O
their O O
offspring O O
. O O

Where O O
the O O
transmitting O O
parent O O
was O O
male O O
, O O
58 O O
. O O

3 O O
% O O
of O O
the O O
offspring O O
were O O
affected O O
, O O
and O O
in O O
the O O
case O O
of O O
a O O
female O O
transmitting O O
parent O O
, O O
68 O O
. O O

7 O O
% O O
were O O
affected O O
. O O

Studies O O
on O O
meiotic O O
drive O O
in O O
DM B B_SPECIES[BIO]/B_DISEASE
have O O
shown O O
increased O O
transmission O O
of O O
the O O
larger O O
allele O O
at O O
the O O
DM B B_GENE/B_DISEASE
locus O O
in O O
non O O
- O O
DM O O
heterozygotes O O
for O O
CTGn O O
. O O

Diagnosis O O
of O O
hemochromatosis B B_DISEASE
. O O

If O O
untreated O O
, O O
hemochromatosis B B_DISEASE/B_GENE
can O O
cause O O
serious O O
illness O O
and O O
early B B_DISEASE
death I I_DISEASE
, O O
but O O
the O O
disease O O
is O O
still O O
substantially O O
under O O
- O O
diagnosed O O
. O O

The O O
cornerstone O O
of O O
screening O O
and O O
case O O
detection O O
is O O
the O O
measurement O O
of O O
serum O O
transferrin O O
saturation O O
and O O
the O O
serum O O
ferritin O O
level O O
. O O

Once O O
the O O
diagnosis O O
is O O
suspected O O
, O O
physicians O O
must O O
use O O
serum O O
ferritin O O
levels O O
and O O
hepatic O O
iron O O
stores O O
on O O
liver O O
biopsy O O
specimens O O
to O O
assess O O
patients O O
for O O
the O O
presence O O
of O O
iron B B_DISEASE
overload I I_DISEASE
. O O

Liver O O
biopsy O O
is O O
also O O
used O O
to O O
establish O O
the O O
presence O O
or O O
absence O O
of O O
cirrhosis B B_DISEASE
, O O
which O O
can O O
affect O O
prognosis O O
and O O
management O O
. O O

A O O
DNA O O
- O O
based O O
test O O
for O O
the O O
HFE O O
gene O O
is O O
commercially O O
available O O
, O O
but O O
its O O
place O O
in O O
the O O
diagnosis O O
of O O
hemochromatosis B B_DISEASE/B_LOCATION
is O O
still O O
being O O
evaluated O O
. O O

Currently O O
, O O
the O O
most O O
useful O O
role O O
for O O
this O O
test O O
is O O
in O O
the O O
detection O O
of O O
hemochromatosis B B_DISEASE
in O O
the O O
family O O
members O O
of O O
patients O O
with O O
a O O
proven O O
case O O
of O O
the O O
disease O O
. O O

It O O
is O O
crucial O O
to O O
diagnose O O
hemochromatosis B B_DISEASE
before O O
hepatic B B_DISEASE
cirrhosis I I_DISEASE
develops O O
because O O
phlebotomy O O
therapy O O
can O O
avert O O
serious O O
chronic O O
disease O O
and O O
can O O
even O O
lead O O
to O O
normal O O
life O O
expectancy O O
. O O
. O O

BACKGROUND O O
& O O
AIMS O O
Israeli O O
Jews O O
of O O
European O O
birth O O
, O O
i O O
. O O
e O O
. O O
, O O
Ashkenazim O O
, O O
have O O
the O O
highest O O
colorectal B B_DISEASE
cancer I I_DISEASE
incidence O O
of O O
any O O
Israeli O O
ethnic O O
group O O
. O O

1 O O
% O O
of O O
American O O
Jews O O
, O O
28 O O
% O O
of O O
their O O
familial O O
colorectal B B_DISEASE
cancer I I_DISEASE
cases O O
, O O
but O O
not O O
in O O
non O O
- O O
Jews O O
. O O

We O O
assessed O O
the O O
I1307K O O
prevalence O O
in O O
Israeli O O
Jews O O
of O O
differing O O
ethnic O O
origin O O
and O O
risk O O
for O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
. O O

RESULTS O O
In O O
persons O O
at O O
average O O
risk O O
for O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
, O O
I1307K O O
was O O
found O O
in O O
5 O O
. O O

0 O O
% O O
of O O
120 O O
European O O
and O O
1 O O
. O O

6 O O
% O O
of O O
188 O O
non O O
- O O
European O O
Jews O O
( O O
P O O
= O O
0 O O
. O O
08 O O
) O O
. O O

It O O
occurred O O
in O O
15 O O
. O O

4 O O
% O O
of O O
52 O O
Ashkenazi O O
Israelis O O
with O O
familial O O
cancer B B_DISEASE/B_GENE
( O O
P O O
= O O
0 O O
. O O
02 O O
) O O
and O O
was O O
not O O
detected O O
in O O
51 O O
non O O
- O O
European O O
Jews O O
at O O
increased O O
cancer B B_DISEASE/B_GENE
risk O O
. O O

Colorectal B B_DISEASE/B_PERSON
neoplasia I I_DISEASE/I_PERSON
occurred O O
personally O O
or O O
in O O
the O O
families O O
of O O
13 O O
of O O
20 O O
Ashkenazi O O
I1307K O O
carriers O O
, O O
8 O O
of O O
whom O O
also O O
had O O
a O O
personal O O
or O O
family O O
history O O
of O O
noncolonic O O
neoplasia B B_DISEASE
. O O

CONCLUSIONS O O
The O O
I1307K O O
APC O O
variant O O
may O O
represent O O
a O O
susceptibility O O
gene O O
for O O
colorectal B B_DISEASE
, I I_DISEASE
or I I_DISEASE
other I I_DISEASE
, I I_DISEASE
cancers I I_DISEASE
in O O
Ashkenazi O O
Jews O O
, O O
and O O
partially O O
explains O O
the O O
higher O O
incidence O O
of O O
colorectal B B_DISEASE/B_LOCATION
cancer I I_DISEASE/I_LOCATION
in O O
European O O
Israelis O O
. O O

Systematic O O
analysis O O
of O O
coproporphyrinogen O O
oxidase O O
gene O O
defects O O
in O O
hereditary B B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
coproporphyria I I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O O
mutation O O
update O O
. O O

Hereditary B B_DISEASE
coproporphyria I I_DISEASE
( O O
HC B B_LOCATION/B_DISEASE
) O O
is O O
an O O
acute O O
hepatic B B_DISEASE
porphyria I I_DISEASE
with O O
autosomal O O
dominant O O
inheritance O O
caused O O
by O O
deficient B B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
coproporphyrinogen I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
III I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O O
CPO O O
) O O
. O O

Clinical O O
manifestations O O
of O O
the O O
disease O O
are O O
characterized O O
by O O
acute O O
attacks O O
of O O
neurological B B_DISEASE
dysfunction I I_DISEASE
often O O
precipitated O O
by O O
drugs O O
, O O
fasting O O
, O O
cyclical O O
hormonal O O
changes O O
, O O
or O O
infectious B B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diseases I I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Skin O O
photosensitivity O O
may O O
also O O
be O O
present O O
. O O

The O O
seven O O
exons O O
, O O
the O O
exon O O
/ O O
intron O O
boundaries O O
and O O
part O O
of O O
3 O O
noncoding O O
sequence O O
of O O
the O O
CPO O O
gene O O
were O O
systematically O O
analyzed O O
by O O
an O O
exon O O
- O O
by O O
- O O
exon O O
denaturing O O
gradient O O
gel O O
electrophoresis O O
( O O
DGGE O O
) O O
strategy O O
followed O O
by O O
direct O O
sequencing O O
in O O
seven O O
unrelated O O
heterozygous O O
HC B B_DISEASE/B_GENE
patients O O
from O O
France O O
, O O
Holland O O
, O O
and O O
Czech O O
Republic O O
. O O

Seven O O
novel O O
mutations O O
and O O
two O O
new O O
polymorphisms O O
were O O
detected O O
. O O

These O O
mutations O O
resulted O O
in O O
the O O
absence O O
or O O
a O O
dramatic O O
decrease O O
of O O
CPO O O
activity O O
. O O

The O O
two O O
polymorphisms O O
were O O
localized O O
in O O
noncoding O O
part O O
of O O
the O O
gene O O
1 O O
) O O
a O O
C O O
/ O O
G O O
polymorphism O O
in O O
the O O
promotor O O
region O O
, O O
142 O O
bp O O
upstream O O
from O O
the O O
transcriptional O O
initiation O O
site O O
( O O
- O O
142C O O
/ O O
G O O
) O O
, O O
and O O
2 O O
) O O
a O O
6 O O
bp O O
deletion O O
polymorphism O O
in O O
the O O
3 O O
noncoding O O
part O O
of O O
the O O
CPO O O
gene O O
, O O
574 O O
bp O O
downstream O O
of O O
the O O
last O O
base O O
of O O
the O O
normal O O
termination O O
codon O O
( O O
+ O O
574 O O
delATTCTT O O
) O O
. O O

Five O O
intragenic O O
dimorphisms O O
are O O
now O O
well O O
characterized O O
and O O
the O O
high O O
degree O O
of O O
allelic O O
heterogeneity O O
in O O
HC B B_DISEASE/B_LOCATION
is O O
demonstrated O O
with O O
seven O O
new O O
different O O
mutations O O
making O O
a O O
total O O
of O O
nineteen O O
CPO O O
gene B B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O O
so O O
far O O
. O O
. O O

Coincidence O O
of O O
two O O
novel O O
arylsulfatase O O
A O O
alleles O O
and O O
mutation O O
459 O O
+ O O
1G O O
> O O
A O O
within O O
a O O
family O O
with O O
metachromatic B B_DISEASE/B_GENE
leukodystrophy I I_DISEASE/I_GENE
: O O
molecular O O
basis O O
of O O
phenotypic O O
heterogeneity O O
. O O

In O O
a O O
family O O
with O O
three O O
siblings O O
, O O
one O O
developed O O
classical O O
late O O
infantile O O
metachromatic B B_DISEASE
leukodystrophy I I_DISEASE
( O O
MLD B B_DISEASE/B_LOCATION
) O O
, O O
fatal O O
at O O
age O O
5 O O
years O O
, O O
with O O
deficient O O
arylsulfatase O O
A O O
( O O
ARSA O O
) O O
activity O O
and O O
increased O O
galactosylsulfatide O O
( O O
GS O O
) O O
excretion O O
. O O

The O O
two O O
other O O
siblings O O
, O O
apparently O O
healthy O O
at O O
12 O O
( O O
1 O O
/ O O
2 O O
) O O
and O O
15 O O
years O O
, O O
respectively O O
, O O
and O O
their O O
father O O
, O O
apparently O O
healthy O O
as O O
well O O
, O O
presented O O
ARSA O O
and O O
GS O O
values O O
within O O
the O O
range O O
of O O
MLD B B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
patients O O
. O O

The O O
late O O
infantile O O
patient O O
inherited O O
from O O
his O O
mother O O
the O O
frequent O O
0 O O
- O O
type O O
mutation O O
459 O O
+ O O
1G O O
> O O
A O O
, O O
and O O
from O O
his O O
father O O
a O O
novel O O
, O O
single O O
basepair O O
microdeletion O O
of O O
guanine O O
at O O
nucleotide O O
7 O O
in O O
exon O O
1 O O
( O O
7delG O O
) O O
. O O

The O O
two O O
clinically O O
unaffected O O
siblings O O
carried O O
the O O
maternal O O
mutation O O
459 O O
+ O O
1G O O
> O O
A O O
and O O
, O O
on O O
their O O
paternal O O
allele O O
, O O
a O O
novel O O
cytosine O O
to O O
thymidine O O
transition O O
at O O
nucleotide O O
2435 O O
in O O
exon O O
8 O O
, O O
resulting O O
in O O
substitution O O
of O O
alanine O O
464 O O
by O O
valine O O
( O O
A464V O O
) O O
. O O

The O O
fathers O O
genotype O O
thus O O
was O O
7delG O O
/ O O
A464V O O
. O O

Mutation O O
A464V O O
was O O
not O O
found O O
in O O
18 O O
unrelated O O
MLD B B_DISEASE/B_LOCATION
patients O O
and O O
50 O O
controls O O
. O O

A464V O O
, O O
although O O
clearly O O
modifying O O
ARSA O O
and O O
GS O O
levels O O
, O O
apparently O O
bears O O
little O O
significance O O
for O O
clinical O O
manifestation O O
of O O
MLD B B_DISEASE/B_LOCATION
, O O
mimicking O O
the O O
frequent O O
ARSA O O
pseudodeficiency O O
allele O O
. O O

Our O O
results O O
demonstrate O O
that O O
in O O
certain O O
genetic O O
conditions O O
MLD B B_DISEASE/B_MEASURE
- O O
like O O
ARSA O O
and O O
GS O O
values O O
need O O
not O O
be O O
paralleled O O
by O O
clinical O O
disease O O
, O O
a O O
finding O O
with O O
serious O O
diagnostic O O
and O O
prognostic O O
implications O O
. O O

Human O O
MLH1 O O
deficiency O O
predisposes O O
to O O
hematological B B_DISEASE
malignancy I I_DISEASE
and O O
neurofibromatosis B B_DISEASE
type I I_DISEASE
1 I I_DISEASE
. O O

Heterozygous O O
germ O O
- O O
line O O
mutations O O
in O O
the O O
DNA O O
mismatch O O
repair O O
genes O O
lead O O
to O O
hereditary B B_DISEASE
nonpolyposis I I_DISEASE
colorectal I I_DISEASE
cancer I I_DISEASE
. O O

The O O
disease O O
susceptibility O O
of O O
individuals O O
who O O
constitutionally O O
lack O O
both O O
wild O O
- O O
type O O
alleles O O
is O O
unknown O O
. O O

We O O
have O O
identified O O
three O O
offspring O O
in O O
a O O
hereditary B B_DISEASE/B_LOCATION
nonpolyposis I B_DISEASE/I_LOCATION
colorectal I B_DISEASE/I_LOCATION
cancer I B_DISEASE/I_LOCATION
family O O
who O O
developed O O
hematological B B_DISEASE
malignancy I I_DISEASE
at O O
a O O
very O O
early O O
age O O
, O O
and O O
at O O
least O O
two O O
of O O
them O O
displayed O O
signs O O
of O O
neurofibromatosis B B_DISEASE/B_GENE
type I I_DISEASE/I_GENE
1 I I_DISEASE/I_GENE
( O O
NF1 B B_DISEASE/B_GENE
) O O
. O O

DNA O O
sequence O O
analysis O O
and O O
allele O O
- O O
specific O O
amplification O O
in O O
two O O
siblings O O
revealed O O
a O O
homozygous O O
MLH1 O O
mutation O O
( O O
C676T O O
- O O
- O O
> O O
Arg226Stop O O
) O O
. O O

Thus O O
, O O
a O O
homozygous O O
germ O O
- O O
line O O
MLH1 O O
mutation O O
and O O
consequent O O
mismatch O O
repair O O
deficiency O O
results O O
in O O
a O O
mutator O O
phenotype O O
characterized O O
by O O
leukemia B B_DISEASE
and O O
/ O O
or O O
lymphoma B B_DISEASE
associated O O
with O O
neurofibromatosis B B_DISEASE/B_PROTEIN[GENE]
type I B_DISEASE/I_PROTEIN[GENE]
1 I B_DISEASE/I_PROTEIN[GENE]
. O O
. O O

Missense O O
mutations O O
in O O
the O O
most O O
ancient O O
residues O O
of O O
the O O
PAX6 O O
paired O O
domain O O
underlie O O
a O O
spectrum O O
of O O
human O O
congenital B B_DISEASE/B_GENE
eye I I_DISEASE/I_GENE
malformations I I_DISEASE/I_GENE
. O O

The O O
spectrum O O
of O O
PAX6 O O
mutations O O
in O O
aniridia B B_DISEASE/B_PERSON
patients O O
is O O
highly O O
biased O O
, O O
with O O
92 O O
% O O
of O O
all O O
reported O O
mutations O O
leading O O
to O O
premature O O
truncation O O
of O O
the O O
protein O O
( O O
nonsense O O
, O O
splicing O O
, O O
insertions O O
and O O
deletions O O
) O O
and O O
just O O
2 O O
% O O
leading O O
to O O
substitution O O
of O O
one O O
amino O O
acid O O
by O O
another O O
( O O
missense O O
) O O
. O O

The O O
extraordinary O O
conservation O O
of O O
the O O
PAX6 O O
protein O O
at O O
the O O
amino O O
acid O O
level O O
amongst O O
vertebrates O O
predicts O O
that O O
pathological O O
missense O O
mutations O O
should O O
in O O
fact O O
be O O
common O O
even O O
though O O
they O O
are O O
hardly O O
ever O O
seen O O
in O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O O
. O O

This O O
indicates O O
that O O
there O O
is O O
a O O
heavy O O
ascertainment O O
bias O O
in O O
the O O
selection O O
of O O
patients O O
for O O
PAX6 O O
mutation O O
analysis O O
and O O
that O O
the O O
missing O O
PAX6 O O
missense O O
mutations O O
frequently O O
may O O
underlie O O
phenotypes O O
distinct O O
from O O
textbook O O
aniridia B B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O O

Strikingly O O
, O O
all O O
four O O
mutations O O
are O O
located O O
within O O
the O O
PAX6 O O
paired O O
domain O O
and O O
affect O O
amino O O
acids O O
which O O
are O O
highly O O
conserved O O
in O O
all O O
known O O
paired O O
domain O O
proteins O O
. O O

Our O O
results O O
support O O
the O O
hypothesis O O
that O O
the O O
under O O
- O O
representation O O
of O O
missense O O
mutations O O
is O O
caused O O
by O O
ascertainment O O
bias O O
and O O
suggest O O
that O O
a O O
substantial O O
burden O O
of O O
PAX6 B B_DISEASE/B_MEASURE
- I I_DISEASE/I_MEASURE
related I I_DISEASE/I_MEASURE
disease I I_DISEASE/I_MEASURE
remains O O
to O O
be O O
uncovered O O
. O O
. O O

The O O
chromosomal O O
order O O
of O O
genes O O
controlling O O
the O O
major O O
histocompatibility O O
complex O O
, O O
properdin O O
factor O O
B O O
, O O
and O O
deficiency B B_GENE/B_DISEASE
of I I_GENE/I_DISEASE
the I I_GENE/I_DISEASE
second I I_GENE/I_DISEASE
component I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
complement I I_GENE/I_DISEASE
. O O

The O O
relationship O O
of O O
the O O
genes O O
coding O O
for O O
HLA O O
to O O
those O O
coding O O
for O O
properdin O O
Factor O O
B O O
allotypes O O
and O O
for O O
deficiency B B_GENE/B_DISEASE
of I I_GENE/I_DISEASE
the I I_GENE/I_DISEASE
second I I_GENE/I_DISEASE
component I I_GENE/I_DISEASE
of I I_GENE/I_DISEASE
complement I I_GENE/I_DISEASE
( O O
C2 O O
) O O
was O O
studied O O
in O O
families O O
of O O
patients O O
with O O
connective O O
tissue O O
disorders O O
. O O

Patients O O
were O O
selected O O
because O O
they O O
were O O
heterozygous O O
or O O
homozygous O O
for O O
C2 B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deficiency I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O O

12 O O
families O O
with O O
15 O O
matings O O
informative O O
for O O
C2 B B_DISEASE
deficiency I I_DISEASE
were O O
found O O
. O O

Of O O
57 O O
informative O O
meioses O O
, O O
two O O
crossovers O O
were O O
noted O O
between O O
the O O
C2 B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O O
and O O
the O O
HLA O O
- O O
B O O
gene O O
, O O
with O O
a O O
recombinant O O
fraction O O
of O O
0 O O
. O O

035 O O
. O O

A O O
lod O O
score O O
of O O
13 O O
was O O
calculated O O
for O O
linkage O O
between O O
C2 B B_DISEASE/B_GENE
deficiency I I_DISEASE/I_GENE
and O O
HLA O O
- O O
B O O
at O O
a O O
maximum O O
likelihood O O
value O O
of O O
the O O
recombinant O O
fraction O O
of O O
0 O O
. O O

04 O O
. O O

18 O O
families O O
with O O
21 O O
informative O O
matings O O
for O O
both O O
properdin O O
Factor O O
B O O
allotype O O
and O O
HLA O O
- O O
B O O
were O O
found O O
. O O

Of O O
72 O O
informative O O
meioses O O
, O O
three O O
recombinants O O
were O O
found O O
, O O
giving O O
a O O
recombinant O O
fraction O O
of O O
0 O O
. O O

042 O O
. O O

A O O
lod O O
score O O
of O O
16 O O
between O O
HLA O O
- O O
B O O
and O O
Factor O O
B O O
allotypes O O
was O O
calculated O O
at O O
a O O
maximum O O
likelihood O O
value O O
of O O
the O O
recombinant O O
fraction O O
of O O
0 O O
. O O

04 O O
. O O

A O O
crossover O O
was O O
shown O O
to O O
have O O
occurred O O
between O O
genes O O
for O O
Factor O O
B O O
and O O
HLA O O
- O O
D O O
, O O
in O O
which O O
HLA O O
- O O
D O O
segregared O O
with O O
HLA O O
- O O
A O O
and O O
B O O
. O O

Distribution O O
of O O
emerin O O
and O O
lamins O O
in O O
the O O
heart O O
and O O
implications O O
for O O
Emery B B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Dreifuss I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
muscular I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dystrophy I B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O O

Emerin O O
is O O
a O O
nuclear O O
membrane O O
protein O O
which O O
is O O
missing O O
or O O
defective O O
in O O
Emery B B_DISEASE
- I I_DISEASE
Dreifuss I I_DISEASE
muscular I I_DISEASE
dystrophy I I_DISEASE
( O O
EDMD B B_DISEASE/B_GENE
) O O
. O O

It O O
is O O
one O O
member O O
of O O
a O O
family O O
of O O
lamina O O
- O O
associated O O
proteins O O
which O O
includes O O
LAP1 O O
, O O
LAP2 O O
and O O
lamin O O
B O O
receptor O O
( O O
LBR O O
) O O
. O O

A O O
panel O O
of O O
16 O O
monoclonal O O
antibodies O O
( O O
mAbs O O
) O O
has O O
been O O
mapped O O
to O O
six O O
specific O O
sites O O
throughout O O
the O O
emerin O O
molecule O O
using O O
phage O O
- O O
displayed O O
peptide O O
libraries O O
and O O
has O O
been O O
used O O
to O O
localize O O
emerin O O
in O O
human O O
and O O
rabbit O O
heart O O
. O O

Several O O
mAbs O O
against O O
different O O
emerin O O
epitopes O O
did O O
not O O
recognize O O
intercalated O O
discs O O
in O O
the O O
heart O O
, O O
though O O
they O O
recognized O O
cardiomyocyte O O
nuclei O O
strongly O O
, O O
both O O
at O O
the O O
rim O O
and O O
in O O
intranuclear O O
spots O O
or O O
channels O O
. O O

These O O
results O O
would O O
not O O
be O O
expected O O
if O O
immunostaining O O
at O O
intercalated O O
discs O O
were O O
due O O
to O O
a O O
product O O
of O O
the O O
emerin O O
gene O O
and O O
, O O
therefore O O
, O O
cast O O
some O O
doubt O O
upon O O
the O O
hypothesis O O
that O O
cardiac B B_DISEASE_ADJECTIVE[DISEASE]
defects I I_DISEASE_ADJECTIVE[DISEASE]
in O O
EDMD B B_DISEASE/B_SPECIES[BIO]
are O O
caused O O
by O O
absence O O
of O O
emerin O O
from O O
intercalated O O
discs O O
. O O

This O O
distribution O O
of O O
emerin O O
was O O
similar O O
to O O
that O O
of O O
lamin O O
A O O
, O O
a O O
candidate O O
gene O O
for O O
an O O
autosomal O O
form O O
of O O
EDMD B B_DISEASE/B_GENE
. O O

In O O
contrast O O
, O O
lamin O O
B1 O O
was O O
absent O O
from O O
cardiomyocyte O O
nuclei O O
, O O
showing O O
that O O
lamin O O
B1 O O
is O O
not O O
essential O O
for O O
localization O O
of O O
emerin O O
to O O
the O O
nuclear O O
lamina O O
. O O

Lamin O O
B1 O O
is O O
also O O
almost O O
completely O O
absent O O
from O O
skeletal O O
muscle O O
nuclei O O
. O O

In O O
EDMD B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O O
the O O
additional O O
absence O O
of O O
lamin O O
B1 O O
from O O
heart O O
and O O
skeletal O O
muscle O O
nuclei O O
which O O
already O O
lack O O
emerin O O
may O O
offer O O
an O O
alternative O O
explanation O O
of O O
why O O
these O O
tissues O O
are O O
particularly O O
affected O O
. O O
. O O

Genetic O O
mapping O O
of O O
the O O
copper B B_DISEASE/B_GENE
toxicosis I B_DISEASE/I_GENE
locus O O
in O O
Bedlington O O
terriers O O
to O O
dog O O
chromosome O O
10 O O
, O O
in O O
a O O
region O O
syntenic O O
to O O
human O O
chromosome O O
region O O
2p13 O O
- O O
p16 O O
. O O

Abnormal O O
hepatic B B_DISEASE/B_ORGANISM_FUNCTION
copper I I_DISEASE/I_ORGANISM_FUNCTION
accumulation I I_DISEASE/I_ORGANISM_FUNCTION
is O O
recognized O O
as O O
an O O
inherited B B_DISEASE
disorder I I_DISEASE
in O O
man O O
, O O
mouse O O
, O O
rat O O
and O O
dog O O
. O O

The O O
major O O
cause O O
of O O
hepatic B B_DISEASE/B_GENE
copper I I_DISEASE/I_GENE
accumulation I I_DISEASE/I_GENE
in O O
man O O
is O O
a O O
dysfunctional O O
ATP7B O O
gene O O
, O O
causing O O
Wilson B B_DISEASE
disease I I_DISEASE
( O O
WD B B_PROTEIN[GENE]/B_DISEASE
) O O
. O O

The O O
ATP7B O O
gene O O
has O O
been O O
excluded O O
in O O
the O O
much O O
rarer O O
human O O
copper B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
overload I I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease O O
non B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Indian I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
childhood I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cirrhosis I B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O O
indicating O O
genetic O O
heterogeneity O O
. O O

We O O
examined O O
whether O O
the O O
WD B B_DISEASE/B_PERSON
gene O O
ATP7B O O
was O O
also O O
causative O O
for O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O O
investigating O O
the O O
chromosomal O O
co O O
- O O
localization O O
of O O
ATP7B O O
and O O
C04107 O O
, O O
using O O
fluorescence O O
in O O
situ O O
hybridization O O
( O O
FISH O O
) O O
. O O

The O O
copper O O
transport O O
genes O O
CTR1 O O
and O O
CTR2 O O
were O O
also O O
excluded O O
as O O
candidate O O
genes O O
for O O
CT B B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O O
they O O
both O O
mapped O O
to O O
canine O O
chromosome O O
region O O
CFA11q22 O O
. O O

2 O O
- O O
22 O O
. O O

5 O O
. O O

A O O
transcribed O O
sequence O O
identified O O
from O O
the O O
C04107 O O
- O O
containing O O
BAC O O
was O O
found O O
to O O
be O O
homologous O O
to O O
a O O
gene O O
expressed O O
from O O
human O O
chromosome O O
2p13 O O
- O O
p16 O O
, O O
a O O
region O O
devoid O O
of O O
any O O
positional O O
candidate O O
genes O O
. O O

RESULTS O O
Chain O O
terminating O O
signals O O
were O O
only O O
identified O O
in O O
patients O O
belonging O O
to O O
the O O
FAP B B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O O
( O O
105 O O
patients O O
) O O
. O O

Amino O O
acid O O
changes O O
were O O
identified O O
in O O
four O O
patients O O
, O O
three O O
of O O
whom O O
belonged O O
to O O
the O O
non O O
- O O
FAP O O
group O O
of O O
colorectal B B_DISEASE/B_NUMBER[MEASURE]
cancer I B_DISEASE/I_NUMBER[MEASURE]
patients O O
. O O

Genotype O O
- O O
phenotype O O
correlations O O
identified O O
significant O O
differences O O
in O O
the O O
nature O O
of O O
certain O O
extracolonic O O
manifestations O O
in O O
FAP B B_DISEASE/B_NUMBER[MEASURE]
patients O O
belonging O O
to O O
three O O
mutation O O
subgroups O O
. O O

This O O
study O O
also O O
provided O O
evidence O O
for O O
the O O
pathological O O
nature O O
of O O
amino O O
acid O O
changes O O
in O O
APC O O
associated O O
with O O
both O O
FAP B B_DISEASE/B_GENE
and O O
non O O
- O O
FAP O O
colorectal B B_DISEASE
cancer I I_DISEASE
patients O O
. O O
. O O

Inherited B B_DISEASE
colorectal I I_DISEASE
polyposis I I_DISEASE
and O O
cancer B B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
risk O O
of O O
the O O
APC O O
I1307K O O
polymorphism O O
. O O

To O O
assess O O
the O O
risk O O
of O O
this O O
common O O
APC B B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allelic O O
variant O O
in O O
colorectal O O
carcinogenesis O O
, O O
we O O
have O O
analyzed O O
a O O
large O O
cohort O O
of O O
unselected O O
Ashkenazi O O
Jewish O O
subjects O O
with O O
adenomatous B B_DISEASE/B_GENE
polyps I I_DISEASE/I_GENE
and O O
. O O
or O O
colorectal B B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O O
the O O
APC O O
I1307K O O
polymorphism O O
. O O

Compared O O
with O O
the O O
frequency O O
in O O
two O O
separate O O
population O O
control O O
groups O O
, O O
the O O
APC O O
I1307K O O
allele O O
is O O
associated O O
with O O
an O O
estimated O O
relative O O
risk O O
of O O
1 O O
. O O

5 O O
- O O
1 O O
. O O

Furthermore O O
, O O
compared O O
with O O
noncarriers O O
, O O
APC O O
I1307K O O
carriers O O
had O O
increased O O
numbers O O
of O O
adenomas B B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O O
colorectal B B_DISEASE
cancers I I_DISEASE
per O O
patient O O
( O O
P O O
= O O
. O O
03 O O
) O O
, O O
as O O
well O O
as O O
a O O
younger O O
age O O
at O O
diagnosis O O
. O O

We O O
conclude O O
that O O
the O O
APC O O
I1307K O O
variant O O
leads O O
to O O
increased O O
adenoma B B_DISEASE
formation O O
and O O
directly O O
contributes O O
to O O
3 O O
% O O
- O O
4 O O
% O O
of O O
all O O
Ashkenazi O O
Jewish O O
colorectal B B_DISEASE/B_PERSON
cancer I I_DISEASE/I_PERSON
. O O

The O O
estimated O O
relative O O
risk O O
for O O
carriers O O
may O O
justify O O
specific O O
clinical O O
screening O O
for O O
the O O
360 O O
, O O
000 O O
Americans O O
expected O O
to O O
harbor O O
this O O
allele O O
, O O
and O O
genetic O O
testing O O
in O O
the O O
setting O O
of O O
long O O
- O O
term O O
- O O
outcome O O
studies O O
may O O
impact O O
significantly O O
on O O
colorectal B B_DISEASE
cancer I I_DISEASE
prevention O O
in O O
this O O
population O O
. O O

Localization O O
of O O
human O O
BRCA1 O O
and O O
its O O
loss O O
in O O
high O O
- O O
grade O O
, O O
non B B_DISEASE
- I I_DISEASE
inherited I I_DISEASE
breast I I_DISEASE
carcinomas I I_DISEASE
. O O

Although O O
the O O
link O O
between O O
the O O
BRCA1 O O
tumour B B_DISEASE
- O O
suppressor O O
gene O O
and O O
hereditary B B_DISEASE
breast I I_DISEASE
and I I_DISEASE
ovarian I I_DISEASE
cancer I I_DISEASE
is O O
established O O
, O O
the O O
role O O
, O O
if O O
any O O
, O O
of O O
BRCA1 O O
in O O
non B B_DISEASE/B_ORGANISM_FUNCTION
- I I_DISEASE/I_ORGANISM_FUNCTION
familial I I_DISEASE/I_ORGANISM_FUNCTION
cancers I I_DISEASE/I_ORGANISM_FUNCTION
is O O
unclear O O
. O O

BRCA1 O O
mutations O O
are O O
rare O O
in O O
sporadic B B_DISEASE/B_PERSON
cancers I I_DISEASE/I_PERSON
, O O
but O O
loss O O
of O O
BRCA1 O O
resulting O O
from O O
reduced O O
expression O O
or O O
incorrect O O
subcellular O O
localization O O
is O O
postulated O O
to O O
be O O
important O O
in O O
non B B_DISEASE
- I I_DISEASE
familial I I_DISEASE
breast I I_DISEASE
and I I_DISEASE
ovarian I I_DISEASE
cancers I I_DISEASE
. O O

Epigenetic O O
loss O O
, O O
however O O
, O O
has O O
not O O
received O O
general O O
acceptance O O
due O O
to O O
controversy O O
regarding O O
the O O
subcellular O O
localization O O
of O O
BRCA1 O O
proteins O O
, O O
reports O O
of O O
which O O
have O O
ranged O O
from O O
exclusively O O
nuclear O O
, O O
to O O
conditionally O O
nuclear O O
, O O
to O O
the O O
ER O O
/ O O
golgi O O
, O O
to O O
cytoplasmic O O
invaginations O O
into O O
the O O
nucleus O O
. O O

In O O
an O O
attempt O O
to O O
resolve O O
this O O
issue O O
, O O
we O O
have O O
comprehensively O O
characterized O O
19 O O
anti O O
- O O
BRCA1 O O
antibodies O O
. O O

These O O
reagents O O
detect O O
a O O
220 O O
- O O
kD O O
protein O O
localized O O
in O O
discrete O O
nuclear O O
foci O O
in O O
all O O
epithelial O O
cell O O
lines O O
, O O
including O O
those O O
derived O O
from O O
breast B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
malignancies I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O

Immunohistochemical O O
staining O O
of O O
human O O
breast O O
specimens O O
also O O
revealed O O
BRCA1 O O
nuclear O O
foci O O
in O O
benign O O
breast O O
, O O
invasive B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lobular I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O O
low B B_DISEASE
- I I_DISEASE
grade I I_DISEASE
ductal I I_DISEASE
carcinomas I I_DISEASE
. O O

Conversely O O
, O O
BRCA1 O O
expression O O
was O O
reduced O O
or O O
undetectable O O
in O O
the O O
majority O O
of O O
high O O
- O O
grade O O
, O O
ductal B B_DISEASE/B_PERSON
carcinomas I I_DISEASE/I_PERSON
, O O
suggesting O O
that O O
absence O O
of O O
BRCA1 O O
may O O
contribute O O
to O O
the O O
pathogenesis O O
of O O
a O O
significant O O
percentage O O
of O O
sporadic B B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
breast I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O O
. O O

